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Abstract 
 
Liver transplantation is a vital medical procedure as it helps to prolong the lives and 
improve the quality of life for a number of people suffering from end stage liver 
diseases.  Unfortunately though, there is a limit to the number of people that may 
benefit from the operation due to a shortage in the number of livers that are donated.  
This shortage, conflicting viewpoints, and a changing mix of patients requiring liver 
transplantation means that it is important to make sure that the livers which are 
donated are used to their greatest potential (utility) and allocated in a way which is 
seen as fair (equity).  This thesis considers various transplant assessment rule, 
allocation rule, demand and supply scenarios, to aid in the understanding of the 
dynamics of the liver transplantation process, and in identifying situations in which 
equity and utility improve. 
 
Survival and Competing Risks Models identify key patient, donor and transplant 
attributes which influence a patients’ progression through the system. 
 
A Discrete Event Simulation model is developed to assess the equity and utility 
outcomes for how a particular scenario allocates liver transplants to patients.  
Parametric distributions generated from relevant Survival and Competing Risks 
models are used to predict the events a patient will experience and to estimate the 
times at which they will experience the events. 
 
Some of the key insights gained into decision making within the UK Liver 
Transplantation System, are: (1) the need to implement simple rules and rules which 
change over time, to obtain the best equity and utility output measures as supply, 
demand and patient mix change; and (2) it is easier to improve the overall utility in 
the system than the equity, due to the implications of prioritisation. 
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Definitions 
 
Acute Liver Disease (ALD) A liver disease which last a duration not exceeding 6 
months. 
 
Cadaveric Donor A person who has recently died and permission has 
been given to use his or her organs for 
transplantation. 
 
Chronic Liver Disease (CLD) A liver disease which last a duration of longer than 6 
months. 
 
End Stage Liver Disease 
(ESLD) 
Liver disease (acute or chronic) which has 
progressed to a life threatening stage and the only 
option is for the patient to receive a liver transplant, 
otherwise they will die. 
 
Graft Failure Graft failure is when the implanted graft (here the 
transplanted liver) becomes damaged and stops 
functioning. 
 
Incremental Cost 
Effectiveness Ratio (ICER) 
The ratio of the change in costs of a therapeutic 
intervention (compared to the alternative, such as 
doing nothing or using the best available alternative 
treatment) to the change in effects of the 
intervention. 
 
Immnuosuppression Suppression of the body’s natural defence (immune) 
system, which is necessary to prevent organ 
rejection. 
 
Living Donations Where a segment from the liver of a healthy person 
is taken and transplanted into the patient. 
 
MELD Score Measures the severity of chronic liver diseases; the 
higher the score, the higher the priority for 
transplantation. 
 
Routine/Elective Classification for patients who are not expected to 
die within 72 hours if they do not receive a 
transplant. 
 
Super Urgent (SU) Classification for patients who are expected to die 
within 72 hours if they do not receive a transplant. 
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Chapter 1 
 
Introduction 
 
1.1 Introduction 
This chapter sets the background for the work performed in this thesis.  It 
describes the UK Liver Transplantation System and identifies specific issues 
which provide the motivation for this study.  These issues are discussed in detail 
and form a basis on which later chapters will build. 
 
1.2 Background to the Liver Transplantation Problem Area 
This section explains the need for liver transplantation, identifies the shortfall in 
the supply of liver transplants with respect to the demand for liver transplants in 
the UK, and considers the expected future trends. 
 
1.2.1 What Does a Liver Do? 
The liver is the largest organ inside a human body and it performs many 
functions that are essential to life, such as making bile to help with the digestion 
of food, filtering poisonous chemicals (including alcohol and drugs), and 
manufacturing proteins that the body needs to stay healthy and grow (The 
American Liver Foundation 2003a). 
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1.2.2 What Can go Wrong? 
There are many types of liver disease which are capable of compromising the 
liver’s function to the extent of threatening a patient’s life.  Diseases of the liver 
fall into two main severity groupings, referred to as Chronic Liver Disease 
(CLD) and Acute Liver Disease (ALD).  The definition of an Acute Liver 
Disease is based on the duration of the disease not exceeding 6 months, while 
liver diseases of longer duration are classified as Chronic Liver Diseases 
(Richardson and O’ Grady 2002). 
 
Acute Liver Diseases have a more rapid onset than Chronic Liver Diseases and 
the most common causes of Acute Liver Disease in Europe are acute Hepatitis 
A, acute Hepatitis B, and reactions to recreational or therapeutic drugs. 
 
Fibrosis is the damage of healthy liver cells which are then replaced by scar 
tissue.  If left untreated, the liver can become so seriously scarred that is cannot 
heal itself.  This stage is called cirrhosis (The American Liver Foundation 
2003b).  Cirrhosis is a consequence of many chronic liver diseases and interferes 
with the flow of blood through the liver and also the many functions of the liver. 
 
A list of the most common liver diseases has been compiled by UK Transplant1 
and is provided in Appendix A (Section A.1.1). 
 
                                                 
1 UK Transplant coordinates organ matching in the UK and is responsible for allocating donated 
organs in an unbiased and fair way (UK Transplant 2007). 
  
Introduction 
 
3 
1.2.3 Treatment 
If a chronic liver disease is diagnosed at an early stage then in most cases the 
damage to the liver can be stopped or reversed through the use of medication 
and/or a change in diet (The American Liver Foundation 2003b), and the liver 
can regenerate itself (Court et al. 2002).  However, the liver is a non-
complaining organ and many people with liver diseases or disorders often 
experience no symptoms (The American Liver Foundation 2003a).  Once a 
patient’s liver disease (whether acute or chronic) has progressed to a life 
threatening stage then the patient is said to have End Stage Liver Disease 
(ESLD).  At this stage no alternative currently exists and either a patient obtains 
a transplant or they will die (The Hepatitis C Trust 2006). 
 
Liver Transplantation is the replacement of a diseased liver with a healthy liver 
allograft.  A liver transplant operation removes all or a portion of the diseased 
liver and replaces it with a whole liver, or a reduced liver or segment (Parents of 
Kids with Infectious Diseases 2006).  Liver transplantation is effective at 
prolonging survival and improving the quality of life of patients with end stage 
liver disease (Bambha and Kim 2003). 
 
Patients awaiting a transplant fall into two groups depending on the severity of 
the disease, and whether or not there is an immediate threat to life.  Patients who 
are expected to die within 72 hours should they not receive a transplant are 
deemed Super Urgent (SU).  Routine/elective patients are expected to die within 
1 year and there is no immediate threat to their life (Scottish Executive 2006). 
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For the future, several artificial-liver systems are being developed and tested to 
help treat patients with liver disease.  In particular, plasmapheresis and the 
molecular adsorbent recycling system are two techniques which have provided 
promising initial results against acute liver disease (Hayes and Lee 2001; Hessel 
et al. 2002).  Their development has, however, been limited due to the relative 
rarity of acute liver failure.  Xenotransplantation (using organ grafts from 
animals in humans) may also become possible in the future (Talbot 2003; Strong 
2001), while research into the potential for injecting healthy cells from donated 
livers directly into patient livers is also showing promising signs.  As the healthy 
liver cells regenerate, the patient’s dysfunctional livers cells are replaced with 
new healthy ones.  There is hope that this technique could help the 20-40 
children (who receive priority for liver transplantation over adult patients) 
currently obtaining liver transplants every year, and in turn free up the supply of 
livers so that more adults may benefit from a transplant.  Although many new 
technologies are being researched, liver transplantation is currently the only 
reliable treatment for people with badly damaged livers. 
 
1.2.4 Scale of the Problem (The Demand) and Donations (The 
Supply) 
To the year ending 31st March 2006 there were 868 new registrations (including 
re-registrations for second or subsequent transplants) onto the UK liver 
transplant waiting list (UK Transplant 2006).  Over the same time period 612 
livers were donated and 601 liver transplants took place.  The number of patients 
present on the liver transplant waiting list on the 31st March 2006 was 365. 
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The Demand 
The size of the waiting list gives an indication of the demand for liver 
transplants but the true extent of this demand is likely to be much larger.  Firstly, 
it has been acknowledged that patients in need of transplantation may not be 
placed on the waiting list if it is thought they are unlikely to receive a transplant 
(ETHOX).  Secondly, a study by Sherwood et al. (2001) concluded that 
abnormal results for liver function are often not adequately investigated, missing 
an important chance of identifying treatable chronic liver disease.  In other cases 
it has been found that general practitioners have been unable to establish what is 
wrong, meaning that many diseases may be left undiagnosed (Walsh 2004). 
 
It is also difficult to measure unmet demand by analysing the number of deaths 
due to liver disease as it will not always be mentioned on death certificates, 
especially if there was more than one cause of death. 
 
The Supply 
The vast majority of UK liver transplants, 98.5% in the year ending 31st March 
2006, come from cadaveric donors (UK Transplant 2006).  Death can occur in 
two ways: (1) from heart-lung function stopping, and (2) from brain function 
stopping.  Donors from the first group are classified as non-heart-beating donors 
and the latter group are classified as heart-beating donors.  Heart-beating donors 
are more commonly used for transplantation, as they lead to higher success rates 
than non-heart-beating donors (University of Edinburgh). 
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Living donations can also be carried out by taking a segment from the liver of a 
healthy person and transplanting this into the patient (The American Liver 
Foundation 2003c; Mutimer 2002).  This is possible because of the ability of the 
liver to regenerate, meaning that both the segment and the remaining section of 
the donor liver will grow to normal size within weeks.  The Human Organ 
Transplant Act 1989 allows living donations so long as no commercial 
arrangements are involved (Neuberger and Price 2003).  Adult-to-child living 
liver transplants have been performed in the UK and in April 2006 the first 
adult-to-adult living liver transplants were made available to patients on the 
NHS in Scotland (UK Transplant 2005a).  The first adult-to-adult living liver 
transplant was performed in England in June 2007 (BBC 2007).  However, due 
to the relatively high donor morbidity and mortality risks involved in donating 
livers in this way, in the past the UK Government were reluctant to allow this 
technique to be widely used.  The risk of complications to the donor is 19% 
(compared to 1% for kidney donors) and the risk of death up to 1% (compared to 
0.03% for kidney donors) (MacGilchrist 2004; UK Transplant 2005a).  Living 
donations and the ethical issues related to this are discussed in more detail in 
Section 1.5.2. 
 
1.2.5 Gap between Demand and Supply 
The number of patients waiting for a liver transplantation currently outweighs 
the number of livers donated for transplantation. 
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Table 1.1 New Registrations, Outcomes and Liver Retrievals for the Year 
Ending 31st March 2006 (UK Transplant 2006). 
Total number of patients (on the waiting list at 31st March 
2005 and new registrations between 1st April 2005 - 31st March 
2006) 
1152 
Number of liver transplants2 601 (52%) 
Number of deaths 89 (8%) 
Number of removals 83 (7%) 
Number of livers retrieved 612 
Number of retrieved livers used 551 
 
From Table 1.1, it can be seen that 89 patients died whilst on the waiting list for 
a liver transplantation; this represents nearly 8% of the number of patients that 
were present on the waiting list that year.  Another 7% were removed from the 
waiting list and most of these will have been removed due to their health 
deteriorating to the extent that their chances of survival post-transplant were not 
strong enough to warrant the procedure.  Note that no central record is kept 
about patients who were removed from the waiting list, but life expectancy for 
these patients is very low.  The general shortage of organs for transplantation 
has been reported in many places, including by the Parliamentary Office of 
Science and Technology (2004). 
 
1.2.6 Future Trends 
The Demand 
Although the general need for liver transplantation is increasing, it is hard to 
specify need in absolute terms due to the reasons discussed in Section 1.2.4.  
                                                 
2 The number of liver transplants is greater than the number of donations used since a donated 
liver may be split between two recipients. 
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However, some cause and effect relationships have been identified for the main 
liver diseases and are outlined below. 
 
Deaths due to end stage liver disease are increasing.  Figure 1.1 gives an 
indication of the increases over the 34 years prior to the year 2004.  In 2001 the 
Chief Medical Officers (CMOs) report in 2001 concluded that there was a great 
concern about the growing prevalence of Chronic Liver Disease, and the 
implications for the future. 
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Figure 1.1 Death rates due to chronic liver diseases from 1970 to 2004 (Office 
for National Statistics; cited by CMO 2001). 
 
A report on the emerging trends in chronic liver disease and the impact on 
demand for liver transplantation (Roderick et al. 2004) identified three chronic 
liver diseases which are likely to increase in prevalence in the near future, and 
hence increase the demand for liver transplantation.  These are: Hepatitis C, 
Non-Alcoholic Fatty Liver Disease (NAFLD), and Alcoholic Liver Disease. 
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There is a high prevalence of Hepatitis C among injecting drug users. Roderick 
et al. (2004) applied Australian predictions to the UK, which indicated between 
a 2.5-fold and 4-fold increase in CLD burden from Hepatitis C over the next two 
decades.  Given the time lag in the evolution of cirrhosis from initial Hepatitis C 
Virus (HCV) infection this prediction is independent of the number of current 
injecting drugs users and the current rate if HCV infection. 
 
For NAFLD they found that the epidemic of obesity and Type 2 diabetes will 
lead to increased incidence of NAFLD.  They predicted that whilst the majority 
of cases will have benign disease a proportion will progress through to Non-
Alcoholic Steato-Hepatitis (NASH) and onto cirrhosis (Roderick et al. 2004). 
 
The Office for National Statistics has reported that the number of deaths in 
England and Wales where the underlying cause was directly related to alcohol 
(such as liver disease and alcohol poisoning) has risen by nearly a fifth (18.4%) 
between the years 2000 and 2004 (BBC 2005).  In 2001 the annual report from 
the chief medical officer highlighted that there is a worrying trend in the number 
of teenagers who drink alcohol and the quantities they consume (CMO Report 
2001), which has led to liver cirrhosis striking at younger ages.  The high level 
of alcohol intake in the UK, particularly among younger age groups has led 
Roderick et al. (2004) to conclude that the prevalence of alcoholic liver disease 
will continue to rise. 
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Demand is increasing for other reasons too.  A greater number of patients are 
suitable and eligible for liver transplantation due to better operative techniques 
and earlier diagnosis (Parliamentary Office of Science and Technology 2004).  
Improvements in surgical techniques and new immunosuppression regimens 
have also enabled the treatment of patients who have a less promising prognosis 
(Neuberger 1999; Neuberger 2003).  Hepatitis B and Hepatocellular cancer are 
two diseases which have recently seen significant improvements in post 
transplantation survival and there have been calls to allow more patients with 
such diagnoses onto the waiting list (Gow and Angus 2002). 
 
A reduction in the size of paracetamol packs, which was imposed in September 
1998, has led to fewer cases of acute liver diseases following attempted 
overdoses (Prince et al. 2000; Hawton et al. 2001).  Overall, however, the trend 
in the number of people suffering from End Stage Liver Disease (ESLD) is 
clearly upward. 
 
The Supply 
The blue bars in Figure 1.2 depict the number of livers donated per year between 
1996 and 2006.  It can be seen that the donation figures have remained more-or-
less constant over the last 10 years.  This is in spite of several government aided 
awareness campaigns which have been targeted at the general public to increase 
the donation rates. 
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Figure 1.2 UK Cadaveric liver programme, 1st April 1996 – 31st March 2006: 
Number of donors, transplants and patients on the active transplant list at 31st 
March (UK Transplant 2006). 
 
The National Health Service (NHS) Organ Donor Register (ODR), which is held 
by UK Transplant (UKT), was set up in 1994 to collect the names of members 
of the public who are willing to donate their organs after their death (UK 
Transplant 2004a).  UKT has increased the number of people on the ODR from 
8 million in 2001 to 13 million in March 2006 through awareness campaigns, 
such as driving licence applications, reminders through the Driver and Vehicle 
Licensing Agency, general practitioner registration and Boots Advantage Card 
applications (UK Transplant 2006; Parliamentary Office of Science and 
Technology 2004). 
 
Increasing the number of people on the ODR is one thing, but they can only 
become potential donors once they die.  At the same time as attempting to 
increase donation rates, Government initiatives have succeeded in reducing the 
  
Introduction 
 
12 
number of fatalities due to road traffic accidents (RTAs), which has led to a 
reduction in the number of donations made in this way.  Improvements in 
paramedical care, neuro-surgical practice, and preventative medicine (such as 
treatment of hypertension) (Parliamentary Office of Science and Technology 
2004) are also likely to have had an impact on the donation rate.  As a result of 
these countervailing effects, the number of donations has not increased as might 
have been hoped. 
 
ABO-compatibility has an immediate effect on whether or not a transplanted 
organ is rejected by the recipient’s body.  (The compatibility rules for the donor 
and recipient’s blood groups are defined in Appendix B, Section B.1).  People 
from different ethnic groups tend to have different blood groups so it is 
important to have donations from all ethnicities to ensure the equity of the 
system. 
 
Table 1.2 shows the number of donors and recipients from different ethnic 
groups, with the disparity in the Asian population very pronounced.  To address 
this, in 2003 the Department of Health launched a South Asian Organ Donor ad 
campaign to encourage more Asians to become donors (Media Moguls 2003).  
The impact appears to have been minimal, with the number of Asians requiring 
a transplant far outweighing the number who have donated livers in 2005/6. 
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Other examples of recent campaigns are those targeted at students, black 
members of the public, and one as a part of the celebrations of the 10th 
anniversary of the NHS ODR (UK Transplant 2004c). 
Table 1.2 Ethnicity of liver donors and recipients, 1st April 2002 – 31st March 
2004 and transplant list patients at 31 March in the UK (UK Transplant 2004c). 
2002-2003 
 Donors 
Transplant 
Recipients 
Active and 
Suspended 
Transplant List 
Patients 
 N (%) N (%) N (%) 
White 675 (97.5) 598 (84.0) 143 (79.0) 
Asian 7 (1.0) 74 (10.4) 17 (9.4) 
Black 4 (0.6) 10 (1.4) 1 (0.6) 
Chinese 2 (0.3) 4 (0.6) 3 (1.7) 
Other 4 (0.6) 26 (3.7) 17 (9.4) 
Not 
Reported 
3 - 0 - 0 - 
TOTAL 695  712  181  
2005-2006 
 Donors 
Transplant 
Recipients 
Active and 
Suspended 
Transplant List 
Patients 
 N (%) N (%) N (%) 
White 594 (95.7) 520 (85.2) 309 (84.7) 
Asian 6 (1.0) 56 (9.2) 34 (9.3) 
Black 10 (1.6) 15 (2.5) 8 (2.2) 
Chinese 0 (0.0) 4 (0.7) 0 (0.0) 
Other 11 (1.8) 15 (2.5) 14 (3.8) 
Not 
Reported 
0 - 0 - 0 - 
TOTAL 621  610  365  
 
Although registering as an organ donor helps to express your willingness to 
donate after death, current practices require that the family of the potential donor 
must give consent for organ donation, regardless of whether or not the deceased 
had been on the Organ Donor Register (UK Transplant c.1999).  A further 
discussion of the donation system follows in Section 1.5.1. 
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UK Transplant regularly carries out audits of potential donors.  One audit report, 
considered all patients who died in an Intensive Care Unit (ICU) between 1st 
April 2003 and 31st December 2005.  Potential heart-beating donors are defined 
as those for whom death was diagnosed following brain stem tests and who were 
judged suitable for organ donation.  Figure 1.3 shows that only 46% of these 
3,707 potential donors actually became organ donors.  85% of relatives were 
approached, but 39% of these refused to give consent for organ donation (UK 
Transplant 2006). 
Organ donation occurred
1693 (46%)
Consent given but organ 
donation did not occur 
189 (5%)
Next of kin not approached
565 (15%)
Consent not given by next of kin 
1,260 (34%)
 
Figure 1.3 Percentage of UK Deaths Resulting in Organ Donation for the 
period 1st April 2003 - 31st December 2005. 
 
Following the 2003/04 audit, UKT provided more detail in their report (Allen et 
al. 2004).  The most significant finding was that non-white families were far less 
likely to give consent for donation than white families (refusal rates for the two 
groups were 77% and 36%, respectively).  They were also slightly less likely to 
be approached in the first place.  Other key factors were the time at which the 
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family was approached and whether or not a Transplant Co-ordinator was 
involved in this approach. 
 
Organ donation rates have remained steady for a number of years, and there is 
little indication that the supply of donated livers is likely to increase in the near 
future (Neuberger 1999). 
 
1.2.7 Summary of Demand and Supply Issues 
The number of people requiring a liver transplant is increasing (Neuberger 1997; 
Neuberger 1999) but despite government awareness campaigns (Neuberger 
2003; UK Transplant 2004b), the supply of livers in the UK has remained fairly 
constant (UK Transplant 2006). 
 
The supply of donated livers currently does not match the demand and this 
shortage is likely to continue, or even increase in the future as it is predicted that 
the number of people requiring liver transplants (particularly for Chronic Liver 
Diseases) will increase. 
 
One of the key motivations for this study arises from this inequality, and the 
resultant need to utilise the available donations as effectively as possible. 
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1.3 Liver Transplantation in the UK 
The first human liver transplant was performed in Denver, USA in 1963 and the 
first in the UK was performed at Addenbrooke’s Cambridge in 1968 (UK 
Transplant 2004d).  Since then, many patients have benefited from the 
procedure.  In the UK in the year to end March 2006, 601 liver transplants were 
performed (UK Transplant 2006). 
 
Healthcare in the UK is mainly provided through a publicly funded NHS.  This 
section briefly outlines the aims of the NHS, explains how liver transplantation 
fits into NHS care, and outlines a few specific issues concerning liver 
transplantation. 
 
1.3.1 The National Health Service 
Any public health service attempts to improve the health of the people it cares 
for.  It does this at various stages of the natural disease progression: prevention 
(education and immunisation), early detection (screening and blood tests), and 
through the provision of treatment (drugs and operations). 
 
The UK NHS was set up in 1948 with the main aim of providing universal, 
comprehensive and free healthcare for all UK residents.  It still remains the main 
provider of healthcare to the population of the UK and is now the largest health 
service in Europe (National Health Service). 
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Over the last 59 years it has experienced many changes, ranging from the setting 
in which it operates and the type of patients it cares for, to the management of its 
resources.  The NHS was established just after the Second World War, when 
society on the whole was used to amenities being rationed, whereas today it 
operates in a consumer based society where knowledge of different treatment 
options is easily obtained, e.g., through internet websites.  Patients are therefore 
more likely to know about many of the options that exist and to demand what 
they see as the right treatment for them. 
 
Offering patients more choice in the treatment they obtain is just one challenge 
that the NHS has had to meet in recent years (BBC 2006).  Another challenge 
concerns the ailments that the NHS must care for.  Initially, the focus 
concentrated on finding treatments and many issues revolved around providing 
acute care.  Partly as a result, the population is now on average living longer; 
hence more are likely to experience chronic diseases, such as coronary heart 
disease, cancer and diabetes.  The good news is that in general chronic illnesses 
can be managed and most patients can continue to live a life of reasonable 
quality.  In many cases chronic illnesses are preventable, through leading 
healthy lifestyles (exercise, diet, not smoking). 
 
In recent years more of the focus of the NHS has shifted from treating illnesses 
to preventing them.  In 2004, the government published a white paper entitled 
“Choosing Health” (Department of Health 2004), which focused on many of the 
issues concerning healthcare now and in the future.  It set out an agenda for the 
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future which included opportunities “for everyone to make their own individual 
informed healthy choices” as this will play a key role in helping to prevent 
chronic diseases in the future. 
 
1.3.2 Liver Transplant Centres 
Currently, liver transplants for adults on the NHS can only take place in one of 
seven liver transplant units in the UK, which are listed in Table 1.3. 
 
Table 1.3 Liver Transplant Units in the UK (British Liver Trust). 
Region Hospital 
East Anglia Addenbrooke’s, Cambridge 
N E Thames Royal Free Hospital, London 
Northern Freeman Hospital, Newcastle Upon Tyne 
S E Thames King’s College Hospital, London 
West Midlands Queen Elizabeth Hospital, Birmingham 
Yorkshire St James’ Hospital, Leeds 
Edinburgh & Lothian Edinburgh Royal Infirmary, Edinburgh 
 
In general, each liver transplant unit is responsible for procuring organs and 
transplanting patients within a particular region of the England (and Ireland), as 
depicted in the map presented in Appendix C. 
 
There are a few exceptions in that other (non liver) transplant units are not 
necessarily based in the same hospitals and sometimes is it easier for one 
hospital to procure all organs from a particular donor.  Also, patients may 
occasionally be registered at a hospital outside of the region in which they 
reside, however at any one time they can only be registered at one hospital. 
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If no patients on the UK Transplant waiting list are suitable or available for 
transplantation, then the donated liver will be offered to patients registered 
privately within the UK or to patients waiting for a liver transplant in the rest of 
Europe. 
 
1.3.3 Falling ill with ESLD to Receiving a Liver Transplant 
Figure 1.4 shows the main stages a patient goes through, from falling ill with 
ESLD to obtaining a liver transplant (from a cadaveric donor).  Once ill with 
ESLD, the patient is referred to a liver unit where they are assessed for 
transplant suitability (Section 1.3.4).  If they are judged suitable then they are 
placed on the UK liver transplant waiting list and wait until a suitable liver is 
donated and allocated (Section 1.3.5) to them, at which point they are 
transplanted. 
 
 
Figure 1.4 Process from a patient falling ill with ESLD to transplantation. 
 
PATIENTS 
WITH ESLD OR AN 
UNACCEPTABLE 
QUALITY OF LIFE 
ASSESSMENT 
PHASE 
ALLOCATION 
PHASE 
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The three key stages in the process depicted in Figure 1.3 are: (1) the diagnosis 
of patients either with ESLD or with liver disease and an unacceptable Quality 
of Life (QoL)3, (2) the assessment phase, and (3) the allocation phase. 
 
Changes in the criterion of any one of these stages will have a direct impact on 
the number and the type of patients within the liver transplantation system.  The 
next two sub-sections detail how the assessment and allocation phases are 
currently implemented in the UK. 
 
1.3.4 Assessment Process 
The assessment phase is the stage at which a decision, subject to pre-defined 
suitability criteria, is made as to whether or not a patient should be placed onto 
the transplant waiting list.  Various tests and interviews are carried out to 
determine how much the patient is likely to benefit from a transplant.  The 
current suitability criteria for transplantation are documented and are designed to 
ensure that the number of patients on the waiting list remains in balance with the 
number of donors and to encourage consistency between units (UK Transplant 
2001a).  The guidelines broadly define the criteria as:  
(A) The patient has an anticipated length of life (in the absence of 
transplantation) of less than one year, or an unacceptable quality of life; 
and 
                                                 
3 In this thesis Quality of Life refers to Health Related Quality of Life (HRQoL).  HRQoL is how 
a person’s health affects their ability to carry out normal social and physical activities.  The 
values this measure can take on range from 0 (inactive/dead) and 1 (full functionality).  HRQoL 
is measured using patient questionnaires. 
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(B) They have greater than 50% probability of survival at 5 years after 
transplantation with a quality of life that is acceptable to the patient 
(Devlin and O’Grady 1999; Neuberger and James 1999; UK Transplant 
2001a). 
 
These criteria are evaluated by the teams within the seven separate liver units (as 
listed in Table 1.3).  Due to the degree of subjectivity, the criteria are dependent 
on the interpretation of the unit at which the patients are assessed.  The unmet 
need is hard to quantify, as there may be little data available about the patients 
that are rejected.  Also it is not known how many patients would be suitable for 
a transplant but are not referred to a transplant centre, perhaps because the 
chances of being placed on the waiting list and being allocated a transplant are 
too small. 
 
Post transplant survival rates are improving due to advances in care during and 
post transplant, (UKTSSA c.1995), and therefore more patients are likely to 
satisfy criterion (B). 
 
There are some reasons which are outlined in the protocols as to why a patient 
may be less likely to be judged a suitable candidate for liver transplantation.  
These reasons include alcohol-induced liver disease, illegal drug use, self-
inflicted conditions, medical and psychiatric conditions, regrafts, malignancy, 
and disease progression to a state where criterion (B) is no longer satisfied as the 
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patient is too ill to survive the transplant.  The age of the patient is also taken 
into account when determining their suitability for transplant. 
 
1.3.5 Allocation Process 
Once patients join the waiting list they are essentially in competition for the 
donated livers.  In the UK, patients must have a compatible blood type to the 
donor’s blood type, if they are to be allocated the donated liver (UK Transplant 
2002a).  Other factors taken into account are weight matching, matching based 
on donor and patient risk groupings, and the geographical location of the patient 
compared to the donated liver. 
 
Figure 1.5 details the allocation process as it is currently implemented.  When a 
liver becomes available, if any children (aged 16 years or younger) with a 
compatible blood group are waiting for a liver transplant then they are 
considered first to receive the donated liver.  Next, the waiting list is checked for 
any compatible super urgent patients.  If there are any then the donated liver is 
allocated to one of them.  If not, then the nearest centre (usually the retrieving 
centre) checks whether or not they have a suitable routine candidate.  If they do 
not then the liver is offered to other centres, based on a balance of exchange 
system.  The balance of exchange system attempts to make sure that the number 
of liver transplants a centre performs roughly matches the number of liver 
retrievals they make. 
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Figure 1.5 A Flow Chart to Represent the Current Liver Allocation Rules. 
 
1.4 Ethical Issues in the Allocation System 
There are a number of ethical aspects associated with the transplantation of 
livers, which may influence future demand. 
 
1.4.1 Cost-Effectiveness of Liver Transplantation 
A liver transplantation costs in the region of £40,000 and the cost of 
immunosuppression treatment for a patient post transplant is roughly £6,500 a 
year for the rest of a patient’s life (BBC 2003; Medical News Today 2004).  
Immunosuppression is the artificial suppression of the immune system, so that 
the body will not reject a transplanted organ or tissue. 
 
A recent study found that all organ transplantation is generally cost-effective, 
particularly in relation to NHS spend.  The exception that they identified was the 
Liver Available & No 
Compatible Children Waiting 
Compatible 
SU 
Patient? 
SU Patient 
Transplanted 
Offered to compatible patients at other transplant centres, 
according to a balance of exchange system 
Nearest 
Centre Patient 
Transplanted 
Routine 
Compatible 
Patient at Nearest 
Centre? 
 
YES 
NO 
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cost-effectiveness of liver transplantation as a treatment for alcoholic liver 
disease (Longworth et al. 2003; UK Transplant 2003a), due to a larger number 
of patients being assessed in this group and not being put forward for transplant. 
 
1.4.2 Assessment for Liver Transplantation 
There is some debate around who should be eligible for liver transplantation.  
Issues include the likelihood that the disease will recur post-transplant and 
whether or not the disease was preventable. 
 
Recurrence of Disease 
Following transplantation some diseases can recur and damage the replacement 
liver, notably Hepatitis B and Hepatitis C (Gow and Angus 2002; UK Transplant 
2001a).  A study in Western Australia found the overall rate of disease 
recurrence to be 10% in a particular cohort of patients (Yusoff et al. 2002).  The 
rate of recurrence was seen to vary significantly between the indications for 
transplantation, with a recurrence rate of 40% in patients initially transplanted 
for Hepatitis B (Rosen 2001).  There are also restrictions currently in place 
which do not allow patients with tumours greater than 5cm in size or with more 
than 3 tumours to proceed to the transplant waiting list (Devlin and O’Grady 
1999).  There is much debate on whether these criteria are too restrictive.  On 
the other hand, it could also be argued that patients without such complications 
might benefit more from a donor liver. 
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Preventable Diseases 
The high profile case of George Best has kept the debate of transplanting 
patients with preventable diseases, alive (Scotsman 2004).  As the Government 
attempts to focus their resources more on preventing chronic diseases it is 
important to consider whether patients with preventable liver disease should 
receive the same priority for liver transplantation as those with non-preventable 
liver disease.  One argument considers the likelihood of compliance to post 
transplant treatment.  A study considering sobriety, drug-compliance and 
adherence to appointments for Alcoholic Liver Disease after liver 
transplantation, found that most patients were compliant but relapse to drinking 
occurred in 13% of recipients.  A patient’s return to alcohol consumption post 
transplant is associated with rapid development of histological liver injury 
including fibrosis, meaning that they potentially require another transplant (Tang 
et al. 1998).  Alcoholic liver disease patients also reported poorer health-related 
quality of life post-transplant compared with other patients (Longworth et al. 
2003; UK Transplant 2003a). 
 
1.4.3 Allocation of Liver Transplants 
There are many conflicting viewpoints and ethical issues surrounding the 
transplant allocation process.  Several other studies have also attempted to assess 
various stakeholder viewpoints.  A survey published in 1998 (Neuberger et al. 
1998) questioned the general public, family doctors and gastroenterologists 
(within the UK) about their views concerning the allocation of donated livers to 
potential recipients of liver allografts.  They established that the priorities of the 
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public differ from those of the medical profession.  The public tend to prioritise 
on a more emotional basis and rank patients with antisocial behaviour (alcohol, 
drug users) lowest. Whereas, the doctors and gastroenterologists consider overall 
outcome, work status and the likelihood of working post transplant as key 
criteria when allocating the livers. 
 
A study in Australia (Browning and Thomas 2001) concentrated on obtaining 
the views of the general public on how organ allocation decisions should be 
made.  They too found that the public prioritise emotionally with the factors of 
younger age and being a parent being key in their decision making.  Other 
factors that they find to be significant are better prognosis post-transplant and 
the length of time spent waiting for a transplant. 
 
Ratcliffe (2000) performed a survey to investigate the nature of public 
preferences to the allocation of donated livers for transplantation.  She 
interviewed both academics and non-academics from a British University.  The 
survey results indicate that most members of the surveyed group thought that the 
post transplant survival chances should be the main deciding factor in the 
allocation of transplants.  However, when faced with a choice situation in which 
there were a limited number of donor organs to allocate between two groups of 
individuals with differing characteristics, the overwhelming majority of 
respondents chose not to abandon the group with the lower expected survival. 
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It is extremely important for public views to be acknowledged within the 
decisions made through the transplantation process as they donate their organs to 
make transplantation possible, and if the system does not portray what they wish 
for then they may be less willing to donate. 
 
1.5 Ethical Issues in the Donation System 
There are a number of ethical aspects associated with the transplantation of 
livers, which may influence future supply. 
 
1.5.1 Opt In or Opt Out 
Currently the UK operates an informed consent (opt in) system for organ 
donation, whereby individuals are asked to register their willingness to be a 
donor after their death (UK Transplant c.1999). In practice, relatives of the 
patient are always consulted and asked to give explicit consent.  If the relatives 
cannot be found, or they refuse to give consent, then organ donation cannot take 
place, even if the deceased had been on the ODR. 
 
Shortages in the number of donations (as discussed above in Section 1.2.5) have 
led to debates on whether a system of presumed consent would be more 
appropriate.  Under this system it is assumed that an individual wishes to be a 
donor unless they have “opted out” by registering their objection to donation 
after their death.  The British Medical Association, many transplant surgeons, 
and some patients’ groups and politicians are keen to change the current system. 
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(BBC 2004; Kennedy et al. 1998).  They argue that although the presumed 
consent system may make little difference to short term donation rates it will 
affect the culture and framework within which discussions about donation will 
take place and oblige everyone to consider whether or not they wish to donate 
their organs after death and to discuss this with their close relatives 
(Parliamentary Office of Science and Technology 2004). 
 
Table 1.4 Legislation, practice and donor rates (Source: Council of Europe; 
National Transplant Organisation; cited by Parliamentary Office of Science and 
Technology 2004). 
Country Legislation Actual Practice 
Donors 
(per million 
people) 
Annual Rate 
2003 
Spain 
Presumed 
Consent 
Informed Consent 33.8 
Belgium 
Presumed 
Consent 
Presumed Consent and 
Family Informed 
24.4 
Austria 
Presumed 
Consent 
Presumed Consent 23.3 
US 
Informed Consent 
with Required 
Request 
Informed Consent with 
Required Request 
22.1 
Ireland Informed Consent Informed Consent 21.1 
Norway 
Presumed 
Consent 
Informed Consent 19.2 
France 
Presumed 
Consent 
Informed Consent 18.3 
Netherlands Informed Consent Informed Consent 14.9 
Germany Informed Consent Informed Consent 13.8 
Sweden 
Presumed 
Consent 
Varies, Recent Changes 12.8 
UK Informed Consent Informed Consent 12.0 
Greece 
Presumed 
Consent 
Informed Consent 6.4 
 
Some arguments for presumed consent stem from the organ donation rates 
observed in different countries.  Table 1.4 shows donation rates by country and 
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the policy in place.  Spain which has the highest donation rates (almost 3 times 
as many donations as the UK) has presumed consent legislation in place, 
however in practice operates a system of informed consent – in that relatives are 
asked whether or not they are in favour of donation (Parliamentary Office of 
Science and Technology 2004). 
 
Studies comparing the Spanish and UK donation systems in more detail found a 
number of additional factors that could account for the relatively high donation 
rates in Spain.  Firstly, it should be noted that there are double the number of 
deaths from road accidents in Spain, greatly increasing the pool of potential 
donors.  There are also significantly lower refusal rates from patient relatives 
(20-24%) compared with 39% in the UK. (UK Transplant 2003b; 2006).  
Refusal rates by patient relatives in the UK have increased from 30% in the early 
1990s to 42% in 2004.  Many factors could be responsible for this increase 
including the Alder Hey (English and Sommerville 2003) scandal in 1999 where 
organs were kept without consent.  Support from the Catholic Church may also 
have an impact on donation rates in Spain (Parliamentary Office of Science and 
Technology 2004).  Finally, the high donation rate in Spain is thought to be 
mainly due to the way organ donation is co-ordinated, with a national network 
of specially trained physicians in charge of the whole process of organ donation.  
The UK has fewer transplant co-ordinators than Spain, despite having a larger 
population, and it is thought that the lack of a ‘transplant culture’ in hospitals is 
also an issue. 
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The Department of Health (2002) is not in favour of a change in legislation to 
that of presumed consent and has not found any evidence that the public would 
overwhelmingly support presumed consent from responses to its Human Bodies, 
Human Choices consultation.  It maintains that changing the legislation would 
be a high risk strategy and believes that without clear public support it may lead 
to reduced donation rates.  Currently the level of public support for changing the 
system is unclear, a poll carried out in 1999 by the Department of Health 
reported that 50% of respondents favoured the current system, 28% supported a 
shift to presumed consent and 22% expressed no preference (UK Transplant 
c.1999). 
 
In June 2004 it was decided in Parliament that the decision as to whether or not 
to donate should be left to the individual (Scotsman 2004). 
 
A more recent survey (Lyall 2005) carried out by the BBC (or their TV 
Programmes Holby City and Casualty identified three main fears the UK public 
had with regards to donating their organs after their death: 
(1) Mis-use: organs taken without consent (possibly due to instances like Alder 
Hey - where organs were taken without permission (English and 
Sommerville 2003)); 
(2) Doctors will be too keen to turn off life-support, so that others may benefit 
from your organs; and 
(3) Accuracy of the brain-stem test in determining whether or not someone is 
dead. 
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1.5.2 Living Donations 
Living donor liver transplantation for adults was developed as an attempt to 
increase the pool of donor organs (Shiffman et al. 2002).  Most living donors are 
relatives of the patient due to the importance of providing a good match between 
donor and recipient.  This is one of the main limiting factors for this technique, 
while further complications arise from medical contraindications in the donor  
(Neuberger and Price 2003). 
 
Neuberger and Price (2003) believe that living liver donation should be 
recommended for patients who are eligible to receive a liver graft but who have 
a high probability of death or clinical deterioration that would preclude 
transplantation before a cadaveric graft became available.  The Royal College of 
Physicians of Edinburgh agree but extend their criteria to include patients with 
hepatocellular carcinoma, where delaying the operation will increase the risk of 
extra-hepatic spread (MacGilchrist 2004). 
 
Initially, there was doubt about the use of living donors, especially after one 
donor died in the US (Josefson 2002).  Since then, research has helped to 
improve understanding about the ideal donors and recipients for this procedure 
(Tan et al. 2005) and many hope that living donations will help to ease the 
chronic shortage of organs currently experienced worldwide.  Factors that may 
reduce the risks associated with the procedure are: selecting younger donors 
(<45 years old), placing allografts in recipients who have not had a prior 
transplant and who are not in the Intensive Care Unit (Abt et al. 2004). 
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1.5.3 Marginal Livers 
There is no specific definition of a marginal liver (Neuberger c.2004).  Many 
authors use the definition that a marginal organ is one where there is a risk of 
initial poor function or primary non-function.  Neuberger suggests some 
characteristics of a marginal liver donor as including: older age, high Body Mass 
Index (BMI), steatosis, brain stem death, and prolonged Intensive Treatment 
Unit stay.  Other reasons include partial liver grafts, and grafts from non-heart 
beating donors.  Other factors include technical factors such as warm and cold 
ischaemic times and recipient factors, and particularly factors regarding the 
closeness of the match (blood group and ethnicity) with the donor.  The shortage 
of organs has led to American transplant centres expanding their criteria for the 
acceptance of marginal donors (Busuttil and Tanaka 2003).  Similarly in the UK 
the use of marginal livers has been expanded, Table 1.5 below depicts the 
increased use of marginal livers in the UK, figures were obtained from UK 
Transplant data (UK Transplant 2004e). 
 
Table 1.5 Marginal Liver Characteristics (UK Transplant 2004e). 
Donor Characteristic 1999 2000 2001 2002 
Donor Age < 65 years 95.1% 94.5% 93.7% 92.0% 
Donor Age >= 65 years 4.9% 5.5% 6.3% 8.0% 
Whole Liver 87.6% 88.1% 87.6% 87.0% 
Split/Reduced Liver 12.4% 11.9% 12.4% 13.0% 
Cadaveric heart-beating donor 100% 100% 99.8% 99.7% 
Cadaveric non heart-beating - - 0.2% 0.3% 
 
There appears to have been an increase in the use of marginal livers (donor age 
greater than or equal to 65 years, split/reduced livers), and the potential for 
increasing the number of transplants that could be carried out is significant.  It is 
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estimated that an increase in the use of non-heart-beating donors may give rise 
to a 25% increase in the number of organs donated within the UK (Patient UK 
c.2005).  The ethical considerations still remain, however, due to the poorer 
survival rates associated with marginal livers. 
 
1.6 Summary 
There are several key reasons for why there is a need to create a model of the 
UK liver transplant system.  These include the gap between demand for liver 
transplantation and the supply of livers from the cadaveric donor pool and the 
many conflicting view points concerning various ethical aspects of the system.  
Considering future trends of demand and supply the gap is likely to increase, in 
particular, due to the increasing number of people falling ill with chronic liver 
disease.  The scarcity of this resource makes it important to allocate the donated 
livers effectively. 
 
There are two key stages within the UK liver transplantation process which 
influence who will eventually be given a liver transplant operation.  These are 
the assessment phase (at which point criteria define if a patient meets the 
requirements to join the waiting list), and the allocation phase (at which point 
patients on the waiting list are prioritised for an available liver transplant 
operation).  The allocation stage and patient assessment stage are complex and 
act as taps that control patient flow through the system, based on the policies in 
place. 
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Many ethical considerations which support the need for a model to be created, 
also exist.  The issues are wide-ranging, however, can be grouped into three 
main areas: equity, utility and operational issues.  Equity and utility issues are at 
the heart of debates concerning who should obtain a liver transplant (e.g., cost-
effectiveness seeks to maximise utility potentially at the expense of equity; 
restrictions on transplants for patients with recurring diseases or patients with 
preventable diseases would again affect utility and equity; and direct changes to 
the allocation rules can affect both equity and utility).  Operational issues also 
exist: some doctors believe that an opt out system would provide a greater 
number of donations, however, politicians think that the decision to donate 
should be left up to members of the public.  The use of marginal and living 
donations is increasing to help alleviate some of the demand, but although new 
technologies are being developed, it will be some time before they can be used 
widely. 
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Chapter 2 
 
Literature Review 
 
2.1 Introduction 
This chapter examines the present tools used to explore transplant assessment 
and allocation decisions, summarises the existing literature and discusses the 
applicability of present techniques within the UK liver transplantation problem 
area. 
 
The chapter ends by summarising the main findings of the literature search and 
formulating the research objectives and questions of the work contained in the 
rest of this thesis. 
 
2.2 Transplant Matching Studies 
Allocation policies for two types of transplant - liver transplantation and renal 
(kidney) transplantation - have been investigated extensively.  This section 
identifies the reasons why the modelling of allocation policies is worthwhile and 
summarises the models which have previously been developed, highlighting 
their key components.  
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2.2.1 Reasons to Model Liver and Renal Transplantation Systems 
Ninety three percent of all patients registered for a transplant in the UK on 31st 
March 2006 were registered for either a liver transplant or a renal transplant (UK 
Transplant 2006). 
 
The three main characteristics of both transplant systems which make the 
investigation of various allocation policies worthwhile, are: 
(1) The shortage in the donations of both types of organs, compared with the 
demand for transplants.  In the year ending 31st March 2006, the number of 
deaths from the liver and renal transplant waiting lists were 89 (8%) and 286 
(3%), respectively (UK Transplant 2006); 
(2) The size of the waiting lists (which means there will generally be a choice as 
to which patient to allocate a donated organ to); and 
(3) The long organ preservation times, increasing the number of options 
available to clinicians in terms of how the available organ could be allocated. 
(The liver can be preserved for around 12-18 hours after removal from the 
donor, while a kidney can be preserved for 24-48 hours.  This is in contrast 
to about 6 hours for most other organs (UNOS 2004). 
 
The number of similarities between liver transplantation and renal 
transplantation mean that similar modelling approaches can be applied to both 
systems.  There are however two additional factors which are important to 
consider in renal transplantation.  Firstly, an additional factor when matching a 
patient with a donor kidney is Human Leukocyte Antigens (HLA), which have 
  
Literature Review 
 
37 
been shown to be important in post transplant graft survival (Claas et al. 2004; 
Opelz 1988).  Secondly, dialysis is also an option for patients with renal failure, 
which means that patients can survive without a transplant, although renal 
transplantation offers a far better quality of life.  As a result, it becomes 
important to compare Quality Adjusted Life Years (QALYs)4 when 
investigating different kidney allocation policies. 
 
2.2.2 Comparing UK and US Systems 
Many liver and renal studies have modelled the systems within the USA.  
However, differences exist between the two countries which mean that these 
studies are not directly applicable to the UK systems.  Clinicians in the USA 
have to consider the issue of distance between where an organ is procured and 
where it is taken to be transplanted (UNOS 2004).  The travel times between 
procurement and transplant must respect the preservation times mentioned above 
(in Section 2.2.1) to ensure initial graft functionality post transplant.  In the UK 
the distances are not as great and all travel times fall within the 12 hour lower 
limit for liver preservation. 
 
Another issue present in the USA is that the patient can choose whether or not to 
accept a donated organ (UNOS 2004).  This issue arises from the fact that 
Americans pay either directly (to the transplant centre) or indirectly (through 
                                                 
4 A QALY is a measure that combines both morbidity and mortality.  The measure is based on 
utility theory which values full health as 1 and death as 0.  Some conditions, like persistent 
severe vegetative state, may be given negative utilities.  If someone with a utility of 0.75, for 
example, has an extra four years of life, then they have three QALYs whereas a completely 
healthy person (with a utility of 1) would have 4 (Davies et al. 2003). 
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medical insurance) for their transplant and those who cannot afford to pay do not 
receive a transplant.  In paying for medical provisions patients are more likely to 
reject an organ which may be marginal (Section 1.5.3) and may instead opt to 
wait for their next offer which may be an organ of higher quality.  The initial 
offer indicates that they have reached the top of the waiting list, and that an 
alternative donor organ is likely to be offered soon.  The rejection of organs 
gives additional time pressures to the US system.  In the UK, there is more of an 
expectation that people will accept any organ allocated to them and as a result 
fewer donations are rejected.   
 
The registration criteria in the USA are less strict than the process in the UK as 
patients in the USA are able to join more than one transplant centre waiting list, 
improving their chances of obtaining a transplant (UNOS 2004).  In addition, 
US patients can join a waiting list as soon as they are diagnosed with liver 
disease.  Hence the US models have concentrated on attempting to capture 
natural history data in great detail.  In the UK, however there are stricter 
assessment rules (Section 1.3.4) and patients must be expected to die within a 
year before they may join the waiting list, therefore a UK model does not need 
to replicate the detailed natural history models created in the USA. 
 
Another difference is that the US model incorporates the Model for End stage 
Liver Disease (MELD) score (see Section 3.7.1 for a detailed definition) in the 
decision as to which patient should be allocated a liver transplant (UNOS 2004).  
The MELD score measures the severity of chronic liver diseases; the higher the 
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score, the higher the priority for transplantation.  In the UK, MELD scores are 
collected but are not used in the national allocation of liver transplant operations. 
 
2.2.3 Previous Transplant Matching Studies 
This section summarises the main models which have been created to represent 
the liver and renal transplant systems in the USA and the UK. 
 
Liver Transplant Matching Models 
Roberts (1992) developed a model to help to understand the optimal time at 
which to offer a transplant to a patient.  He used Markov processes to describe 
the transitions between different disease states and evaluated the strength of 
different selection criteria by using Monte Carlo Simulation.  The key outcome 
analysed was the life expectancy of the patient and this was measured using 
survival analysis.  The difficulty with the modelling approach he took is that it 
only considered the selection strategy used by one US transplant centre to 
estimate if a transplant increased survival over the natural history and he was 
only able to consider the outcomes that had occurred at that transplant centre.   
 
Howard (2001) compared various basic allocation policies.  The allocation rules 
which were investigated are: sickest-first priority rule (SFPR), first-come first-
served (FCFS), and service in random order (SIRO).  He simulated the arrival of 
donors and patients and assessed the impact of the different policies against a 
measure of patient survival and health post transplant, while also considering the 
fairness of the policies at allocating equally to patients with an urgent need for a 
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transplant, and those with a less urgent need.  The main finding was that 
compared to a FCFS queue or SIRO, a ‘sickest first’ policy resulted in worse 
patient outcomes when the demand-to-supply ratio is high.  The model however 
failed to capture several of the key factors within the US transplant system 
which would affect the success of transplants carried out, including the 
following: locations of procurement and transplant and the transport times 
between them, re-transplantation, and organ (weight and blood group) matching.  
The main limitation was that of insufficient data which made it hard to extend 
the model to incorporate all the regions within the USA. 
 
UNOS Liver Allocation Model (ULAM) (Harper et al. 2000; Pritsker, A et al. 
1995; Pritsker, A et al. 1996) is the simulation model used by the United 
Network for Organ Sharing (UNOS), a tax exempt, medical, scientific and 
educational organisation that operates the national Organ Procurement and 
Transplantation Network (OPTN), in the US.  The main motivation in building 
ULAM was to compare proposed liver allocation policies on a national basis, at 
a time when the number of patients on the waiting list was growing faster than 
the number of liver organs being donated.  A suite of outcomes are considered to 
assess different policies, ranging from the relative survival rates of patients, to 
the fairness of the system created.   
 
The model created incorporates features that are present in other models such as 
initial waiting list composition, patient and donor arrival streams, allocation 
policies, and mortality and re-listing rates post transplant.  Additional issues the 
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model attempts to deal with include medical urgency status which changes as a 
patient’s illnesses progresses, liver offer/acceptance rates, and increasing 
survival rates post transplant (that would result from better immunosuppression 
medication regimens, drugs available pre-transplant, and advancements in 
transplant techniques).  The model has been accepted by clinicians as a result of 
their involvement in its creation.  Although the model does consider medical 
urgency, it does not look at the causes of liver failure and how these affect the 
overall outcomes.  ULAM also does not attempt to make predictions concerning 
future demand and supply (e.g., the anticipated increase in the number of 
Hepatitis C cases, discussed in Section 1.2.6). 
 
More recently, a group from Pittsburgh (Kreke et al. 2002a; Kreke et al. 2002b; 
Shechter et al. 2005) have developed a more robust model based on ULAM, 
which attempts to allow the inclusion of inputs that are not influenced by the 
current policy.  Their approach has been to separate the modelling of the biology 
and natural history of the disease from the allocation and selection mechanism.  
They managed to prove the concept of modelling the biology and natural history 
of a liver disease by validating a model which incorporated a separate disease 
progression module and a survival module (with and without transplant), to 
predict the time-course of individual patients as they progress through their 
disease, and estimate pre- and post- transplant mortality and re-transplantation.  
The outputs of the model included survival times, cost, waiting time information 
and information on the number of wasted organs.  They acknowledge several 
limitations, the most important being that the natural history module is based on 
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data from a single site (the University of Pittsburgh Medical Center UPMC), 
whose patients are not representative of the national population.  Another 
important limitation Kreke et al. (2002a) acknowledge is that the proportional 
hazards assumption (as detailed in Section 2.4.1) which is assumed by the Cox 
models may not be satisfied (Kreke et al. 2002a).  Alagoz et al. (2005) have 
continued working on this model to develop more realistic approximations in 
capturing the changes in clinical characteristics of patients with end-stage liver 
disease to be used to calibrate the natural disease progression model.   
 
A group from Brunel (Baldwin et al. 2000; Eldabi et al. 2001) have developed 
the only model of the UK liver transplant allocation system, with the motivation 
to evaluate the cost-effectiveness of liver transplantation for the Royal Free 
Hospital liver unit, and to assess whether an alternative allocation policy would 
be more cost-effective.  Their model (LiverSim) incorporated expected 
outcomes with, or without transplant and reflected the patterns of care that 
would be obtained in both circumstances.  A Discrete Event Simulation model 
was created to model a patient’s progression through the assessment, candidacy 
(on the waiting list) and transplant phases, and the cost associated with each 
phase.  They evaluated Incremental Cost Effectiveness Ratios (ICERs) for 
several policies (including priority to patients with high/low waiting times, 
high/low patient age, high/low clinical severity, and various clinical severity 
groupings).  Their results identified that the cost-effectiveness of liver 
transplantation is improved by giving priority to younger patients and those least 
severely ill, when compared to the policy that was in place at the time.   
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The main limitations of the LiverSim model, are: 
- Only two liver diseases were considered (alcoholic liver disease and primary 
biliary cirrhosis); 
- Super Urgent patients were not included; and 
- Quality of Life (QoL)/Quality Adjusted Life Years (QALYs) were not 
evaluated. 
Although the two most common diseases (representing 30% of the adult patients 
who joined the UK liver transplant waiting list between 1999 and 2002) were 
considered these are not necessarily representative of the less common diseases, 
in terms of costs.  Super Urgent patients are also important since they take 
priority over other patients and generally incur substantial ICU costs over a few 
days pre-transplant.  QoL/QALYs are also important for use in establishing the 
cost-effectiveness of Liver Transplantation, since QALYs are a standard 
measure used to evaluate the benefit of treatment by NHS/DoH, therefore 
considering ICERs alone is not sufficient (Austin 2007). 
 
A later study by Longworth et al. (2003) considered midterm cost-effectiveness 
in terms of the costs per QALY.  Again they only considered a limited number 
of liver diseases (those for which prognostic models were available: primary 
biliary cirrhosis (PBC), alcoholic liver disease, and primary sclerosing 
cholangitis (PSC)).  The disease groupings investigated represented 37% of the 
patients who joined the UK liver transplant waiting list between 1999 and 2002.  
They found that PBC and PSC were cost-effective, however, alcoholic liver 
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disease was less cost-effective, in part due to the higher number of alcoholic 
liver disease patients assessed for each transplant. 
 
Renal Transplant Matching Models 
In the USA, the UNOS Kidney Allocation Model (UKAM) (Taranto et al. 2000) 
is a model that is being developed following the success of ULAM.  The 
motivation in developing UKAM was to enable the evaluation of various 
cadaveric kidney and kidney-pancreas transplant allocation policies.  The model 
is very similar to ULAM but has been developed to take into account the main 
differences between the two systems, such as the use of dialysis to treat patients 
awaiting a transplant.  A Markov transition matrix has been constructed to 
model how a patient’s sensitivity to donor antigens changes during the time they 
spend on the waiting list.  The authors’ hope is that UKAM like ULAM will be 
able to provide a means of helping people navigate through the complex issues 
involved in the allocation of donated kidneys. 
 
Another model in the USA that compares various kidney transplant allocation 
policies has been developed by Zenios et al. (1999; 2000). They used Monte 
Carlo Simulation to measure the relative equity of policies across different age, 
gender and ethnic groups; while considering the relative efficiency of different 
policies in terms of patient survival and quality-adjusted life expectancy.  The 
model also incorporated HLA matching rules and blood group compatibility 
between patients and donors.  An area where the model could be made more 
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robust is in identifying factors which influence mortality on the waiting list and 
in graft survival post transplant. 
 
Key Components to Define as Identified from Previously Developed Transplant 
Matching Models 
From the previously developed transplant matching models, three areas have 
been identified that require defining and modelling in order to capture the 
current liver transplant assessment and allocation system and to provide a basis 
for the evaluation of alternative assessment and allocation policies.  These are: 
(1) The identification of suitable measures for comparison between policies; 
(2) The identification of a technique by which to estimate the time a patient 
remains in a particular state; and 
(3) The identification of a methodology by which to model patient progression 
through the system. 
These areas are discussed over the next three sections and appropriate 
Operational Research (OR) and Statistical methodologies, and their strengths 
and weaknesses are evaluated.  Examples of where the methodologies have 
previously been used within health services are also outlined. 
 
2.3 Identifying Suitable Model Outcomes  
Liver transplantation is the only treatment available for End Stage Liver Disease 
(ESLD) and as already identified there is a shortage in the number of donated 
livers with respect to the number of patients requiring liver transplants (Section 
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1.2.5).  The challenge for clinicians when choosing an allocation policy for 
donated livers is to yield the best patient outcomes (be the most effective), while 
being fair to all patients (encouraging equity amongst all patient groups) (UK 
Transplant 2005b). 
 
2.3.1 Equity (Fairness) 
Equity measures convey the overall fairness of the liver allocating system in 
allocating livers across different patient groups.  To ensure equality and fairness, 
everyone should have equal access to organ transplantation (Douglas 2003). 
 
Neuberger et al. (1998) found that members of the public are willing to 
exchange an overall reduction in the efficiency of the transplantation system for 
a fairer or more equitable means by which to allocate donated livers to patients 
on the waiting list.  The American Medical Association has defined certain 
criteria by which it is unacceptable to select patients for organ transplantation 
(Douglas 2003), which aid to ensure equity amongst the different patient groups.  
These are:  
(1) Ability to pay; 
(2) Contribution of the patient to society; 
(3) The behavioural contribution of the patient to his or her medical condition; 
and 
(4) The past use of medical resources. 
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In the UK there are no formal rules, however, the selection protocols for liver 
transplantation have been designed so that they should not discriminate against a 
patients’ assessment for transplantation by any of the above points (Section 
1.3.4). 
 
Equity measures may be represented in various ways (e.g., as waiting times, or 
the percentage of patients transplanted within groups), across a range of 
categories (e.g., disease type, geographical region, gender, age, ethnicity) 
(Pritsker et al. 1996).  The figures obtained for each equity measure must be of 
comparable magnitude across all groupings to resemble a fair policy.  For the 
system to be fair, it has to be fair at every stage: 
(1) Falling ill to referral - which patients are referred to the liver units by their 
General Practitioners; 
(2) Referral to joining the waiting list - which patients are judged suitable for 
transplantation; 
(3) Waiting list to transplant - which patients are allocated a donated liver; and 
(4) Transplant to re-listing - which patients from those that require another 
transplant, are actually re-listed. 
 
Equity in the first of these stages is often the hardest to evaluate since the 
number of patients who are referred to a liver unit may only represent the tip of 
the iceberg, and there may be very little information available about patients 
who are never referred (as discussed in Section 1.2.4). 
 
  
Literature Review 
 
48 
2.3.2 Utility (Effectiveness) 
Utility measures help us to determine the overall benefit gained under a 
particular allocating system (UK Clinical Ethics Network 2004). 
 
Surveys have shown that most physicians who perform transplants believe that 
patients should be treated solely on their capacity to survive and benefit, 
regardless of the cause of their organ failure (Ghent 1996; cited by Douglas 
2003).  Neuberger et al. (1998) confirmed that doctors and gastroenterologists 
regard utility as a key driver when allocating donated livers. 
 
Neuberger (2003), argues that selection of patients for listing should be based on 
utility.  He acknowledges that there are discriminatory factors with applying a 
utility based approach, he however argues that these are acceptable because they 
are based on objective and validated risk factors.  Examples are given to indicate 
why allocation should not necessarily be ‘fair’, when determining the most 
efficient allocation policy.  These include:  
- A 70-year-old is less likely to receive a graft than a similar 40-year-old; not 
because of their age but because older age is associated with a worse 
outcome (Garcia 2001; cited by Neuberger 2003); and  
- An alcoholic person or drug user with ESLD may not be offered a liver 
transplant; not because of why they developed liver disease but because 
there is a good chance that they will not comply with post-transplant 
treatment, leading to a recurrence of liver disease. 
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Since there is no alternative treatment to liver transplantation for ESLD, an 
appropriate utility measure to assess the total benefit gained under a particular 
policy is the total Life Years (LYs) gained.  The LYs gained represents a 
straightforward measure of the increase in survival under a certain policy, and is 
obtained from the calculation below: 
ransplant) without te(death tim-                                   
)transplant-post e(death tim                      
LYs)in gain (



 
where E(x) is the expected value of x. 
 
The calculation of Quality Adjusted Life Years (QALYs) (Davies et al. 2003), 
normally provides a better indication of the actual use and impact of the 
healthcare resources but it requires collection of years of Quality of Life (QoL) 
data.  It becomes more relevant when modelling the renal transplant system, as 
patients receiving dialysis can survive for some time without transplant, but 
experience a relatively poor quality of life.  QoL is, however, a very subjective 
measure and would not necessarily provide a reliable means of finding the 
“best” policy, for patients with ESLD. 
 
Process and outcome utility measures include the total costs incurred; the 
number of transplants performed; the number of donated organs that are wasted; 
and the number of patients to benefit from transplantation, or to suffer from graft 
rejection, or recurrence of liver disease.  Utility measures indicate the overall 
impact of the policies and are designed to capture the overall effect that 
transplantation or non transplantation has.  Again, to identify the true 
effectiveness of the liver transplantation system, utility measures must be 
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monitored at all stages, to identify the end outcomes of all the patients that could 
benefit from a liver transplant. 
 
2.3.3  Balancing Equity and Utility 
There are several concerns in using equity and utility measures.  Normally, 
creating equity between patients will not maximise the utility of donated liver 
organs, and vice versa (Bleichrodt et al. 2004; Sassi et al. 2001).  Therefore, 
there may be a need to balance these measures against one another.  It is also 
important to take into account the opinions of different stakeholders within the 
liver transplantation system as they will have their own views about how 
patients should be prioritised (as discussed in Section 1.4.3). 
 
2.3.4 Previous Transplant Matching Studies 
Of the previous models, those concerned with effectiveness and cost-
effectiveness tend to only consider utility measures.  For example, LiverSim 
(Eldabi et al. 2001) considers the average LYs gained and the average costs for 
both the transplant and non-transplant processes (through the calculation of 
ICERs), and Roberts (1992) considers the average life expectancy of the patients 
under varying selection criteria in order to find the optimal time at which to 
transplant and hence utilise the donated livers most effectively. 
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The Pittsburgh model (Kreke et al. 2002a) measures QALYs, the costs spent on 
ESLD, the number of patient deaths while waiting, the average waiting time, and 
the number of wasted organs. 
 
Zenios et al. (1999) include similar outputs (patient survival, QALYs, waiting 
time to transplant, and likelihood of transplantation) and considers them by 
selected patient groupings (ethnicity, gender, age less than or greater 50 years 
old).  Zenios et al. (2000) consider the equity-utility trade-off in kidney 
transplantation and analyse how this trade-off can be alleviated. 
 
All the other models also investigate both equity and utility.  Howard’s model 
(2001) contains a utility measure which is based on the loss of health 
transplanted patients experience which he defines as the difference between the 
actual 3-month graft success rate and the 3-month graft success rate if the patient 
were transplanted immediately after listing.  He defines an inequitable policy as 
one in which patients listed in one health state receive a much greater probability 
of receiving an organ than patients listed in other health states. 
 
The liver transplant model with the most comprehensive equity and utility 
outputs is ULAM (Pritsker et al. 1996).  Within ULAM; medical, patient and 
system outputs are evaluated and compared between policies as outlined in 
Table 2.1.  UKAM (Taranto et al. 2000) contains a similar range of both equity 
and utility measures. 
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Table 2.1 Measures present in the output module of ULAM (Pritsker et al. 
1996). 
Type of 
Measure 
Measure 
Equity 
Total (non-repeating) transplants 
Probability of receiving a transplant (once on waiting list) 
Waiting time distribution from joining waiting list to transplant 
Probability of dying from the waiting list 
Waiting list size through time 
Utility 
Total (non-repeated) transplants 
Total other patients removed or died on waiting list 
Percent of transplanted patients that survive 
Total patients re-listed 
Size of the end waiting list 
Gain in Life Years (LYs) 
 
Many of the previous models have concentrated on measuring the effectiveness 
(utility) of the system in using the donated livers, however, a few studies have 
also considered the equity-utility trade-off, to varying extents.  The equity-utility 
trade-off is important within the UK liver transplantation system since most 
transplants are provided through the NHS and so there is a need that all 
taxpayers should receive an equal chance of transplantation, as well as a need to 
provide value for money (maximising utility). 
 
2.4 Estimating the Time Spent in a Particular State 
We need to identify a technique which allows us to estimate how long a 
particular patient will spend in a certain state before progressing to another state.  
The estimation of times is a key aspect of the modelling of the liver 
transplantation system.  It will determine the rate at which people die from the 
waiting list and the rate at which patients are re-listed post-transplant.  A 
realistic representation of the liver transplant waiting list is crucial to the 
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accuracy of the model and in ensuring that the allocation policies are 
implemented correctly.  Being able to estimate the expected times to both pre-
transplant events (such as death) and post-transplant events (such as death and 
graft failure5) will also enable us to calculate the additional life years gained by 
a patient from receiving a transplant. 
 
The most appropriate statistical inference techniques for this purpose are 
survival analysis or competing risks analysis.  Survival analysis and competing 
risks analysis concern the modelling of data where the variable of primary 
interest is the time interval (T) between some specified origin and an event of 
interest occurring.  Table 2.2 outlines the events of current interest and the 
corresponding origins. 
 
Table 2.2 Events of Interest within the Liver Transplantation System and the 
Corresponding Times of Origin. 
Event of Interest Time of Origin 
Death or Removal from the waiting list Time joined the waiting list 
Death or Graft Failure post transplant Time of transplant 
Re-listing post transplant Time of transplant 
 
Survival data cannot be modelled through common statistical procedures used in 
data analysis (Collett 2003), such as linear and multiple linear regression, 
because: 
(A) Survival times are generally not symmetrically distributed.  Data will tend to 
be positively skewed, i.e., if a histogram of times is plotted it will have a 
longer “tail” to the right of the mode than to the left; and 
                                                 
5 Graft failure is when the implanted graft (here the transplanted liver) becomes damaged and 
stops functioning.  As a result the patient will die within a day. 
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(B) Survival times are frequently censored (not observed exactly).  For example, 
when considering the outcome of “death or removal from the waiting list”, 
not all the patients who will experience this outcome will be observed to do 
so within the observation period of the study.  Some will go on to experience 
death or removal after the study has stopped gathering data.  This type of 
censoring is called right-censoring - the true survival time is “to the right of” 
(greater than) the time for which the patient was followed-up.  Other reasons 
for having to censor data include patients being lost to follow-up or when the 
cause of death is unclear. 
 
There are several types of models which exist in survival analysis and each 
make different underlying assumptions.  The simplest models assume the 
Proportional Hazards (PH) assumption and where this assumption does not hold, 
Accelerated Failure Time (AFT) models need to be considered.  The PH 
assumption implies that if viewed across time, one patient will always be  
times more likely to experience a particular event than another patient.  The AFT 
assumption implies that the chances of one patient’s survival diminishes   times 
faster than that of another patient.  Both types of model are discussed in more 
detail below, in Sections 2.4.1 and 2.4.2, respectively. 
 
One important assumption that all survival analysis models make is that the 
censored times for a particular event occur at random (i.e., the censored times 
are not due to a common cause) (Collett 2003).  This assumption may not apply 
in the current situation, when modelling the time until death from the waiting 
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list.  In this case, all patients who received a transplant and all those removed 
from the waiting list would have to be censored at the time that these events 
occurred.  However, both events, particularly removals, are likely to be 
dependent on the health of the patient – which is likely to be relatively poor.  
Moreover, they are both likely to be dependent on the patient’s time to death – 
the event we are trying to model.  In this case a more appropriate technique 
would be Competing Risks modelling (Hutton and Hemming 2006).  Competing 
Risks (CR) modelling allows for the above aspects to be taken into account and 
enables several events to be modelled at the same time, meaning that the 
assumption about independence of events does not need to hold.   
 
General Forms 
For all forms of survival and competing risks modelling we have the option of 
developing non-parametric models and parametric models, to capture the 
underlying survival times.  Parametric models are more efficient when 
embedded in a simulation model and are preferred over non-parametric models. 
 
Ideally we want to model the distribution of survival time, T, as a function of 
several explanatory variables (patient, donor and system characteristics, as 
appropriate).  Both survival models and competing risks models allow for this 
type of inference.  The techniques that are used in selecting covariates for both 
types of model are similar to those used in linear regression and are described in 
Section 3.6.3 [B] (Collett 2003). 
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Definitions in Survival Analysis 
When summarising survival data, there are four functions that are of interest: 
(1) The distribution function, )(tF , which describes the probability distribution 
function of the survival times. 
 
(2) The survivor function (survival function), S(t): 
)(1)()( tFtTPtS  ,    (2.1) 
which is the probability that an individual survives beyond time t .  )(tS  exists 
for non-negatives values of time, t , is a continuous non-increasing function, and 
1)0( S . 
 
(3) The probability density function, f(t): 
dt
tdS
dt
tdF
tf
)()(
)(   
which represents the underlying distribution of the random variable T. 
 
(4) The hazard function, h(t): 
t
tTttTP
ttS
tf
th



)|(
0
lim
)(
)(
)(


   (2.2) 
which tells you how likely the event is to occur at (or around) a particular time 
t , given that the event has not occurred before then. 
 
Kaplan-Meier Estimate 
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The Kaplan-Meier Estimate provides a non-parametric version of the survival 
function.  To obtain the Kaplan-Meier estimate a series of time intervals is 
constructed such that one death time is contained in a particular interval and this 
death time is taken to occur at the start of the interval (Note: More than one 
death may occur at the start of a particular interval). 
 
The Kaplan-Meier Estimate, )(ˆ tS , of the survival function is then given by: 









 

k
j j
jj
n
dn
tS
1
)(ˆ     (2.3) 
where jn  = the number of individuals who are alive just before time t(j)  
(including those who are about to die at this time), 
jd  = the number who die at this time. 
 
A large amount of computer space and processing would be required to use the 
Kaplan-Meier estimate for sampling purposes.  However, plotting Kaplan-Meier 
estimates can give an indication of the underlying distribution of the survival 
functions, and this provides a useful way of comparing survival between 
different groups.  More detail about Kaplan-Meier estimates and an example of 
its application are provided in Appendix D.  
 
The observed hazard function can be used to determine which statistical 
modelling technique is the most appropriate to use.  The appropriate survival 
model for various forms of the hazard function are summarised in Appendix E. 
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2.4.1 Proportional Hazard Models 
Basic Definition 
The Proportional Hazards (PH) assumption implies that one patient will always 
be   times more likely to experience a particular event than another patient.  
This is true of the hazard rates for patients j and k in Figure 2.1 below. 
time, t
h
a
z
a
rd
, 
h
(t
)
h0(t)
hk(t)
hj(t)
 
Figure 2.1 Hazard functions depicting the proportional hazards assumption. 
 
Method 
The PH model (Cox regression model) is the most general survival regression 
model because it is not based on any assumptions concerning the nature or shape 
of the underlying survival distribution.  The model assumes that the underlying 
hazard rate is proportional to various combinations of the independent variables 
(covariates) (Forster 2004).  The hazard function, )(thi , for some individual, i, 
with a set of explanatory variables defined as 
T
ipii xx ),...,( 1x can therefore be 
expressed by the following equation: 
)()exp()( 0 thth
T
ii x     (2.4) 
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where Tp ),...,( 1    is a vector of regression coefficients and )(0 th  is called 
the baseline hazard function. 
 
The most commonly used parametric versions of the PH model use Exponential, 
Weibull and Gompertz distributions to describe the survival time distributions.  
Non-parametric versions of the PH model can also be created; these assume that 
the baseline hazard function, )(0 th , is non-parametrically modelled. 
 
Advantages and Disadvantages 
Authors like to use proportional hazard models because the base distribution is 
the same for all the covariates, and the risk over time changes between 
covariates by a constant factor.  This allows for clearer assertions to be made 
(e.g., a patient with characteristic A will always be 3 times more likely to die 
than a patient with characteristic B) and a clear method of application.  Another 
advantage of the proportional hazard model is that no functional form is 
imposed on the baseline hazards (Ahn 1994).  This is very useful, especially in 
situations where the hazard function fluctuates a number of times.  Proportional 
hazard models are easily fitted, as routines exist in many standard statistical 
packages (Goldstein and Harrell c.1996). 
 
A disadvantage arises in that relatively few probability distributions are 
available for the modelling of survival times within the proportional hazards 
modelling approach (Collet 2003), and the distributions that are available require 
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the hazard function to increase or decrease monotonically6.  There are however, 
numerous situations in which it is expected that the hazard function will change 
direction.  For example, following a heart transplantation a patient faces an 
increasing hazard of death over the first ten days or so after the transplant, while 
the body adapts to the new organ and medications.  The hazard then decreases 
with time as the patient recovers.  Another disadvantage is that the model 
assumes that there is always a constant proportional difference between the 
hazards experienced by two individuals (e.g., patient i will always be   times 
more likely to experience death, compared to patient j), which may also be an 
unrealistic assumption. 
 
Examples 
Proportional hazards modelling has been used in a number of situations, ranging 
from reliability applications to healthcare applications. 
 
Crowley and Hu (1977) were one of the first to use survival analysis techniques 
that incorporated several covariates in approximating post heart transplant 
survival.  They considered the following covariates and created an exponential 
PH model to predict post transplant survival, (factors found to be significant are 
marked by an asterix): 
– Transplant status *; 
– Waiting time to transplant; 
– Calendar time of transplant; 
                                                 
6 A monotonic function is one which is either strictly increasing or decreasing (i.e., does not 
change direction). 
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– Age at acceptance onto the waiting list; 
– Age at transplant *; 
– Previous open-heart surgery *; and 
– Three measures relating to the tissue match between patient and donor *. 
From this they were able to produce estimates for relative risks between groups 
and concluded that heart transplantation can prolong survival for certain younger 
patients if a suitably matched heart can be found. 
 
Sohn et al. 2007, developed a Weibull survival model to help analyse the 
characteristics of employees who have longer occupational lifetimes (the length 
of time spent working for the same company).  Their findings were that 
employees with the following characteristics had relatively longer occupational 
lifetimes: 
- Those at the managing director level; 
- Those who are relatively old; 
- Those who entered the company earlier; 
- High school graduates; 
- Those who were involved in technical service; and 
- Those married to female employees. 
 
Kandinov et al. 2006 implemented the proportional hazards approach to evaluate 
the effect of cigarette smoking, tea and coffee consumption on the progression 
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of Parkinson’s disease, and found that these variables do not have an effect on 
modifying the disease in patients already diagnosed. 
 
2.4.2 Accelerated Failure Time Models 
Basic Definition 
The Accelerated Failure Time (AFT) assumption implies that although the shape 
of the survival curves are similar, one patient (patient i) will move along the 
survival curve   times faster than another patient (patient j), as depicted in 
Equation (2.5). 
 0 allfor  )()(  ttStS ji     (2.5) 
 
Method 
AFT models allow for non-monotonic hazard functions.  They are less 
restrictive than PH models as they do not enforce the proportional hazards 
assumption, and the need for a monotonic underlying hazard function (Collet 
2003).  AFT model do, however, assume the same underlying survival curve for 
every patient and the only thing that differs is the speed at which the patient 
travels along the curve.  In order to describe the underlying survival times there 
are several parametric forms of accelerated failure time models which are often 
suitable.  These include: Weibull, Log-Logistic, Lognormal, Gamma and Inverse 
Gaussian.  Note that for Weibull, PH and AFT are the same. 
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Advantages and Disadvantages 
AFT models can cope with hazard functions changing direction, capturing both 
the increasing hazard in the days immediately following a heart transplant, and 
the decreasing hazard thereafter.  Again many standard statistical packages 
include functions by which to fit AFT models (Goldstein and Harrell c.1996).  
AFT models take on parametric functions to describe the underlying survival 
times.  For most of these functions is it relatively straightforward to perform 
Monte Carlo sampling in order to generate times by when a certain patient will 
experience a particular event within a simulation model.  However, the 
interpretation of AFT models is less straightforward than for PH models. 
 
Examples 
Aitkin et al. (1983) considered data from the same transplant centre as Crowley 
and Hu (1977), their main aim being to determine whether survival improved for 
those who received a transplant compared with those who did not.  They noted 
that the hazard of death initially increases post transplant for about 60 days and 
then declines after this.  They too modelled survival time as a function of 
patients’ attributes and transplant status but found the proportional hazards 
assumption was not satisfied by the data and so chose to fit AFT models instead.  
They compared various AFT models to those previously developed by Crowley 
and Hu and Kalbfleisch and Prentice (cited by Crowley and Hu 1977).  They 
found that the underlying hazard function fitted more closely to the AFT models 
(lognormal, Weibull, piecewise exponential) than to the proportional hazards 
model established by Crowley and Hu (1977), previously.  They also concluded 
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that the immediate short-term effect of heart transplant on survival was to 
increase the hazard, especially for older patients, however, the estimated long-
term hazard appeared much lower for all patients post transplant.  Their findings 
about different patient characteristics were that: 
– Younger patients who received a transplant survived longer, especially those 
entering the program at an early stage; 
– Age is significant as it affects survival post-transplant, but not pre-transplant; 
– Calendar time is important because the pre-transplant survival improved 
markedly during the first 6 years of the program (which the data covered).  
This can largely be accounted for by improvements technology, transplant 
techniques/skills and practice; and 
– Waiting time was found to be important because a declining hazard pre-
transplant indicates a better prognosis for patients who have survived the 
initial waiting period. 
 
Aitkin et al. (1983) were able to fit lognormal survival models to patients 
survival times, pre- and post-heart transplantation.  Their aim in developing 
these models was to assess the effect of a heart transplant on the number of years 
a patient lived.  However, they were unable to make any conclusive statements 
as they lacked information on the longer term survival of the non-transplanted 
group. 
 
Lambert et al. (2004) managed to show that parametric accelerated failure time 
models can also capture in detail patient survival following kidney transplant. 
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2.4.3 Competing Risks Model 
Basic Definition 
Competing Risks (CR) can be used to model a situation where there is more than 
one type of outcome (e.g., there are a discrete number of possible causes of 
death) (Crowder 2001; David and Moeschberger 1978). 
 
Method 
The proportional hazards assumption described in Section 2.4.1 can be applied 
to CR models, by taking on a non parametric or Weibull baseline hazard 
function.  Alternatively, CR models may also apply the AFT assumption 
(Section 2.4.2) by inferring non parametric, Weibull, Log-Logistic, Lognormal, 
Gamma, or Inverse Gaussian, forms for the survival function. 
 
In CR the hazard function ),( tjh  for cause j  is: 
t
tTjCttTP
t
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tjf
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where  T  = the time to failure, 
 C  = the cause of failure, 
 j  = the cause (1...p), 
)(tS  = the overall survival function, 
),( tjf  = probability distribution function of survival times to event j . 
 
and the overall hazard function is given by: 
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
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A simple test using the definition of the hazard function (which does not account 
for any type of censoring) as given in Equation (2.8), can help to determine if 
the censored times are independent of the cause.  For a particular outcome i the 
hazard rate is defined as: 
N
tn
tE ii
)(
)(       (2.8) 
where  i = the occurring event, 
ni(t) = the number of events of type i that occurred at time t, 
N = the total number of patients observed. 
 
Equation (2.8) is used to plot curves for each of the censored events that may 
occur (Hemming and Anzures-Cabrela 2006).  For example, if we wish to model 
the time between a patient joining the waiting list and the patient’s death, then 
we need to plot the hazard rate curves for the times which will need to be 
censored: (1) time to removal, (2) time to transplantation, and (3) time to 
suspension.  If these curves are all of a similar shape and size, then the times to 
be censored are independent of cause and survival modelling is appropriate.  If 
the curves differ in shape then each event needs to be modelled as an outcome 
and a competing risks model is more appropriate. 
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Advantages and Disadvantages 
CR models are not commonly developed and do not appear in standard 
statistical packages.   
 
CR models do not require the censored data to be independent from anything 
which causes them to be censored.  If there is a specific cause of censoring then 
this can be included in the CR model as a separate event.  This means that the 
overall estimates produced are less prone to bias caused by censored events.  
 
Examples 
Competing Risks models have been identified as an appropriate methodology 
for modelling many different aspects of reliability (Bedford), including the 
modelling of failure for two or more independent risks.  Bailey et al. (2003) 
describe competing risks as an appropriate way in which to model the competing 
events which occur in the transplantation process: transplantation, death while 
awaiting the transplant, removal for other reasons, and death post-transplant.  
They stressed the need to consider these events in combination, rather than in 
isolation or one at a time.  
 
2.4.4 Previous Transplant Matching Studies 
Many of the previous transplant matching models have used survival models in 
varying degrees to approximate times to death (pre- and post-transplant) and 
graft failure post-transplant, a few of the most relevant are outlined below. 
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ULAM (Harper et al. 2000) uses non-parametric survival curves to estimate 
post-transplant mortality.  These are stratified by a patient’s medical urgency 
status at transplant, their previous transplant status, and the transplant centre 
volume. 
 
The Pittsburgh model (Kreke et al. 2002a) also makes use of non-parametric 
survival distributions to approximate both the time to graft failure and death 
post-transplant.  They implement Cox models based on the biological 
characteristics of the patient, the quality of the graft (transplanted organ) and 
patient-graft interactions at the time of transplant. 
 
Eldabi et al. (2001) use prognostic models, which employed Kaplan-Meier 
techniques, in estimating survival with and without transplant which have been 
developed by Huges et al. (1992) for primary biliary cirrhosis and Anand et al. 
(1997) for alcoholic liver disease.  They sampled appropriate survival times, 
based on the patient attributes captured in each of the models (Anand et al. 
1997; Eldabi 2000; Huges et al. 1992) 
 
Zenios et al. (1999) estimate the survival of patients on the waiting list by using 
constant hazard rate models split by age, sex and race.  They estimate post-
transplant graft and patient survival by using Kaplan-Meier techniques which 
are based on readily attainable covariates.  These include covariates relating to: 
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– The patient (age, sex, race, height, weight, blood type, tissue type, diabetes, 
primary or repeat transplant, number of pre-transplant blood transfusions, 
peak and current panel reactivity, functional status); 
– The donor (age, sex, race, blood type, tissue type, cause of death); and  
– The transplant operation (kidney cold ischemic time). 
 
2.5 Modelling Patient Progression Through a System 
The different stages of a transplant system can be seen as a series of states which 
the patients progress through.  There are two very different approaches that can 
be taken when modelling patient progression through a system: 
(1) Mathematical Modelling – Decision Trees; Markov models; and 
(2) Simulation of the system – System Dynamics (SD); Discrete Event 
Simulation (DES). 
Both have their advantages and disadvantages and various studies which assess 
their advantages and disadvantages have been performed (Barton et al. 2004; 
Cooper et al. 2006; Cooper et al. 2007; Karnon 2002). 
 
Decision Trees capture the different routes through the system, the probability of 
progressing down each of them, and the associated costs.  By evaluating the 
decision trees it is possible to determine the probability of experiencing different 
outcomes, and the cost value of the outcomes.  Cooper et al. (2007) found that 
decision trees were most commonly used to model short term interventions (e.g., 
diagnostic tests, thrombolysis and revascularisation).  Markov models are based 
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on a similar concept, but with a time element to them; describing the probability 
of entities progressing from one state to another during a fixed time period.  The 
evaluation of Markov models can yield the average time spent by entities in each 
state; and the associated costs and benefits of these (Cooper et al. 2007).  
Cooper et al. (2007) found that Markov models were commonly employed when 
considering long term interventions (e.g., statins and other drugs). 
 
Simulation modelling can also take into account resource constraints in the 
system; along with any interaction between entities and resources.  They are 
flexible techniques, modelling large periods of time very efficiently – a problem 
for Markov models.  They can deal with variability, uncertainty, and can help to 
facilitate communication with, and comprehension by, healthcare professionals 
through the use of graphical interfaces (Brailsford and Hilton 2001).  Two 
commonly implemented simulation techniques within healthcare are System 
Dynamics (SD) and Discrete Event Simulation (DES).  Several studies attempt 
to compare various aspects of SD and DES methodologies.  These papers 
highlight technical differences (Brailsford and Hilton 2001), conceptual 
differences (Lane 2000), and key differences in SD and DES approaches to 
problem solving (Morecroft and Robinson 2005). 
 
The rest of Section 2.5 reviews the three techniques commonly applied to health 
care systems where costs are not the main emphasis – Markov Models, System 
Dynamics and Discrete Event Simulation.  Their strengths and weaknesses are 
discussed, and examples of their use are provided. 
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2.5.1 Markov Models 
Method 
Markov processes are probabilistic models which form a special category of 
stochastic processes.  Under this technique, events are modelled as transitions 
from one health state to another over a fixed time period.  The transitions are 
determined by conditional probabilities and patients progress through the 
differing states until they reach an absorbing state, for example, death. 
 
A key property of Markov processes is the memory-less property, i.e., the 
probability that the random variable Xt takes a particular value xt depends only 
on xt-1 and not the previous values xt-2, xt-3, …, x0.  With regard to the 
transplantation system, this means that a patient’s transition from one state of a 
disease to the next state depends only on the current state occupied and not on 
the previous history of the patient. 
 
Advantages and Disadvantages 
The memory-less property is unrealistic in the context of liver disease since a 
patient’s medical history is likely to influence their future disease progression 
(e.g., re-listed patients may experience significantly different outcomes to those 
listed for their first transplant, and Markov models would not be able to 
incorporate this).  Markov models also use fixed time cycles, which can lead to 
problems.  If the time cycle is long compared with the frequency with which 
events occur then individual events cannot be captured at the exact time that 
they occur (Sonnenberg and Beck 1993).  If shorter time cycles are used, then 
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time taken to process the model will be that much longer.  This means that 
Markov models tend to be more useful for events that take place over long 
periods of time (Karnon and Brown 1998).  They are also more effective when 
the hazard rate remains the same over time (Sonnenberg and Beck 1993).  When 
looking at liver transplants, however, the chances of experiencing complications 
post transplant is much higher straight after the operation, and reduces thereafter 
(Collett 2003). 
 
Semi-Markov models solve some of the issues raised above.  They allow for 
extra states to be included in order to capture changes in risk over time.  For 
example, one way to model changing risks would be to introduce two post 
transplant states.  This of course assumes that there are two distinct states, with 
measurable risk levels associated with each.  They can also be applied over 
varying time cycles, but the more states that are used, the more complex the 
model becomes, and the longer they take to evaluate. 
 
Markov and Semi-Markov models are useful when considering simple chronic 
and long-term interventions and where the patients within the cohort under 
observation follow similar transition probabilities (Cooper et al. 2007).  For 
these problems, such models are reasonably fast to run, are intuitive in their 
conception and can be very powerful for helping to enhance understanding of 
the systems that they model.  As more and more assumptions are made about a 
system, the complexity of the Markov models can increase rapidly; becoming 
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very dense and losing transparency.  Markov models can also be difficult to 
adapt to capture different scenarios. 
 
Examples 
Markovian methods have been applied in modelling various issues which 
emerge in healthcare.  These include:  
– Considering the progression of patients through intensive care units (Kapadia 
et al. 2000); 
– Identifying the number of patients who are likely to enrol for a clinical trial 
(Felli et al. 2005); and 
– Modelling the progression of coronary heart disease patients through various 
stages of their illness (Cooper et al. 2007). 
 
2.5.2 System Dynamics 
Method 
System Dynamics (SD) is a deterministic technique that takes a holistic 
approach to modelling complex systems through a series of causal loops, which 
incorporate elements of feedback in the system.  A simulation model is created 
to capture the flow of entities through the system over time, and this can be used 
to assess the overall impact of different policies.  Mathematically, a SD model is 
made up of several sets of difference equations which attempt to define the 
flows between the stocks (e.g., to capture patient flows within the system), 
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where state changes are modelled as being continuous (Brailsford and Hilton 
2001). 
 
Advantages and Disadvantages 
SD models combine both qualitative and qualitative techniques, and hence can 
capture various aspects of complex systems through the use of descriptive or 
judgemental information (i.e., expert opinion) as well as numeric data 
(Brailsford and Hilton 2001; Lattimer et al. 2004).  This can also help in making 
the models understandable to a wider audience.  By modelling feedback loops in 
the system they can incorporate highly dynamic relationships between different 
elements of the system, which are often ignored when specific processes are 
studied (Morecroft and Robinson 2005).  As a result they are useful tools for 
developing an understanding about the entire system and are often used on a 
strategic level for evaluating the impact of different policy options (Brailsford 
and Hilton 2001; Lattimer et al. 2004; Morecroft and Robinson 2005). 
 
SD concentrates on stocks of entities, rather than on modelling each individual 
separately.  This does remove some of the complications when estimating the 
different parameters involved, particularly with regard the amount of data 
required to achieve this and the level of validation required.  On the downside, 
this does also place restrictions on the usefulness and accuracy of the models.  In 
particular, there is no way of evaluating how polices impact on specific 
individuals, or the length of time they spend in particular states (Lattimer et al. 
2004).  The complexity of the models is often limited by the complexity of the 
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difference equations at their heart, which can become unsolvable (Pidd 1992).  
SD does also lack the flexibility of other simulation techniques, particular in its 
modelling of the dwelling time in each state (Brailsford and Hilton 2001).  Any 
simplifications made will ultimately impact on the mathematical accuracy of the 
results (Lattimer et al. 2004). 
 
Examples 
Evenden et al. (2005) created a system dynamics model to investigate the cost-
benefit associated with screening intervention for the Chlamydia infection.  
They observed three patient groups – those susceptible to Chlamydia, those 
infected with Chlamydia, and those susceptible to sequelae (long term medical 
consequences) - and performed cost-benefit analysis to assess the viability of 
providing each group with the screening intervention.  The modelling identified 
that prior infection did not lead to immunity from Chlamydia, hence that re-
infection is a key characteristic in the long-term prevalence of Chlamydia.  They 
were also able to conclude that the damage caused by infection increases the risk 
of sequelae (to up to 20%) and that sequelae costs were considerable.  Risk 
groupings were defined based on the following attributes: transmission event, 
new partnership, and infected partner.  They established that screening provides 
immediate cost benefits for both the high and low-risk groups.  This was 
achieved through a reduction in the number of infections, as well as a long term 
reduction in costs of sequeale. 
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2.5.3 Discrete Event Simulation 
Method 
The aim of a Discrete Event Simulation (DES) is to create a model which 
mimics the behaviour of a real-life system over time.  DES is a stochastic 
technique that allows for the modelling of individual entities through a set of 
logically separate processes (events).  These events can either take place at pre-
arranged times, or the event times can be assigned during the simulation.  DES 
techniques process events in continuous time order by using a future events list 
which maintains a list of all events that are scheduled to take place and the time 
at which each will occur.  In maintaining the future events list and using it to 
identify the next event to occur, DES models generally run more slowly than 
Markov models and SD models (Pidd 1992). 
 
Advantages and Disadvantages 
The key element that DES offers over SD is the ability to model systems at an 
individual level (Barton et al. 2004).  This enables the modeller to capture the 
variability in donors and patients, while recording every event that occurs and 
providing the user with a very detailed set of results. 
 
The main advantages (Law and Kelton 2000; Pidd 1992; Robinson 2004) in 
using discrete event simulation models are that they can be easily understood by 
health planners (especially with the aid of packages that allow creation of visual 
models), they can easily incorporate different stages and various factors, making 
potential models very flexible.  DES imposes no implicit assumptions associated 
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with the methodology and so this adds to their flexibility.  DES models can 
incorporate variability and so lead to a more realistic model.  DES models allow 
for the modelling of very complex scenarios with ease (and does not have to rely 
on equations being solvable).  Once a base model is generated, alternative 
scenarios are easy to code and so the model can investigate many different 
scenarios as well as monitoring a number of outputs.  DES models can 
incorporate both statistics information from expert opinions and can reduce the 
risk of reliance on potentially erroneous or unavailable data.  The models can 
include intangible components and investigation of extremes which could be 
rare but critical.  DES models update the model at times when events occur i.e., 
implement variable time steps, as to when the model is updated and solved and 
so can capture all events when they occur and no detail is lost.  DES models can 
also take into account what happened in previous states very easily which is 
important in healthcare modelling. 
 
There are also a few problems that exist in implementing DES models 
(Brailsford and Hilton 2001; Karnon 2003), which include that the DES model 
has to be run a large number of times for the results to be statistically significant, 
especially when the system under consideration is highly variable.  It can be 
difficult to validate the model, especially where the scenario is complex.  DES 
models require a greater time to develop than Markov and SD models.  If the 
DES model is very complex, then it can be hard to isolate and understand what 
is going on in the model and determine cause and effect relationships.  DES 
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models can take a long time to run; and parameter estimation can be a problem 
and DES models often require vast amounts of data. 
 
Examples 
DES models are widely used in the healthcare context.  Common applications 
include:  
- Assessing the cost-effectiveness of interventions such as screening or 
vaccination (Davies et al. 2003; Rauner et al.  2003); 
- Assessing the benefit of interventions such as screening or vaccination 
(Brailsford et al. 1998; Cooper et al. 2002); 
- Considering the effects of changes in policy (Pritsker et al. 1995; Eldabi et 
al. 2001; Taranto et al. 2000; Zenios et al. 1999); and 
- Projecting future demand for health services (Roderick et al. 2004). 
 
Davies and Roderick (1998) and Roderick et al. (2004) developed a DES model 
to help to predict the future demand for renal replacement therapy in England.  
Their overall findings implied a substantial growth in the renal replacement 
therapy population to 2010 (with an average annual growth of 4.5-6%) with the 
greatest increases within the elderly and those with haemodialysis.  The model 
also showed that a steady state would not be obtained for at least another 20 
years beyond 2010.  The model allows healthcare planners to gain insight into 
future demand and can aid in future resource planning. 
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2.5.4 Previous Transplant Matching Studies 
Markov Models 
Roberts (1992) used Markov models to capture model dying post-liver 
transplant.  He did this by defining probabilities of death for the three stages: 24 
hours, 30 days, and long-term after transplantation.  The probabilities were 
based on factors deemed, by a previous study at Deaconess Hospital, to be 
significant in survival within each of the stages (Roberts et al. 1989; cited by 
Roberts 1992).  These factors are presented in Table 2.3 below. 
 
Table 2.3 Significant clinical factors for survival at differing times after 
transplantation. 
Stage Factors Important for Survival 
24 Hours 
Creatinine 
Prior Right Upper Quadrant surgery 
30 Days 
Creatinine 
Life support 
Long-Term 
Re-transplant 
Crossmatch reaction 
Infection 
Bilirubin 
Malnutrition 
 
Although Roberts (1992) managed to apply Markov techniques to the problem 
area, he notes that the model has yet to produce usable “answers” to the problem 
of the optimal timing of liver transplantation in end-stage liver disease because 
of the lack of adequate data to calibrate the model. 
 
Howard’s model (2001) and the ULAM model (Harper et al. 2000) implemented 
Markov matrices to describe the transitions of patients between UNOS disease 
statuses and the states of removal from the waiting list, death, and temporarily 
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inactive/suspended.  Since there are few disease states (three in Howard’s and 
four in ULAM), the transitions between the states will occur over substantial 
lengths of time, hence Markov modelling was ideal for the limited objectives of 
these studies. 
 
System Dynamics 
None of the models in the literature have implemented SD techniques.  This is 
mainly because they are considering the consequences of decisions made on an 
individual basis - who should be listed for a transplantation; who should be 
allocated a particular liver; how much better off will someone be if they receive 
a transplant - and SD is not able to answer these types of question. 
 
Discrete Event Simulation 
Of the transplant matching studies; ULAM (Harper et al. 2000), the Pittsburgh 
model (Kreke et al. 2002a), LiverSim (Eldabi et al. 2001), UKAM (Taranto et 
al. 2000), and Zenios’ model (Zenios et al. 1999); have all employed DES to 
model patients progressing through the transplantation systems.  DES allows for 
the monitoring of individual patients and hence is more useful than a SD model 
for observing the impact of policy changes that are based on characteristics of 
individual patients.  DES also allows for conditional events (unlike Markov 
models) and the arrival of separate streams of entities, which will be useful in 
defining when a transplant may take place and the arrival of both patients and 
donors into the system. 
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The main limitation of SD which DES overcomes is the granularity of 
interactions that can be observed.  For this current model we wish to consider 
interactions between donors and patients and consider outcomes of individual 
patients.  SD only considers the general flows of patients and donors and not the 
individuals within the system.  SD also cannot allow for matching between 
donors and patients.  DES can consider the general flows, the individual 
interactions, and the criteria by which to match a donated liver to a patient and 
hence is more useful in the current context. 
 
Brailsford and Hilton (2001) and  Barton et al. (2004) acknowledge that the 
decision as to which modelling technique should be adopted depends on the 
purpose of the model (i.e., what sort of questions the model needs to answer).  
SD focuses more on the overall behaviour of certain aspects of a system, while 
DES follows individual patients through the system.  Hence SD models have 
been used to examine strategic decisions, whereas DES models have 
traditionally been applied at tactical, operational levels.  DES also overcomes 
the main limitations of Markov Models, as it can easily incorporate both non-
constant hazards over time and can base outcomes on all prior events. 
 
2.6 Research Objectives and Questions 
Chapters 1 and 2 have identified the key motivations of this thesis.  The aim of 
this research is to study the UK liver transplantation system, creating a model 
based on available clinical and social data with which to explore the impact of 
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different assessment and allocation decisions on various equity and utility 
measures. 
 
It has been illustrated in this chapter how little has been done to explore UK 
liver transplantation allocation rules and to investigate new policies.  No attempt 
has been made to develop a model for the UK which brings together detailed 
survival analysis across all transplantable liver diseases and explores adaptive 
methodologies by which to generate policies.  Some studies have been carried 
out in the US, but these have concentrated on identifying detailed natural 
histories.  The UK system is different in that patients are only placed onto the 
waiting list once their life expectancy falls under a particular level – one year.  
This means that the modelling of disease histories is less important.  The model 
which has been created and described in this thesis considers many of the 
shortfalls in previous models and attempts to develop a model which is suited to 
the UK liver transplant system.   
 
The specific research objectives and questions that this work aims to answer, are 
identified next (in Sections 2.6.1 and 2.6.2, respectively). 
 
2.6.1 Research Objectives 
The research objectives for this work (covering the three aspects, identified at 
the end of Section 2.2.3) are: 
(1) The identification of suitable measures to enable comparison between 
policies; 
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(2) The identification of a technique by which to estimate the time a patient will 
stay in a particular state (events and survival); and 
(3) The identification of a methodology by which to model patient progression 
through the system. 
 
2.6.2 Research Questions 
The research questions this work aims to answer, are: 
 
Suitable Measures to Enable Comparison Between Policies 
‘Can we get a better understanding of whether alternative allocation policies can 
improve both equity and utility, simultaneously?’ 
 
‘Does the complexity of the allocation rules affect the equity and utility 
outcomes?’ 
 
‘Do the policies which improve equity and/or utility, continue to do so as 
demand and supply changes?’ 
 
Estimating Events and Survival 
‘Can we find a parametric distribution using statistical techniques that can be 
sampled from within a DES?’ 
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Patient Progression 
‘Can a simulation answer questions in the UK context about equity and utility 
within the transplant allocation and assessment process?’ 
 
2.7 Summary 
This chapter began by summarising the literature on previous transplant 
matching studies.  Many of the studies are from the USA and although there are 
characteristics in common, these are not directly applicable to the UK 
transplantation systems due to inherent differences in how the two systems 
operate.  Most of the models are not suitable for evaluating different policies as 
they do not capture all the detail that is required.  In order to do this it is 
necessary to: 
– Model outcomes in terms of both equity and utility; 
– Model all patient groups; 
– Identify the likely trends in future demand and supply; and 
– Include the assessment phase within the model. 
 
From the literature search three key areas, which form the research objectives, 
were identified as important aspects for consideration when developing a 
representative model of the liver transplant matching problem:  
(1) The identification of suitable measures to enable comparison between 
policies; 
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(2) The identification of a technique by which to estimate the time a patient will 
stay in a particular state (events and survival); and 
(3) The identification of a methodology by which to model patient progression 
through the system. 
 
The previous transplant matching models have all captured these three elements 
to varying extents.  However, no single project has looked at all three in the 
context of the UK Liver Transplant System. 
 
A review of OR and Statistical techniques commonly employed in healthcare 
applications and which enable the modelling the three key aspects identified is 
presented.  The review includes a discussion of equity and utility measures, 
Survival and Competing Risks models, Markov models, System Dynamics and 
Discrete Event Simulation.  A summary of the advantages and disadvantages of 
using these techniques is given with identification of how the previous transplant 
studies have used them. 
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Chapter 3 
 
Methodology 
 
3.1 Introduction 
This chapter sets out the methodology required to develop the DES model 
(Hepatica) for investigation into the dynamics of the UK liver transplantation 
system, under various assessment and allocation policies.  A list of experimental 
factors and key response measures is given, with a detailed outline of the 
structure of Hepatica.  The chapter ends by summarising the experimental 
design to consider various changes to the current assessment and allocation 
policies. 
 
3.2 Objectives and Choice of Models 
3.2.1 Problem Situation 
It was identified in Chapter 1 (Sections 1.2.5-1.2.6) that the number of patients 
requiring liver transplantation exceeds the number of livers donated and that the 
trends in demand and supply suggest the gap will increase in the future.  As a 
result, it is important to utilise the donated livers in a way which generates the 
best overall patient outcomes, while ensuring that all patients on the waiting list 
have a fair chance of receiving a transplant. 
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Section 1.3.3 established the main parts of the liver transplantation system at 
which policies can be adjusted to influence the outcomes of the system: 
(1) The Assessment Phase (where a patient’s suitability for transplant is 
assessed); and 
(2) The Allocation Phase (when donated livers are allocated to one of the 
patients on the waiting list). 
 
3.2.2 Modelling Objectives 
Hepatica seeks to overcome many of the limitations identified in the previous 
models, in particular: 
- Estimates of future demand and supply (which are detailed in Section 3.3.1 
and 3.3.2); 
- Changes to criteria implemented in the assessment phase (as outlined in 
Section 3.3.3); 
- All liver diseases that can be treated by a liver transplant; 
- Super urgent patients.  This is a significant inclusion as they receive priority 
for liver transplantation; 
- Survival times to be based on key patient, donor and transplant attributes (as 
outlined in Section 3.7.2); and 
- Factors in the system itself which explicitly influence the decision as to who 
is allocated a donor (as described in Section 1.3.5), for example, the location 
of the patient and the donor. 
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The modelling objectives have been discussed in Section 2.6 and are 
summarised below: 
- The identification of suitable measures to enable comparison between 
policies; 
- The identification of a technique by which to estimate the time a patient will 
stay in a particular state (events and survival); and 
- The identification of a methodology by which to model patient progression 
through the system. 
 
3.2.3 Choice of Model 
Chapter 2 identified three key areas which require consideration when 
developing a model of the UK liver transplantation system (Section 2.2.3).  
These are, to identify:  
(1) Suitable measures for comparison between policies; 
(2) A technique by which to estimate the time a patient remains in a particular 
state; and 
(3) A methodology by which to model patient progression through the system. 
The solutions identified are outlined below. 
 
(1) Outcome Measures 
The overall responses considered in Hepatica fall into the two groups of equity 
and utility measures.  These were chosen to enable an assessment to be made 
about how fair a particular policy is in allocating liver transplants across various 
  
Methodology 
 
89 
patient groups, and of how effectively a policy uses the donated livers.  The 
actual measures considered are outlined in detail in Section 3.4. 
 
(2) Estimating the Time Spent in a Particular State 
Survival models or competing risks models are appropriate for capturing the 
times that patients spend in particular states, since the datasets used to develop 
the models will be censored.  Survival analysis and competing risks models 
allow for parametric distributions to be generated, which will allow for the 
development of distributions that can be easily sampled from, and used within 
the DES model. 
 
(3) Modelling of Patient Progression 
Discrete Event Simulation was chosen for the modelling of patient progression 
through the liver transplantation system since it takes into account a number of 
patient attributes, and allows for patient and donor-level modelling. 
 
The DES model will only consider adult patients (those aged 17 and over), as 
the adult patients make up most of the waiting list, and the liver diseases that 
adults suffer from differ considerably from those which children experience. 
 
Hepatica is programmed in Witness as the software provided all of the 
functionality required within the model. 
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Terminology 
Within the rest of this thesis the term scenarios will be used to denote the 
situations considered by each run of the DES model.  Each scenario will 
therefore consist of a set of experimental factors (i.e., current and future demand, 
current and future supply, assessment rules, and allocation rules), which are 
explained in more detail in Section 3.3. 
 
3.3 Experimental Factors/Inputs 
The experimental factors are the elements of the model that can be adjusted 
when considering various scenarios and within the scope of Hepatica they fall 
under the four headings: 
(1) Demand Factors - Adult Patients requiring Liver Transplants; 
(2) Supply Factors - Liver Donations made to Adult Patients; 
(3) Assessment Rule Factors - Patient Eligibility for Receiving a Liver 
Transplant; and 
(4) Allocation Rule Factors - Patient Priority for Transplant and Donor to 
Patient Matching. 
The various factors to be investigated are outlined in detail in the remainder of 
this section. 
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3.3.1 Demand Factors - Adult Patients requiring Liver 
Transplants 
The baseline for the experimental demand factors is the number of patients 
observed to have joined the liver transplant waiting list from 1 January 1999 to 
31 December 2002 (UK Transplant 2004e).  Additional factors have been 
created following work performed by Roderick et al. (2004) (detailed in Section 
1.2.6), which predicted increases in the number of sufferers from Alcoholic 
Liver Disease, Non-Alcoholic Fatty Liver Disease (NAFLD) and Hepatitis C. 
 
For Alcoholic Liver Disease the actual experimental factors used are based on 
the alcohol consumption trends for the years 1974 to 2004 (Institute of Alcohol 
Studies 2006).  Similarly, increases in NAFLD are assumed to follow trends in 
obesity (Zaninotto et al. 2006).  For Hepatitis C, the findings from Roderick et 
al. (2004), are taken to define the three different trends: 2.5-fold, 3-fold, and 4-
fold increase in the number of Hepatitis C sufferers emerging for liver 
transplantation. 
 
Four different demand factors are considered, the base factor D1 assumes a 
constant number of adult patients falling ill within each of the disease groupings, 
based on the average number of patients joining the waiting list each year 
between 1999 and 2002.  The other factors (D2, D3 and D4) assume an increase 
in demand over time.  Factors D2, D3, and D4 differ only by the rate of patients 
requiring liver transplants due to Hepatitis C.  All the trends defined within the 
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factors fit proportionally with the cited references and are illustrated in Figure 
3.1 and Table 3.1, below. 
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Figure 3.1 Constant Demand Factor (D1). 
 
Table 3.1 Demand Factors to be Investigated. 
 
Constant 
Demand 
(D1) 
Demand 
Increasing 
(D2) 
122 extra 
over 4 
years 
Demand 
Increasing 
(D3) 
193 extra 
over 4 
years 
Demand 
Increasing 
(D4) 
146 extra 
over 4 years 
Hepatitis C 75 71 142 95 
Alcoholic Liver 
Disease 
101 25 25 25 
Non Alcoholic Fatty 
Liver Disease 
42 26 26 26 
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3.3.2 Supply Factors - Liver Donations made to Adult Patients 
Figure 3.2 shows the number of liver transplants which have been performed on 
adult patients over the period 1 April 1999 to 31 March 20067.  After increasing 
by 17% between the years 2000/01 and 2003/04, the number of transplants have 
fallen by the same margin between the years 2003/04 and 2005/06. 
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Figure 3.2 The number of adult (patients aged 17 years and above) liver 
transplants to take place in the UK, from 1 April 1999 to 31 March 2006 (UK 
Transplant 2001b; 2003c; 2004f; 2005c; 2006). 
 
The supply factors created consider possible changes to the number of adult 
transplants performed over the course of the next 20 years.  The differences 
between these factors are discussed below and are illustrated in Figure 3.3. 
 
 
                                                 
7 Please note that the data available for creating the demand factors (in Section 3.3.1) was based 
on calendar years, while for the supply factors the data used is based on financial years.  
Although this is not ideal, due to donation rates remaining more-or-less constant over the years, 
the overall results will not/should not be affected greatly. 
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Constant Supply (S1) 
From Figure 3.2 it can be seen the number of adult liver transplants carried out 
fluctuates around an average of 553.  The first factor (S1) assumes that this 
number will not vary significantly in the future and is based on a constant 
number of liver transplants being available to adults each year.  Factor S1 
generates a possible 565 adult transplants a year, based on an average of the last 
four years (i.e., from 2002/03 to 2005/06). 
 
Declining Supply (S2) 
From Figure 3.2 it can be see that the number of adult liver transplants taking 
place over the most recent 3 years, (2003/04 to 2005/06), has been declining.  
Therefore, factor (S2) considers the effect of a declining number of transplants 
being available.  The decline is assumed to continue at the average rate for these 
three years, which is 43 fewer donations per year. 
 
Increasing Supply, over 10 years (S3) and over 20 years (S4) 
Two factors (S3 and S4) examine the hypothetical effect of increasing the 
number of livers donated (which could result from successful awareness 
campaigns (Section 1.2.6) or as a result from a change in legislation to an Opt-
Out policy (Section 1.5.1)).   Factors S3 and S4 consider situations where the 
donation of livers for use in adult transplants increases to the same levels as 
Spain (as outlined in Section 1.5.1), over the course of the next 10 years (S3) or 
20 years (S4).  An increase in donations rates of this magnitude may not be 
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likely, but it is of interest to explore the potential benefits obtained from the 
number of donations increasing to these levels. 
 
The factors assume a pro rata increase for the number of liver donations 
available.  This may underestimate the effect of an increasing donation rate, 
since children receive priority within the current system (Section 1.3.5) and so 
most children in need of a liver transplant, already receive a transplant. 
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Figure 3.3 Supply Factors to be Investigated. 
 
3.3.3 Assessment Rule Factors - Patient Eligibility for 
Receiving a Liver Transplant 
Currently, patient suitability for transplantation is judged on strict definitions of 
pre- and post-transplant life expectancies, as outlined in Section 1.3.4.  The 
original intention was to incorporate the assessment process into the model.  
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This would allow for different assessment criteria to be tested, affecting the 
number of patients joining the waiting list and the severity of their disease.  
However, due to data limitations (as presented in Section 4.3.3) this has not been 
possible.  Instead, the potential impacts of changes to the assessment criteria 
have been mimicked by making changes to the prognoses of patients who arrive 
on the waiting list (within the revised model, Section 4.3.3).  Changes to the 
assessment criteria need to be investigated since if the supply falls further 
relative to demand, the assessment rules will need to be made more restrictive in 
order to keep the size of the waiting list as a manageable level. 
 
To achieve this, three assessment rule factors have been created where the 
prognoses of patients are varied, but in each case the same number of patients is 
added to the waiting list each year. 
 For the base factor (A1), patients have the same prognosis as observed for 
UKT patients between 1999-2002. 
 The second factor (A2) represents the situation where assessment rule A 
(current life expectancy) is made more restrictive, and in order to be eligible 
for transplantation, patients have to be at a later stage of their disease than is 
currently the case. 
 The third factor (A3) represents the situation where assessment rule A 
(current life expectancy) is made more restrictive, and in order to be eligible 
for transplantation patients have to be at an earlier stage of their disease than 
is currently the case. 
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Factors A2 and A3 will be constructed by either multiplying all the generated 
Death/Removal times (Equations (4.3) and (4.4) Section 4.4.2) by 0.9 (for 
poorer prognosis) or multiplying by 1.1 (for better prognosis). 
 
3.3.4 Allocation Rule Factors - Patient Priority for Transplant 
and Donor to Patient Matching 
To determine feasible allocation rule factors (i.e., those which would be realistic 
to implement) some work was performed to identify the components which 
could be used in determining possible alternative factors, and these are listed in 
Table 3.2. 
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Table 3.2 Allocation Rule Components. 
Factor Priority To 
Matching by donor and patient 
blood groups 
Identical blood groups. 
 
ABO-compatible blood groups (Appendix B). 
 
Incompatible blood groups (Appendix B). 
Matching by patient and donor 
centre 
Local patients. 
 
National patients. 
 
Nationally to super urgent patients and locally to 
routine patients. 
Priority by patient liver 
transplant number 
Patients waiting for their first transplant. 
 
Patients waiting for their successive transplant. 
Priority by patient age 
Youngest patient. 
 
Oldest patient. 
Priority by the amount of time a 
patient has been waiting for a 
liver transplant 
Patient with the shortest waiting times. 
 
Patient with the longest waiting times. 
Matching donor’s weight to 
patient’s weight 
Donor and patient weights are the closest. 
Allocation based on the 
expected survival benefit (i.e., 
Utility)* 
Patients who have worst pre-transplant prognosis. 
 
Patients who will gain most survival benefit 
between pre-transplant and post-transplant 
prognoses. 
 
Patients who with the best post-transplant 
prognosis. 
Allocation based on equity 
between patient groups 
A policy which is based on improving the equity 
for patient groups that have received fewer 
transplants in proportion to the rest of the patient 
population, under all other allocation rules.  
Allocate always with the aim to being both 
compatible and equitable across this attribute. 
* In practice, a policy which considers survival times would not be feasible for implementation 
since accurate estimates of survival would not be attainable, however, the results from 
investigating this type of policy will give us insight into what the best possible utility outcomes. 
 
The allocation rule factors considered at the outset are listed in Table 3.3.  After 
observing the results of scenarios which incorporated these factors, additional 
allocation rule factors were formed by running two or more factors in parallel.  
The process by which extra factors were identified is explained within the 
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experimental design section of this chapter (Section 3.8).  This section outlines 
the alternative allocation rules to be investigated, as defined at the outset. 
 
Table 3.3 Allocation Rule Factors to be investigated (full details in Appendix F). 
Factor 
Name 
Allocation Rules 
L1 
Old base allocation rules (Allocation rules in place up to July 2006, 
modelled for validation purposes.) 
L2 
Current base allocation rules (Allocation rules in place since July 2006, 
modelled to create a baseline which to compare all other models to.) 
L3 Priority given to patients with any compatible blood group to the donor 
L4 Priority given to patients with an identical blood group to the donor 
L5 
Priority given to patients in the same centre where the donated liver is 
retrieved 
L6 No priority given to patients from the retrieving centre 
L7 Priority given to patients registered for their first transplant 
L8 Priority given to patients registered for a successive  transplant  
L9 Priority given to younger patients 
L10 Priority given to older patients  
L11 Priority given to patients who have been waiting the shortest time  
L12 Priority given to patients who have been waiting the longest time  
L13 
Priority given to patients where the absolute difference between donor and 
patient weight is minimised 
L14 
Priority given to patients with the soonest death or removal time (i.e., 
worst pre-transplant prognosis) 
L15 Priority given to patients with the best prognosis post transplant 
L16 
Priority given to patients with best prognosis compared to expected 
prognosis without a transplant 
L17 
An adaptive policy which attempts to make allocation decisions through 
keeping track of equity measures, for groups not fairly transplanted across, 
within the other allocation policies 
 
The allocation rules were changed in July 2006 based on findings summarised in 
a Liver Advisory Group report (Hamilton and O’Neill 2006).  The study 
compared patients within the two time periods 2001/02 and 2003/04 and found a 
significant increase in the median waiting time to transplant for blood group O 
patients between the two years.  They also found that in 2003/04, blood group O 
patients waited significantly longer to receive a transplant than blood group A 
and B patients; with median waiting times 132 days compared with 73 days and 
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41 days respectively.  These differences had not been found within the 2001/02 
cohort of patients.  Also, a smaller proportion of blood group O patients were 
transplanted in 2003/04 and a larger proportion had died after one year of 
registration onto the waiting list.  Again, these differences were not present in 
the 2001/02 data.  These findings resulted in the allocation rules being amended 
to allow blood group O donors to be allocated to blood group O patients before 
blood group B patients. 
 
The allocation rule that is currently in place (factor L2 below) gives priority to 
patients with a blood group which is compatible to the donor’s, to super urgent 
patients and to patients from the centre associated with the retrieval area of the 
donor.  The allocation rule also imposes the restriction that livers donated from 
donors with blood group O must go to a patient with blood group O (if there is 
such a patient on the waiting list) before any other compatible patient.  Factor L1 
represents the policy that was in place during 1999-2002 (when data for this 
project were collected) and this factor is used in validating the initial DES model 
(Chapter 5).  Factor L1 is similar to L2 except that in L1, patients with blood 
group O or B both received priority for livers donated from blood group O 
donors.  Factor L2 will be used when generating the base case scenario, which 
will be compared with the alternative polices detailed below.  
 
The exact priority orderings for each of the allocation factors listed in Table 3.3 
are presented in Appendix F.  All of the factors L3-L17 are designed to identify 
the effects of changing the priority orderings for transplantation, on utility and 
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equity.  Factors are designed to apply stringent (e.g., L4 and L5) and more 
relaxed (e.g., L3 and L6) rules compared to the current allocation policy (L2).  
They also consider patient characteristics, such as the number of previous 
transplants a patient has had (L7 and L8), a patient’s age (L9 and L10), the time 
the patient has been waiting (L11 and L12), and patient weight (L13).  Factors 
L14-L16 use survival and competing risks models to predict pre-transplant and 
post-transplant death times for all patients and then allocate the liver transplants 
to patients based on giving priority to the patient who: 
– Will gain the most LYs from receiving the transplant (based on the 
competing risks models’ prediction, Equations (4.3) and (4.4) Section 4.4.2) 
– L14; 
– Will gain the most LYs from the transplant (based on the survival model 
prediction, Equation (4.6) Section 4.5.2) – L15; and  
– Has the best prognosis with a transplant compared to their expected 
prognosis without a transplant – L16. 
L14-L16 will seek to maximise the utility measures.  L17 on the other hand will 
be devised to create greater equity across the group for which policies 
represented in factors L2-L16 are most unfair. 
 
3.4 Responses/Outputs 
As already discussed (Section 3.2.2), one of the objectives for modelling is to 
compare various assessment and allocation policies to help identify alternative 
policies which: 
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(1) Provide the most equity (encourage fairness) between various patient 
groups within the pool of ESLD sufferers; and 
(2) Allocate the donated livers in the most effective way (i.e., yielding the 
best overall patient outcomes). 
 
No single measure exists to assess both the effectiveness and fairness of 
differing policies.  In fact, to identify the overall fairness and effectiveness of the 
liver transplantation system, equity and utility measures must be considered at 
various stages within the transplantation process (as explained in Sections 2.3.1 
and 2.3.2). 
 
In the UK, patients are listed on the WL if they meet the requirements for 
transplantation and are estimated to have a more than 50% probability of 
survival at 5 years after transplantation with a quality of life acceptable to the 
patient (as explained in Section 1.3.4).  This approach restricts transplantation to 
those who are most likely to benefit from the procedure, and the emphasis of 
utility rather than equity has ethical issues (Neuberger c.2004). 
 
The response measures recorded will determine whether the modelling 
objectives have been met, as well as, by how much they fell short, if the 
modelling objectives were not met. 
 
As mentioned in Section 2.3.4, ULAM (Pritsker et al. 1996) provides the most 
comprehensive list of equity and utility measures.  Table 3.4 below summarises 
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the equity and utility measures which Hepatica uses and indicates where the 
measures are present in ULAM. 
Table 3.4 Output Measures for Hepatica. * are measures which are present in 
the output module of ULAM (Pritsker et al. 1996). 
Stage 
Type of 
Measure 
Measure 
Statistical Test/ 
Observation to be 
made 
Probability of being referred 
to a liver unit 
Similar percentages 
across groups 
Equity 
Probability of dying before 
hospital referral appointment 
Similar percentages 
across groups 
Referral to 
liver unit 
(by GP) 
Utility 
Probability of dying before 
referral 
Minimum across 
policies 
Probability of joining the 
waiting list 
Similar percentages 
across groups 
Equity Probability of dying in 
assessment stage/previous to 
the assessment stage 
Similar percentages 
across groups 
Outcomes 
from 
referral 
(referral  
assessment 
and referral 
 join the 
waiting list) 
Utility 
Probability of dying before 
joining the waiting list 
Minimum across 
policies 
*Probability of receiving a 
transplant (once on WL) 
Similar percentages 
across groups 
*Probability of dying or 
being removed from the 
waiting list 
Similar percentages 
across groups 
*Waiting list size through 
time 
Similar size across 
time 
*Probability of dying or 
suffering graft failure post 
transplant 
Similar percentages 
across groups 
*Probability of being re-
listed post transplant 
Similar percentages 
across groups 
Equity 
*Probability of experiencing 
death or graft failure post 
transplant 
Similar percentages 
across groups 
*Size of the end waiting list Minimise the size 
*Gain in Life Years (LYs) 
per transplant 
Maximum across 
policies 
Life Years in the System per 
patient 
Maximum across 
policies 
*Number of wasted livers Minimise 
*Percentage patients re-
listed (within 1 year)  
Minimise percentages 
*Probability of experiencing 
death or graft failure post 
transplant (within 1 year) 
Maximum across 
policies 
Outcomes 
from the 
waiting list 
(WL  
transplant, 
WL  death 
and WL  
removal) 
and post 
transplant 
outcomes 
Utility 
*Probability of dying or 
being removed from the 
waiting list 
Minimum across 
policies 
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3.4.1 Equity Measures within Hepatica 
Equity measures convey the overall fairness of the liver allocating system and as 
identified in Section 2.3.1 equity measures need to be considered at all stages 
within the liver transplantation system; from a person falling ill with End Stage 
Liver Disease to their eventual death.  The previous liver transplant matching 
studies, including the ULAM, only consider equity at the stage of the allocating 
of livers and therefore do not capture the overall extent to which the system is 
equitable.  Other studies, including LiverSim do not consider how equitable their 
policies are.  In the US, this issue is less of a concern since everyone with ESLD 
can be listed for transplantation. 
 
In the UK, equity of access to liver transplantation by the geographical location 
of the patient, must also be considered at the stage of referral to the liver unit, 
then progression to the waiting list, and the eventual outcome.  This is because 
there are only seven liver units and none of these are located in South West 
England (as depicted in Appendix C), so there could potentially be an 
unrepresentative number of patients being referred from this area.  Appendix G 
reports on analysis performed on the probability of being assessed as suitable to 
join the waiting list, based on where the patient was resident, within a particular 
liver transplant unit.  Appendix G also reports on some work which Roderick 
performed in evaluating the probability of obtaining a transplant, once on the 
waiting list, by patient residence.  The main limitation of both analyses is that 
they assume that patient demographics within all parts of the UK are similar.  
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Both analyses however do report that no patient seemed to have an advantage in 
obtaining a liver transplant, based on where they lived. 
 
The main equity output measures that Hepatica considers are listed in Table 3.4.  
The table also describes the statistical and observational techniques which were 
employed in identifying the policies which are equitable and the policy which is 
the most effective.  The equity measures are recorded by the groupings: age, 
location, blood type, transplant number, and disease type.  ULAM considered 
additional measures which included the local use of organs and the impact of 
this on organ donation rates within the region, policy impacts on geographic 
areas, costs of transplantation, transitions between medical statuses, the 
distances livers travel, and the time different patient groups spend waiting for a 
liver transplant.  These factors are not considered explicitly within Hepatica for 
the following reasons: 
- This study is not focusing on factors connected to organ donation rates; 
- Currently there is evidence to suggest that equity exists amongst different 
geographic areas within the UK (Appendix G) and there is no reason to 
suppose this will change; 
- The major costs resulting from transplantation will remain the same (we will 
still have the same number of transplants take place);  
- Transitions between medical statuses will be less likely than within the US 
system, as patients in the UK are placed on the WL only if they are expected 
to die within a year; and 
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- The time different patient groups spend waiting for a transplant only begins 
to matter:  
 If patients in particular groups miss out on transplantation, or  
 If a delay in certain groups receiving a transplant affects the post 
transplant outcome which they experience.   
These two aspects are already being monitored within the measures:  
 The percentage of deaths and removals from the waiting list, and  
 The proportion of re-lists and death/graft failure events post 
transplant. 
 
Table 3.4 lists equity measures that will determine achievement or non 
achievement of the modelling objectives.  In terms of equity we are seeking to 
improve the fairness of the allocation of donated livers, or the progression of 
patients from one state to another, by patient group.  To measure this aspect we 
can observe the actual number of patients experiencing particular events and 
compare this to the expected number to experience the events across the patient 
groups (i.e., total patients in the group multiplied by the overall percentage of 
patients to experience that particular event).  If we sum up the absolute 
differences across the groups, we obtain an indication of how “unfair” the policy 
is across the groups for a particular event.  Ideally, we wish this sum to be as 
small as possible, for the policy to be fair.  If we calculate this statistic for the 
base scenario then we can determine if the alternative policies meet our 
objective for modelling (identifying a policy which improves equity), or fails to 
do so. 
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Chapter 6 Section 6.2.2 presents equity values of the current system, over the 
years 1999 to 2002, as calculated using the UK Transplant data set (UK 
Transplant 2004e). 
 
3.4.2 Utility Measures within Hepatica 
Utility measures convey the overall utilisation of the donated livers and how 
effective by different parts of the system operate.  As explained in Section 2.3.2, 
utility measures attempt to evaluate the benefit gained through implementing a 
certain policy.  The previous liver transplant matching models have concentrated 
on: (1) identifying the gains in survival due to liver transplantation, (2) the cost-
effectiveness of liver transplantation, and (3) more recently some modellers have 
started to consider the effect of liver transplantation on a patient’s QoL (Kerke et 
al. 20002b). 
 
The main utility output measures that Hepatica considers are listed in Table 3.4.  
These measures will be considered for a particular policy, and not separately by 
patient groups, as we wish to identify the overall ability of a policy to effectively 
use the donated livers.  The main utility aspects that are considered in previous 
liver transplant matching models, and not within Hepatica, are: 
 The costs involved in liver transplantation, (since there is currently no 
alternative to liver transplantation, and either a patient is transplanted or 
they soon die, it is more important to consider patient survival); 
 The QALYs gained under various policies are important.  However, as 
patients who are placed on the waiting list are so near death it is more 
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important to identify the impact of a policy on overall survival (i.e., Life 
Years gained per transplant).  QoL data has a key limitation, in that it is 
subjective and different groups of patients may view the same QoL, 
differently (Davies et al. 2003); and 
 In many medical systems the average waiting time would also provide us 
with a utility measure.  However, this measure is not relevant in this 
situation as the average waiting times will just resemble the average 
times between successive donated livers, within the observation period.  
Thus, this measure becomes meaningless in this context, in terms of 
representing how effectively a particular policy is in providing patients 
with liver transplant on a timely basis. 
 
To identify whether a new policy achieves the objectives for modelling the 
utility measures from the new policy as outlined in Table 3.4 are compared (as 
indicated in column 4) to the values obtained from analysis of the base scenario. 
 
Previous liver transplant matching studies which consider the total number of 
LYs gained under a particular policy, use the Total Gain in Life Years per 
Transplant calculation depicted in Equation (3.1).  Hepatica also evaluates this 
measure in addition to the Total Life Years in the System per Patient, as depicted 
in Equation (3.2).  This latter measure attempts to obtain an idea of how well a 
policy picks patients for transplantation, with the aim of maximising the total 
number of LYs of the whole patient cohort.  This will give more insight into 
how patients might be chosen to utilise donated livers “optimally”. 
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Total Gain in Life Years per Transplant: 
 
N
EE
Ii
ii

 )lantednot transp if Death time()ted transplanif Death time(
 (3.1) 
where  I =  the set of all the patient transplants that took place, 
 N = the total number of transplants to take place (i.e., count of I), 
)ted transplanif Death time(iE  = the time a patient is predicted to die, 
once they receive a transplant, 
)lantednot transp if Death time(iE  = the time a patient is predicted to 
die, once they have joined the waiting list. 
 
Total Life Years in the System per Patient: 
 
M
EE
Jj
jj

 )onregistratifirst on  Death time()Death time Final(
   (3.2) 
where  J =  the set of all patients who joined the waiting list, 
 M = the total number of patients to join the waiting list (i.e., count of J), 
)day Death time Final(jE  = the time at which a patient eventually dies 
(if they receive no transplant then the time they are predicted to die, once 
they have joined the waiting list; if they receive a transplant then the time 
they are predicted to die post transplant), 
)onregistratifirst on  Death time(jE  = the time a patient is predicted to 
die, once they have joined the waiting list for the first time, within the 
observation period. 
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3.4.3 Overall Scoring of Values 
Attempting to improve the utility measures of the system may sometimes have 
an adverse effect on the equity measures.  For example, the overall potential 
gain in LYs will be dependent on the age of the patient, and so trying to 
maximise this measure may lead to the elderly, who will generally be expected 
to have their lives extended by fewer years, not being treated at all.  Conversely, 
a policy which aims to maximise allocation fairness (improve equity within the 
system) will allocate to all age groups at the expense of maximising utility 
measures.  Another important factor for which a similar effect may arise is 
disease group, where some disease groupings have poorer prognoses post 
transplant (e.g., patients with diseases that commonly recur as discussed in 
Section 1.4.2).  Hence, the “best” policy will not simultaneously maximise 
utility and equity and so the measures will need to be prioritised into an order of 
relative importance.  This issue resembles one of the main trade-offs and ethical 
issues within organ allocation (as discussed in Section 2.3.3). 
 
As some policies will create equity between patient groups and may not 
maximise the utility of the donated liver organ, and vice versa, it is important to 
define how to balance measures observed in Hepatica.  The main objective of 
our modelling is to identify policies which improve upon the equity and utility 
outputs of the base scenario, therefore, each of the equity and utility measures 
produced by various scenarios, were compared to the measures observed from 
the base scenario.  It was then decided whether the values returned by a 
particular scenario were either: (1) better than (i.e., an improvement), (2) the 
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same as (i.e., no improvement), or (3) worse than (i.e., the new policy results in 
a negative affect on the measure) those returned by the base scenario.  Most 
values were considered the same if they fell into a band of 2.5% greater or less 
than the value observed as the base scenario value.  The only exceptions were 
the utility measures which evaluated the total life years gained per transplant and 
the total life years per patient in the system; for these measures we used the 95% 
confidence intervals to determine whether the scenario is (1) better than, (2) the 
same as, or (3) worse than the base scenario in extending the life years for the 
patients.  If the CI overlapped then it was assumed that the new scenario could 
not be shown to have changed the number of LYs over the base scenario, i.e., 
was not any better or worse than the original scenario.  If the CI of the scenario 
was outside of the CI of the base scenario then the policy was either assumed to 
be better or worse than the base scenario, depending on which CI covered higher 
values.  Each value was then given 1 point, 0 points, or -1 points, corresponding 
to whether the outcomes were better than, the same as, or worse than the base 
scenario outcomes.  These values were then weighted and summed together (as 
explained in Section 6.2.2), to rank the policies in terms of improvement. 
 
The weighted sum representing the improvement in equity was then plotted 
against the weighted sum representing the improvement in utility.  This graph 
was then analysed to identify the policies that improve equity and utility (and the 
results are reported in Chapter 6). 
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3.5 Simulation Model Outline 
The idea behind this thesis is to model patient progression through the liver 
transplantation system.  The intention is to find the most appropriate match 
between a donated liver and one of the patients on the waiting list, by examining 
their (individual) characteristics.  We also wish to know the outcomes, with and 
without transplantation, that are experienced by each of the patients so that we 
may compare various matching policies and assess the overall utility of various 
policies (as discussed in Section 3.4.2). 
 
3.5.1 DES Model Structure 
Figure 3.4 below details the simulation model to be developed (Hepatica).  The 
diagram captures the stages that a patient passes through from initial referral.  It 
includes the patient flows after referral based on the stages outlined in Figure 1.4 
(Section 1.3.3) and extended to include post transplant outcomes.  Hepatica 
includes: (1) the referral stage, and (2) the assessment stage, which are 
reconsidered in Chapter 4 when the sub-models are created. 
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Figure 3.4 A flow diagram to depict the process once a patient is diagnosed with 
ESLD. 
 
The focus of Hepatica has been to incorporate the key stages of the process 
where the observed responses (as outlined in Section 3.4) of a particular policy 
need to be evaluated.  This section outlines the sub-models developed to enable 
predictions at the various stages within Hepatica.  The appropriate modelling 
techniques for each of the transitions and flows are explained in Section 3.6.  
Tables 3.5 to 3.7 summarise the scope of the model and the level of detail to be 
incorporated. 
 
 
 
 
 
Patient Referral 
To a Liver Unit 
Assessment 
At Liver Unit 
Death/ 
Removal 
Join the 
Waiting List 
Livers Donated 
Re-Listing 
Liver Allocated 
& Transplanted 
Death/ 
Graft failure 
Not Referred to 
Liver Unit 
Not assessed/assessed 
& not placed on list 
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Table 3.5 Model Scope - Components included. 
Component Justification 
Patients Arrivals (ill 
will ESLD) 
Determines the demand for transplantation and the 
patient flow rates through the transplantation 
process 
Donors Arrivals Determines when a transplant may take place 
Patient Referral to 
Liver Unit 
A patient must be referred to a liver unit, as an 
initially step to obtaining a liver transplant.  
Determines patient flow through the system 
Assessment Phase 
A patient needs to pass the assessment phase (i.e., 
to be judged suitable for transplant) in order to be 
placed onto the WL and obtain a transplant.  
Determines patient flow through the system 
Waiting List/Queue for 
Transplant 
A transplant is allocated to patients that are on the 
liver transplant WL.  Determines patient flow 
through the system 
Allocation 
The process by which it is decided who will 
receive a liver transplant.  Determines patient flow 
through the system 
Re-list post transplant 
Patients that also require transplant.  Determines 
patient flow through the system 
Death/Removal from 
WL 
If a patient is removed or dies from the WL, then 
they are no longer waiting for a transplant.  
Determines patient flow through the system 
Death/Graft Failure 
from transplant 
Overall outcome.  We know that these patients 
will no longer require another transplant.  
Determines patient flow through the system 
 
Table 3.6 Model Scope - Components excluded. 
Component Justification 
Number of Liver 
Transplant Surgeons 
Not relevant for the overall outcomes that are being 
evaluated 
Number of Liver 
Transplant Units 
Not relevant for the overall outcomes that are being 
evaluated 
Government 
Campaigns 
Have not affected donations significantly.  But add 
to “What-If” scenarios by changing the supply 
Opt-In/Opt-Out 
Not likely to change, however, added to “What-If” 
scenarios by changing the supply 
 
 
 
 
 
 
 
 
 
  
Methodology 
 
115 
Table 3.7 Components - Level of Detail Included in Hepatica 
Component Detail Comment 
Patients 
Patient inter-
arrivals 
Sets the patient flow into the system. 
Modelled as a distribution 
Patient 
attributes 
Helps to determine eventual outcomes.  
Modelled as several distributions 
Donors 
Donor inter-
arrivals 
Determines when a transplant may take 
places.  Modelled as a distribution 
Donor 
attributes 
Helps to determine eventual outcomes.  
Modelled as several distributions 
Referral 
Phase 
Process 
Determines who is put forward for 
transplant.  Represented by a set of rules 
Assessment 
Phase 
Process 
Determines who is put forward for 
transplant.  Represented by a set of rules 
Waiting 
list/Queue 
for 
Transplant 
Queuing 
Required to determine waiting times and 
determine the number and type of patients 
waiting for a transplant at any one point in 
time 
Allocation Process 
Determines who is allocated a transplant.  
Represented by a set of rules 
Re-list post 
transplant 
Process 
Determines who requires another transplant.  
Represented by a set of rules 
Death or 
removal 
from waiting 
list 
Times 
Determines the time at which a patient will 
die or be removed from the WL i.e., no 
longer requiring a transplant.  Modelled as 
several distributions 
Death or 
graft failure 
from 
transplant 
Times 
Determines the time at which a patient will 
die or suffer from graft failure and hence no 
longer require a liver transplantation.  
Modelled as several distributions 
 
The key phases of the model as depicted in Figure 3.4, are: 
(1) Arrivals (patient referrals to a liver unit and liver organs donated); 
(2) Assessment Phase (the process by which it is determined whether a patient 
is suitable for transplant and hence whether they should join the waiting list 
or not); and 
(3) Allocation/Transplant Phase (the process by which a donated liver is 
allocated to a patient so that the patient may have a transplant); 
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(4) Outcomes (these are death or removal from the waiting list; death or graft 
failure or re-listing once transplanted). 
 
To be able to capture these key phases, Hepatica must include the following 
components: 
(1) Patient Generation and Patient Attribute Assignment; 
(2) Donor Generation and Donor Attribute Assignment; 
(3) Transplant Assessment Rules; 
(4) Survival Time Generation {(1) the time from joining the waiting list to 
dying or being removed, (2) the time from receiving a transplant to dying 
or suffering from graft failure, (3) the time from receiving a transplant to 
being re-listed for another liver transplant operation}; 
(5) Maintain a list of candidates on the waiting list; and 
(6) Transplant Allocation Rules. 
Sub-models that capture these aspects are discussed in the next section. 
 
3.6 Techniques used for Developing the Sub-Models 
3.6.1 Arrivals and Attributes Generation 
Patient and Donor Generation and Attribute Assignments 
Analysis was performed for both patient and donor arrivals.  Several aspects 
require modelling to represent the arrivals adequately, these are:  
(1) The time of arrival (or the number of arrivals in a certain time period); and  
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(2) The characteristics of the arrivals and any inter-dependencies between these 
characteristics. 
 
The characteristics that influence patient outcomes were determined when 
creating the models which capture the transitions between different states 
(Sections 4.4.2 and 4.5.2).  It was these patient and donor characteristics which 
needed to be taken into account within part (2) of the analysis described above. 
 
The following methodology is implemented when capturing patient and donor 
arrivals into the liver transplantation system.   
 
Arrival Times 
Donor arrivals are expected to occur at random and independently of one 
another, therefore a Poisson process should provide a suitable means of 
modelling their rate of arrival (Winston 1994).  Similarly a Poisson process 
should also be applicable to the rate of patients arriving on the waiting list for 
their first transplant (those arriving for successive transplants are generated 
through the “re-listing transition” as described in Section 4.5.1).  Stat::fit was 
used to identify the most appropriate distribution to capture the arrival times. 
 
Assignment of Characteristics 
When patients or donors arrive into the system a set of characteristics must be 
assigned to them.  These characteristics (or attributes) will help to determine 
which patient will receive the donated liver and the eventual outcomes 
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experienced by the patients.  The attributes that require assigning are therefore 
the covariates from the survival and competing risks models and the factors 
which the allocation policy uses to determine which patient is allocated a 
donated liver (e.g., transplant centre, transplant urgency, blood group).  There 
will also be inter-dependencies between attributes (e.g., patients requiring a 
super urgent transplant status will not have liver cancer), and these dependencies 
need to be taken account of when assigning the attributes on arrival. 
 
Three statistical techniques were used in determining the dependencies between 
attributes.  The technique used was dependent on the nature of the two attributes 
under consideration; 
(1) The Chi-Squared Statistic was calculated for the relevant contingency table 
where both attributes took on discrete values; 
(2) The t-Statistic was calculated in comparing means where one attribute took 
on continuous values and the other discrete values; and 
(3) The Pearson Correlation Statistic was calculated for cases where both 
attributes took on continuous values. 
 
3.6.2 Assessment Outcome Model 
Assessment Rules: Referral to join/not join the waiting list 
Logistic regression is used to predict whether an event will take place or not, and 
to identify the variables that contribute significantly to this prediction.  It allows 
for the modelling of dichotomous outcomes and is applied here to patients who 
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were referred to the Birmingham Liver Unit, with the outcome of interest being 
whether they are selected for the waiting list (1) or not (0), (Centre for Applied 
Statistics, Lancaster University). 
 
Model Development 
The logistic regression models were created using SPSS using the forward 
stepwise regression procedure, with entry value set to 0.05 and removal value 
set to 0.10.  Under these criteria the model is built up by adding one covariate at 
a time, to decide if a particular covariate should enter into the model in addition 
to the previous x variables, a comparison is made between Model A (which 
contains x covariates) and Model B (which contains x+1 covariates).  If the 
score statistic implies that Model B is better than Model A at the 95% 
significance level, then the covariate is included within the model.  After a new 
covariate has been introduced into a model, a check is made to make sure that all 
the covariates in the model still improve the model – this is tested by omitting 
each covariate and checking that the inclusion of the covariate significantly 
increases the accuracy of the model (test at the 90% level using the Likelihood-
Ratio statistic).  Tough entry and removal values (0.05 and 0.10) were 
implemented to make sure only variables that were significant in the overall 
outcome were included in the resultant models.   
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Goodness of Fit 
The developed models were analysed for their goodness-of-fit by using the 
following statistics to assess the models’ capability for adequately capturing the 
outcomes: 
- The Percentage of Correct Classifications - which assesses the 
performance of the model created by calculating the percentage of patient 
outcomes correctly classified by the model; 
- Cox and Snell R2 Statistic - which quantifies the percentage of variation in 
the response that is explained by the model.  The R2 statistic cannot be 
computed exactly for logistic regression models, but SPSS computes 
approximations to these, which can be used; and 
- Hosmer and Lemeshow Test (significance) - at each step, this is a 
goodness-of-fit test of the null hypothesis that the model adequately fits the 
data.  If the null is true, the statistic should have an approximately chi-square 
distribution with the displayed degrees of freedom.  If the significance of the 
test is small (i.e., less than 0.05) then the model does not adequately fit the 
data (Garson 1998). 
 
3.6.3 Waiting List Outcome Model and Post Transplant 
Outcome Models 
Survival Time Generation 
Survival analysis and competing risks techniques are appropriate for modelling 
outcomes from the waiting list and outcomes from transplantation because: 
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(1) Both situations have a well-defined time origin, these are: 
a. The time the patient joined the waiting list; and 
b. The time at which a patient received their transplant. 
(2) The outcomes of interest are the times to certain events occurring (defined as 
end points in survival analysis and competing risks): 
a. From joining the waiting list, the times to transplantation, death, or 
removal ; and 
b. From receiving a transplant, the times to either re-listing or death and 
graft failure. 
(3) Not all the events will have been observed by the end of our data collection 
period (this is called censoring and was explained in more detail in Chapter 
2 Section 2.4). 
 
Survival or competing risks models were created to capture all the outcomes 
modelled in Hepatica, as reported in Sections 4.4 and 4.5.  SPSS , S-Plus and 
MS Excel, software packages were used along with the development process 
outlined next. 
 
Model Development - Choice between Survival Modelling and Competing Risks 
Modelling 
There are several decisions which must be made when developing the models 
that estimate the times that patients spend in particular states.  As already 
discussed in Section 2.4 the first is to decide whether a survival model or a 
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competing risks model is more appropriate.  This decision can be made by 
determining whether the following assumption holds:  
The survival times are independent of any mechanism that causes the 
individual’s survival time to be censored. 
If this assumption holds then survival analysis is appropriate, if it does not hold 
then competing risks analysis is more appropriate.  This assumption can be 
tested using Equation (2.8) as described in Section 2.4.3. 
 
Survival times need to be estimated once a new patient joins the waiting list, and 
once a patient receives a transplant.  From both these stages, patients can 
experience one of several events which are of interest: 
(1) The next event that a patient may experience after joining the waiting list, is 
one of either Death, Removal, Transplantation, or Suspension; and 
(2) The next event that a patient may experience after receiving a liver 
transplant, is one of either Death, Graft Failure, or Re-Listing back on to the 
waiting list. 
When analysing the available data it is likely that many of the times to these 
events are censored due to common causes.  This might mean that the 
assumption required for the survival models (that times which are censored need 
to be independent of cause) does not hold, and competing risks modelling is 
more appropriate. 
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Model Development - Survival Model Development Process 
Section [A] describes the preliminary analyses performed to identify which type 
of survival model (PH or AFT as introduced in Sections 2.4.1 and 2.4.2) was 
appropriate for capturing the survival times.  Section [B] goes on to outline the 
process by which parametric survival models were developed, and how this can 
be extended to create a competing risks model.  Section [C] describes how the 
goodness of fit of the models developed, was assessed. 
 
[A] Preliminary Analysis 
The main aims of this analysis were to identify which type of survival model(s) 
(PH or AFT) appropriately captured the features of the data and to identify 
which covariates resulted in significantly different survival curves, across their 
respective levels.  The tests [A.i]-[A.iii], were performed for all the covariates 
identified as relevant outcomes drivers from the different stages.  The analysis 
also helped to decide whether a stratified model was necessary (i.e., different 
models for different covariate values e.g., two separate models by transplant 
urgency status (super urgent and routine)). 
 
[A.i] To identify if the Proportional Hazards (PH) assumption was met, the 
log cumulative hazard function is plotted against log time (Log-Cumulative 
Hazard Plots), stratified by each covariate level.  The log cumulative hazard 
function is calculated based on the Kaplan-Meier (K-M) estimate for survival. 
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If the PH assumption holds, the vertical distance between the curves is constant 
(as shown in Figure 3.5).  For the Weibull model to be appropriate, a series of 
straight parallel lines, would emerge.  Where the lines have slope 1, an 
Exponential model would be appropriate. 
 
If lines are parallel but not straight, then a non-parametric (Cox) regression 
model would be appropriate.  However, for use in the simulation we need a 
parametric distribution. 
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Figure 3.5 Example of curves that satisfy the PH assumption. 
 
[A.ii] To identify if the Accelerated Failure Time (AFT) assumption was 
met, the cumulative hazard (again estimated using K-M estimates for survival) 
is plotted against log time (Cumulative Hazard Plots), stratified by each 
covariate level. 
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If the horizontal distance between the curves (as shown in Figure 3.6) is constant 
(i.e., through log time) then an AFT model is suitable for modelling purposes.  
Steps [A.ii.a] and [A.ii.b] were then employed to identify which of a log-logistic 
AFT model or a lognormal AFT model would be more appropriate. 
 
Figure 3.6 Example of curves that satisfy the AFT assumption. 
 
[A.ii.a] To test the appropriateness of a log-logistic AFT model, the log odds 
against log time graph was plotted (Log Odds Plots), stratified by each covariate 
level. 
 
If the lines obtained were parallel and straight then the log-logistic AFT model 
was suitable.  If the lines were straight but not parallel then a stratified log-
logistic AFT model was applicable.  If the lines were parallel but not straight 
then another proportional odds model was applicable. 
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[A.ii.b] To test the appropriateness of a lognormal AFT model, the  
-1(1-S(Time)) by Log(Time) graph was plotted, stratified by each covariate 
level.  If the lines obtained were parallel and straight then a lognormal AFT 
model was suitable. 
 
[A.iii] Log Rank and Wilcoxon test statistics: To test for differences between 
the survival distributions of the different patient groups the test statistics Log 
Rank and Wilcoxon test (also known at the Breslow Test) statistics were also 
analysed, to determine which covariate values lead to significantly different 
survival curves.  The Log Rank statistic was calculated where the PH 
assumption applied and the Wilcoxon statistic where the AFT assumption 
applied. 
  
[B] Parametric Model Development Process 
The following process was used in creating parametric distributions which were 
identified at stage [A] as potentially suitable in capturing the outcome being 
considered. 
 
Null8 models were first created for each of a set of the potentially suitable 
parametric distributions.  Then the Lˆlog2  statistic was used to assess the 
agreement between the model and the data (Collett 2003).  The statistic is based 
on the maximised likelihood Lˆ  value of each model.  For a given set of data, the 
                                                 
8 A null model is one that contains no explanatory covariates in the linear component of the 
model, hence the model does not attempt to distinguish between two groups of patients. 
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larger the value of the maximised likelihood, the better the agreement between 
the model and the observed data. 
 
The following covariate selection procedure was used: 
a) Fit survival models that contain each of the covariates one at a time.  
Compare these models with the null survival model using the Lˆlog2  
values obtained.  (Here the null models are used as a basis for 
comparison and in this step to help identify whether a particular 
parameter improves the fit of the model significantly). 
b) Fit the covariates that appear significant at step a), together.  Keep in the 
model those that significantly increase the Lˆlog2 , omit those that do 
not.  Drop each covariate in turn and check the effect of omitting each. 
c) Add the covariates not significant in step a) to the model from step b) 
and check if they are now significant, in the presence of other covariates. 
d) Check that no term can be omitted without significantly increasing the 
value of Lˆlog2 , and that no term included significantly reduces 
Lˆlog2 . 
 
A rigid application of a particular significance level was not used and also 
decisions on whether to include or to omit a covariate were based on 
significance levels which allowed covariates to easily enter the model (Collett 
2003).  The covariates counted as significant at step a) are those significant at 
least at the 85% level, and for the rest of the stages, the significance level was 
taken to be 90%.  Using a manual selection procedure as opposed to an 
  
Methodology 
 
128 
automatic one, provided more control over which covariates to include in the 
model, when there was a choice of bringing in more than one covariate. 
 
Model Development - Competing Risks Model Development Process 
Competing risks modelling is not as standard as survival analysis and standard 
software packages do not include routines which perform this analysis.  In their 
paper (Lunn and McNeil 1995) outline a methodology in which a dataset can be 
adapted to allow for a form of competing risks analysis to be implemented 
through using standard statistical packages.  However, their approach makes the 
assumption that the risks being considered are independent of one another.  This 
may not be true for the outcomes from the waiting list, as if a patient is likely to 
die soon then they might receive a higher priority for transplantation, and hence 
transplantation time will be dependent on death time. 
 
This approach does allow for the modelling of competing risks and was 
implemented when developing the competing risks models, in conjunction with 
the process outline in [A] and [B].  For stage [A] instead of plotting by 
covariates, for the CR models the plots were by outcome (Hemming and 
Anzures-Cabrera 2006).  This identified if a PH model or an AFT CR model was 
appropriate.  Lunn and McNeil (1995) have applied their methodology to the 
Cox regression model.  Here it has been extended to include parametric models 
for the underlying hazard function. 
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[C] Goodness of Fit 
To evaluate how well a particular survival model or competing risks model 
captured the outcomes observed in the data, Cox-Snell residuals9 were analysed 
(more details are presented in Appendix H), and plots of the K-M estimate were 
compared to the fitted models. 
 
[C.i] Cox-Snell residuals: Cox-Snell residuals, 
iC
r , were used to analyse the 
model fits.  The way in which to calculate the residual depends on the 
distribution being considered, and the different forms are presented in Appendix 
H.  The Kaplan-Meier estimate of the survivor function of the Cox-Snell 
residuals, denoted )(ˆ
iC
rS , was obtained and )(ˆlog
iC
rS  was plotted against 
iC
r .  
A straight line with unit slope and zero intercept resembles that the fitted model 
is appropriate (Collett 2003).  A test was also performed to determine which 
model approximated a straight line closest to one with unit slope through the 
origin, by using linear regression. 
 
[C.ii] Plots of Kaplan-Meier Survival and the Estimated Model: Kaplan-
Meier curves were plotted along with the fitted model to help in visualising the 
fit of the model developed, against the observed data. 
 
 
                                                 
9 Note: residuals can only be calculated for the patients that have experienced the outcome being 
modelled.  The patients whose values are censored are therefore not plotted, when analysing 
residuals (Collett 2003). 
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3.7 Data used for the Sub-Models 
3.7.1 Description of the Data 
Assessment Stage Data 
Information about patients who are referred to a liver unit is only available from 
that individual liver transplant unit.  The data analysed for this thesis were 
collected from Birmingham Liver Unit (BLU), and consist of all adult patients 
(aged 16 and above) who were referred to BLU between 1st January 1999 and 
31st December 2002.  Of interest was whether or not they had been given a place 
on the waiting list.  These data were used to develop an understanding about 
which patients are likely to be placed on the waiting list following referral to a 
liver unit, and whether certain patient characteristics play a significant part in the 
decisions made.   
 
Transplant Data 
Information about all patients who join the waiting list is available from UK 
Transplant.  For this thesis, data was obtained for all adult patients (aged 17 or 
older) who joined the UK liver transplant waiting list between 1st January 1999 
and 31st December 2002.  Details of their patient history were recorded up to 6th 
October 2003. 
Information about liver donors is also available from UK Transplant.  Data were 
provided on all donors whose livers were transplanted into adult patients 
between 1st January 1999 and 31st December 2002. 
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These data were used to develop an understanding about the life expectancy of 
patients on the liver transplant waiting list, and which patient characteristics are 
the strongest predictors of this.  Similarly, the data were also used to estimate 
life expectancy post-transplant based on patient, donor, and transplant 
characteristics. 
 
3.7.2 Risk Factors 
In order to model patient and donor arrivals, and patient transitions it is 
necessary to determine the arrival distributions, activity time distributions, and 
the risk factors that drive these.  An initial list of risk factors was determined by 
looking at previous literature, obtaining the opinions of medical experts, and 
researching how the system currently operates by consulting UKT 
documentation (UK Transplant 2001a).  The factors considered were then 
restricted to data attainable from UKT and BLU and covered 4 main categories: 
Patient Demographics, Donor Related Measures, Transplant Related Measures, 
and Clinical Measures.  The risk factors identified were different for the pre-
waiting list and post-waiting list models, and are explained in more detail below. 
 
Assessment Stage Risk Factors 
The factors considered in pre-transplant models are summarised in Table 3.8.  
The first factor considered is primary liver disease, since different diseases will 
affect patients over various timescales.  A study analysing the French liver 
transplant waiting list identified transplant urgency and region (geographical 
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location of the patient) as being key predictors in determining the life 
expectancy of a patient on the waiting list (Suc et al. 2000). 
 
The MELD score, measures the severity of illness for chronic liver disease 
sufferers and it is currently used in the US to determine who should receive a 
donated liver (Wiesner et al. 2003).  The score replaces the Child-Turcotte-Pugh 
score which had been used previously (Wiesner et al. 2001).  The MELD score 
relies on more objective measures (which are based on clinical tests) and has 
been found to accurately predict short-term mortality from liver disease (Kamath 
et al. 2003), and more accurately than the Child-Turcotte-Pugh score (Wiesner 
et al. 2003).  The MELD score has also been found to be successful at predicting 
mortality across a range of chronic liver diseases (Said et al. 2004).  Other 
factors considered include patient gender (Fink et al. 2007), and patient age. 
Table 3.8 Pre-Transplant Risk Factors Considered in the Analysis. 
 Pre-Transplant Risk Factors 
Patient and Disease Related 
Characteristics 
Primary Liver Disease at Registration 
Transplant Urgency 
MELD score 
Gender 
Patient Age at Registration 
Geographical Location Centre 
 
Transplant Risk Factors 
Post-transplant risk factors also include donor characteristics and transplant 
characteristics.  The requirement for this thesis is to investigate medium to long-
term survival of patients post-transplant, since we want to determine the effect 
of a policy on the total number of life years gained.  Many studies have 
previously concerned themselves with determining short-term outcomes (Avolio 
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et al. 2004).  Studies have been performed to identify factors affecting post-
transplant survival (Adam et al. 2000; Angelis et al. 2003; Gonzalez et al. 1994; 
Lin et al. 1998). 
 
Table 3.9 Post-Transplant Risk Factors Considered in the Analysis. 
 Post-Transplant Risk Factors 
Patient Characteristics 
First Transplant 
Primary Liver Disease at Registration 
Recipient Age 
Transplant Urgency 
Recipient Body Mass Index (BMI) 
Recipient Gender 
Clinical Characteristics MELD score 
Donor Characteristics 
Donor Age 
Donor Cause of Death 
Transplant Characteristics 
Donor-Recipient ABO match 
Cold Ischaemic Time (minutes) 
Completeness of Liver Used 
Donor-Recipient Rhesus match 
Donor-Gender to Recipient-Gender 
Donor Weight minus Recipient Weight 
 
These studies have identified various factors as key to post-transplant survival.  
Those which have been identified as appropriate to this work are summarised in 
Table 3.9.  Previous studies have also found that transplant centre-related 
factors, such as the number of liver transplants performed are significant in 
determining outcomes (Adam et al. 2000).  It was decided, however, that there 
are too few transplant centres in the UK – seven – to be able to make a reliable 
assessment of this.  Other variables that may influence post transplant survival, 
but were not considered in our analysis due to a lack of data, included: Donor 
Type (Cadaveric Heartbeating, Cadaveric Non-Heartbeating, Living 
(related/unrelated), Domino). 
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Some people would expect that the time spent waiting for a liver transplant 
would be an indicator as to when a patient will die, however it has been shown 
(Freeman et al. 2000) that waiting time provides a poor indication of actual 
death time, mainly due to patients joining the waiting list at varying stages of 
their disease, and so this covariate is not considered in the analysis. 
 
Simplification of Variables 
Some of the factors listed in Tables 3.8 and 3.9 took on a number of different 
values and so had to be simplified.  Appendix A lists all the diseases that are 
indications for transplantation (this list was obtained from UK Transplant).  It 
also shows the groupings which indicate how the diseases were aggregated and 
simplified so that they could be used in this analysis.  The disease groupings 
implemented were based on a Liver Advisory Group paper (Hudson et al. 2005), 
amended by splitting the Cirrhotic diseases group into smaller groups so that the 
groups were more comparable in size.  The groupings also reflected the disease 
categories which have been identified as important because their occurrence is 
likely to increase in the future (Section 1.2.6).  Other risk factors which were 
simplified, are: donor cause of death, MELD score, and patient body mass index 
(as outlined in Appendix A). 
 
3.8 Experimental Design 
Two types of experimental design are commonly employed within simulation 
experiments; (1) full-factorial, and (2) fractional-factorial (Kelton and Barton 
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2003; Law and Kelton 2000).  However, neither of these approaches is 
appropriate within the context of this work.  Assuming that each factor can take 
on one of two levels and there are k input factors, the full factorial approach 
identifies 2k different combinations of input factors.  Within the context of this 
thesis we have initially defined 4 types of input factors (demand, supply, 
assessment rule, and allocation rule), which take on a varying number of levels 
(4, 4, 3, and 17, respectively).  This implies a minimum10 of 4x4x3x17 = 816 
experiments to perform under the full-factorial methodology.  This is an 
extremely large number of experiments to perform and analyse.  One approach 
to limit the number of experiments required is the fractional-factorial design.  
This approach performs a fraction of all the possible factor-combinations (Law 
and Kelton 2000), and the levels which are chosen to run are identified at 
random.  This approach is appropriate where the levels are based on ordinal 
inputs (e.g., identifying the effect of employing 2, 3, 4, or 5 cashiers), but 
provides a non-intuitive means for this study, as many of the factors are not 
based on numerical aspects, for example, blood group or centre match.  
Therefore, a new experimental design, as described below, was developed to 
analyse which of the experimental factors (as outlined in Section 3.3) most 
improved the equity and utility measures. 
Experimental Design Implemented 
The experimental design implemented is as follows: 
                                                 
10 The number given is a minimum since several of the levels within the allocation factor could 
be combined to construct new levels, for example, L3 gives priority to patients with a compatible 
blood group and L6 to patients nationally, combining L3 and L6 would give a policy which gave 
priority to compatible patients nationally. 
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(1) Run the base scenario which assumes the current assessment (A1) and 
allocation (L2) rules and constant future demand (D1) and supply (S1); 
(2) Run 23 other scenarios in which only one factor level change is made 
(i.e., run the remaining scenarios outlined in Table 3.10); 
(3) Analyse the results from steps (1) and (2) to identify (using methods 
outlined in Section 3.4.3) which of the scenarios in step (2) made 
improvements in the equity and/or utility measures, from the base 
scenario considered in step (1); 
(4) Join up the allocation policies (where possible) found in (3) to create 
“alternative” allocation policies for investigation; and 
(5) Run a full factorial experiment using the allocation factors identified in 
(3) and the most likely future demand and supply factors. 
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Table 3.10 The Base Scenario and Scenarios where only One Factor Level is 
Changed. 
Scenario Demand Supply Assessment Allocation 
Base 
scenario 
D1 S1 A1 L2 
L3 D1 S1 A1 L3 
L4 D1 S1 A1 L4 
L5 D1 S1 A1 L5 
L6 D1 S1 A1 L6 
L7 D1 S1 A1 L7 
L8 D1 S1 A1 L8 
L9 D1 S1 A1 L9 
L10 D1 S1 A1 L10 
L11 D1 S1 A1 L11 
L12 D1 S1 A1 L12 
L13 D1 S1 A1 L13 
L14 D1 S1 A1 L14 
L15 D1 S1 A1 L15 
L16 D1 S1 A1 L16 
L17 D1 S1 A1 L17 
A2 D1 S1 A2 L2 
A3 D1 S1 A3 L2 
S2 D1 S2 A1 L2 
S3 D1 S3 A1 L2 
S4 D1 S4 A1 L2 
D2 D2 S1 A1 L2 
D3 D3 S1 A1 L2 
D4 D4 S1 A1 L2 
 
3.9 Summary 
This chapter started by summarising the key reasons and objectives for 
modelling the UK Liver Transplant System.  It outlined all the methods which 
are implemented in developing a model for capturing the assessment and 
allocation phases, in order to understand how changes within these phases affect 
the overall outcomes experienced by patients. 
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Hepatica is also designed to incorporate the experimental factors (inputs) which 
capture future demand, future supply, alternative assessment rules and 
alternative allocation rules.  These input factors are based on the likely or viable 
changes which may affect the UK system. 
 
Hepatica allows the measurement of key equity and utility outputs.  A 
methodology for the comparison of equity and utility outputs from the various 
scenarios (as defined by the input factors, Section 3.3) is constructed, to enable 
evaluation of any improvements made by the new scenarios (in particular, new 
assessment and allocation rules).  The utility measures considered are:  
– Life years in the system per patient;  
– Life years gained per transplant; 
– The percentage of patients re-listed within 1 year of receiving a transplant; 
– The percentage of patients to experience death or graft failure within 1 year 
of receiving a transplant; and 
– The percentage of patients to experience death or removal from the waiting 
list, and the number of livers wasted. 
The level of equity within the system was also considered by looking at the 
outcomes that different patients experienced following their arrival onto the 
waiting list, and post-transplant.   
 
This chapter also outlined the specific processes, tests and risk factors employed 
in developing the relevant sub-models.  It also explained the techniques used to 
test the adequacy (i.e., goodness-of-fit) of the models developed. 
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The experimental design used to run the various scenarios in Hepatica was also 
presented.  Normal strategies, such as, full-factorial and fractional-factorial 
designs were explained not to be applicable in this study and therefore a new 
approach has been constructed. 
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Chapter 4 
 
Statistical Sub-Model Development 
 
4.1 Introduction 
This chapter outlines the development of the sub-models which are used within 
Hepatica to determine the flow of patients through the liver transplantation 
system and the arrival of donated livers.  The flows and arrivals help to maintain 
a liver transplant waiting list and determine the outcomes experienced by the 
patients.  As a result of the analyses described in this chapter, the structure of 
Hepatica shown in Section 3.5.1 is reassessed. 
 
4.2 Statistical Sub-Model Development Process 
The general process of model development incorporated the steps outlined in 
Table 4.1, below. 
 
Each model type (e.g., logistic regression model, survival model) requires 
slightly different procedures within some of the steps, in particular within steps 
6 and 7, and these were elaborated on in Sections 3.6.2-3.6.3. 
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Table 4.1 Overall Sub-Model Development Process. 
Step Overall aim of the step Questions to be answered 
(1) 
Identification of required 
models. 
What transition or arrival requires 
modelling? 
Why does it require modelling? 
(2) 
Identification of data 
required and where to 
obtain the data from. 
What data is required? 
What stage of the liver transplantation 
process will this data come from? 
Where will this data be obtained from? 
(3) 
Initial cleaning of the 
data, to eliminate any 
erroneous entries. 
Are there any inconsistencies and 
inaccuracies within the data? 
Are missing values obtainable from other 
data sources? 
(4) 
Initial data analysis and 
data restructuring, to aid 
with understanding 
features of the data. 
Are there any additional covariates or 
recalculated covariates required? 
Do any of the variables need to be 
grouped? 
Basic descriptive analyses utilised to 
identify what distributions the various 
covariates had (e.g., shape of age/weight 
distributions). 
Are there any dependencies that we need 
to be aware of? 
(5) 
Identification of relevant 
mathematical modelling 
approaches. 
What mathematical modelling technique 
is appropriate and why? 
(6) Model development. Which models need developing? 
(7) 
Evaluation of the 
“goodness-of-fit” of the 
models developed. 
How accurately do the developed models 
capture the data? 
Which model is the best in capturing this 
particular transition or arrival? 
 
Some of the steps in Table 4.1 (steps 1, 2, 5, 6 and 7) have been discussed in 
previous chapters and will only be summarised in this chapter.  The actions 
taken in step 3 were similar across all the models which were developed and 
within this step the data were assessed for any items that may have been 
inaccurate (outliers, typing mistakes).  This was done by checking the values 
present in the datasets and making sure that they fell into ranges that seemed 
reasonable.  If they did not, the data points were checked at source. 
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4.3 Assessment Outcome Model 
4.3.1 Development 
The assessment outcome model attempts to capture the patient characteristics 
that influence which patients “join the waiting list”.  Logistic regression was 
identified as being the appropriate modelling technique to capture these 
outcomes (Section 3.2.3).  The data required to create this sub-model are only 
held at individual liver units (Section 3.7.1); in this case the data used were 
obtained from Birmingham Liver Unit.  Patients referred to a liver transplant 
unit with liver failure are placed on a national waiting list if deemed by their 
consultant to meet the assessment criteria (Section 1.3.4).  The likelihood of a 
referred patient being placed on the waiting list is dependent on individual 
patient characteristics (e.g., age, liver disease, urgency, as summarised in 
Section 3.7.2).  Table 4.2 summarises the data regarding these characteristics 
that were available for analysis. 
 
The data was structured with an indicator that represented whether or not a 
particular patient had been placed onto the waiting list; this indicator represented 
the response variable of the logistic regression model.  Of the 736 patients to be 
referred to Birmingham Liver Unit within the observation period, 62.4% were 
eventually placed on the waiting list. 
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Table 4.2 Covariates considered in the Assessment Outcome Model. 
Covariate Appropriate Values Discussion 
Gender 
Male, Female. The prognosis for many diseases 
varies by gender. 
Age 
Age in years. The UK Transplant guidelines 
determine the age of an adult as 17 
for listing onto the waiting list.  
However, before the patients can 
be listed, they need to go through 
an assessment phase, hence 16 year 
olds are also considered in this part 
of the analysis. 
Primary liver 
disease 
Disease groups as 
outlined in Section 
A.1.2 (Appendix A). 
The primary liver disease will 
influence prognosis and is also one 
of the variables by which 
assessment and allocation 
decisions can be changed. 
MELD score 
Both as a continuous 
value based on the 
original score, and as 
a factor variable as 
explained in A.3 
(Appendix A). 
MELD score measures the severity 
of a chronic liver disease (Section 
2.2.2). 
Transplant 
urgency 
Routine, Super 
Urgent. 
Will influence how quickly a 
patient is assessed. 
 
Model Development 
Initially, a decision had to be made as to how to utilise the available MELD 
scores.  Firstly, they are only applicable to chronic liver disease patients.  
Secondly, there is the option to either treat them as a single continuous variable, 
or to group the scores together to leave four factor variables (as explained in 
Section A.3, Appendix A).  Three approaches were therefore trialled in 
modelling the outcome from referral, and these are summarised in Table 4.3.  
Appendix I reports on the details of the development of these models. 
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Table 4.3 Approaches Analysed for the Assessment Outcome Model. 
Approach 
Super Urgent/Acute 
Patients 
MELD Score as a independent 
variable 
A 
Included when developing 
the logistic regression model 
Excluded the MELD score in the 
analysis 
B 
Excluded when developing 
the logistic regression model 
Included the MELD score as a 
continuous variable 
C 
Excluded when developing 
the logistic regression model 
Included the MELD score as 
factor variables 
 
Analysis of the data showed that 95.3% of all super urgent/acute patients were 
placed on the waiting list.  For models B and C it was assumed that all super 
urgent/acute patients were listed onto the waiting list, and the MELD score is 
only used as a factor for the remaining patients who are suffering from chronic 
liver disease (since the score is not applicable to patients with super urgent or 
acute liver diseases). 
 
Goodness-of-Fit 
The goodness-of-fit tests used are summarised in Table 4.4.  The percentage of 
correct classifications is defined as: 
N
ba 
  (4.2) 
where  a = number of observed patients not listed & to have a calculated 
response value of “0” from the model, 
b = number of observed patients listed & to have a calculated response 
value of “1” from the model, 
N = the total number of patients. 
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Table 4.4 Goodness-of-Fit Tests the Assessment Outcome Model. 
A
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A Super Urgent/Acute 
Liver Disease 
Unknown Liver Disease 
Cryptogenic Liver 
Disease 
Alcoholic Liver Disease 
Hepatitis C 
Age 
No 69.0 (logistic 
model for all 
patients) 
0.14 0.82 
B Unknown Liver Disease 
Cryptogenic Liver 
Disease 
Alcoholic Liver Disease 
Hepatitis C 
Age  
MELD score 
Yes 66.2 (logistic 
model for routine 
patients) 
+ 
736
61
3.95   
(super urgent 
cases) 
= 74.1 
0.10 0.98 
C Unknown Liver Disease 
Cryptogenic Liver 
Disease 
Alcoholic Liver Disease 
Hepatitis C 
Age  
MELD group 2 
Yes 66.2 (logistic 
model for routine 
patients) 
+ 
736
61
3.95   
(super urgent 
cases) 
= 74.1 
0.12 0.76 
* when all super urgent patients are assumed to be listed, they were excluded 
from the development of the logistic regression model and the last two columns 
report statistics for just the logistic regression model which considered just the 
routine patients. 
 
4.3.2 Final Model 
From Table 4.4 we can see that Approach B provides the best fit, since it 
classifies the greatest percentage of patients into the correct outcome groups 
(compared to the observed outcomes), explains roughly the same amount of 
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variation as the other models, and the model fits the data most closely when 
considering the Hosmer and Lemeshow test.  Table 4.5 outlines the details of 
this logistic regression model and Figure 4.1 presents a box plot of the predicted 
probabilities by the observed outcomes, of those suffering from Chronic Liver 
Diseases. 
 
Table 4.5 Logistic Regression Model B - for capturing the Assessment Outcomes 
for Chronic Liver Disease Patients. 
Covariate B/coefficient 
Significance of 
Wald statistic 
Exp(B) 
Age -   .022 .007 .978 
Unknown Liver Disease - 1.503 <0.001 .222 
Cryptogenic Liver Disease - 1.068 <0.001 .344 
Alcoholic Liver Disease - 1.457 <0.001 .233 
Hepatitis C -   .594 .014 .552 
MELD score -   .026 .021 .974 
Constant 2.641 <0.001 14.021 
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Figure 4.1 Box Plot of the Predicted Probabilities as Estimated using the Final 
Model from Approach B, by the Observed Outcomes of Not Listed or Listed. 
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Interpretation and Evaluation of the Resultant Model 
From the model details in Table 4.5 (column 3), we can see that each of the 
variables present in the final model are significant at the 95% level.  The model 
helps us to identify some key factors which influence whether or not a patient 
suffering from chronic liver disease joins the waiting list.  All the coefficients of 
the factors are negative which means that: 
(1) As the age of the patient increases the patient is less likely to be placed on 
the waiting list (the likelihood of being listed decreases by 2.2% for every 1 
year increase in patient age).  This seems a reasonable representation since 
older patients may be less likely to be listed onto the waiting list, as they are 
more likely to have complications (other illnesses) which may make a liver 
transplant less viable; 
(2) If the patient had an illness that falls into one of: unknown liver disease, 
cryptogenic liver disease, alcoholic liver disease and hepatitis C, they are 
less likely to be placed on the waiting list (by 77.8%, 75.6%, 76.7%, and 
44.8% respectively) than those not diagnosed with any of these diseases.  
This is a reasonable approximation, since patients with alcoholic liver 
disease are assessed to more stringent criteria which will restrict the number 
who join the waiting list.  Hepatitis C patients may also miss out due to the 
likelihood of their disease recurring.  There may be uncertainty as to the 
benefit to be gained from a liver transplant where the cause of liver disease is 
unknown; and 
(3) As the MELD score (continuous values) increases by 1 unit the patient is 
2.6% less likely to be placed onto the waiting list.  Table 4.6 shows how the 
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likelihood of being listed onto the waiting list by MELD group, from the 
observed data.  From groups 2, 3, and 4, the model applies as the probability 
of listing is decreasing.  However, group 1 patients are less likely to be listed 
than group 2 patients, and this is contrary to what the logistic regression 
model predicts.  This contradiction could be due to dependencies between 
other factors which are consider in the model and also due to only 95 
patients having a MELD score captured by MELD group 1, while 576 
patients had MELD scores represented by the other groups. 
 
Table 4.6 Percentages of Patients observed as listed within the Birmingham 
data, by MELD Group. 
Group % Listed within Group Total Number in Group 
MELD 1 55.2 95 
MELD 2 68.0 379 
MELD 3 50.4 156 
MELD 4 47.4 41 
Super Urgent Patients 95.3 65 
 
 
4.3.3 Overall Evaluation 
Overall, it was not possible to provide a convincing statistical analysis of the 
selection procedure for the waiting list for patients with ESLD.  From Figure 4.1 
it can be seen that the resultant model does not adequately differentiate between 
patients who joined the waiting list and those that did not.  There were several 
limitations to the analysis performed and hence the use of the logistic model was 
not accurate in capturing the overall outcome.  The key issues were: 
- No adequate differentiation between those placed on the waiting list and 
those that are not.  Only 74% were correctly placed through using a logistic 
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regression model to predict the outcome for the chronic liver disease 
sufferers and by assuming that all super urgent patients were listed; 
- Limited data were available: MELD score, age, disease groups, gender.  Pre- 
and post-transplant life expectancies, on which the decision to list a patient 
on the waiting list is based, were not truly captured.  These measures were 
hard to obtain as consultants are not given specific guidelines on how to 
assess the survival pre- and post- transplant.  Patients are placed on the 
waiting list when their consultant broadly feels that they fit the survival 
criteria outlined in the assessment criteria (as detailed in Section 1.3.4); and 
- The patient mix, in terms of disease groupings and age distributions that 
joined the waiting list from Birmingham Liver Unit is not statistically similar 
to the patient mix that joined the waiting list from all over UK (as analysed 
in Appendix I, Section I.4). 
 
As a result it was decided to abandon the plan to create a model to represent the 
assessment phase.  Instead, analysis was performed on patients who arrived 
straight onto the waiting list (as described in Section 4.6) and the information 
from this allowed for the generation of  patient characteristics and arrival rates, 
within Hepatica.  Changes to the assessment criteria can still be simulated by 
changing the rate of arrivals, and the prognoses of patients who are placed on the 
waiting list.  This would provide a rudimentary way in which to evaluate the 
likely impact of any changes to the assessment process.  
 
The revised model structure of Hepatica is depicted in Figure 4.2 below. 
  
Statistical Sub-Model Development 
 
150 
 
Figure 4.2 Revised Flow Diagram of Events Captured in Hepatica. 
 
4.4 Waiting List Outcome Model 
4.4.1 Development 
Once a patient joins the waiting list there are a number of different outcomes 
that they can experience.  Most patients will either receive a transplant, or will 
die.  Some will be removed from the waiting list completely, while others will 
be suspended for a short period. 
 
Suspension refers to the situation where a patient is taken off the waiting list 
temporarily, perhaps because they are suffering from another illness and must 
recover before they will have a realistic chance of surviving the transplantation 
process.  The intention is that all patients who are suspended from the waiting 
list will re-join it at some point.  As such, it is not the final outcome for the vast 
majority of patients.  Table 4.7 below indicates that of all the patients who 
joined the waiting list between the start of 1999 and the end of 2002, only four 
patients were recorded as suspended on 6th October 2003.  No information is 
available about the number of patients who were suspended and then re-joined 
Death/ 
Removal 
Patients 
Arrive on 
the  
Waiting List 
Livers Donated 
Re-Listing 
Liver Allocated 
& Transplanted 
Death/Graft 
Failure 
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the waiting list, which means that it is not possible to model this event with any 
accuracy.  This outcome was therefore omitted from the model. 
 
Table 4.7 Frequencies of eventual patient outcomes from the waiting list. 
Status 
Patients who joined the waiting list from 1/1/99 to 
31/12/02, as known on 6/10/03 
Number Percentage (%) 
Transplanted 2049 83.5 
Removed 181 7.4 
Dead 208 8.5 
Suspended 4 0.2 
Active* 11 0.4 
Grand Total 2453  
* patients still on the waiting list as on 6/10/03 
 
The time until transplant is dependent on the allocation policy in place and the 
characteristics of the donors and patients.  As such, it is not a transition that 
needs to be modelled explicitly, although it would be expected that the modelled 
times to transplant should be comparable to those experienced in reality. 
 
The key requirement for Hepatica is therefore to estimate transition times to 
removal and/or death from the point that a patient joins the waiting list, and how 
these are dependent on the characteristics of the patient. 
 
Information about the outcomes experienced by patients once they have joined 
the liver transplant waiting list is obtained from UK Transplant (Section 3.7.1).  
The dependent variables analysed were the different outcomes experienced and 
the time until these occurred.  The patient characteristics previously discussed in 
Section 3.7.2 (and listed in Table 4.8 below) are those covariates believed to 
influence these outcomes and the transition times between events. 
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Table 4.8 Covariates considered for the Waiting List Outcome Model. 
Covariate Appropriate Values Discussion 
Primary 
Liver Disease 
Disease groups as 
outlined in Section 
A.1.2 (Appendix A). 
The primary liver disease will 
directly influence prognosis. 
Transplant 
Number 
First, Successive. Patients waiting for successive 
transplants will in general be more 
ill. 
Gender 
Male, Female. The prognosis for many diseases 
varies by gender. 
Transplant 
Urgency 
Routine, Super 
Urgent. 
Will influence patient prognosis. 
Centre 
Registered at 
A, B, C, D, E, F, G. Different centres may interpret 
registration criteria slightly 
differently.  Other aspects may vary 
by centre (e.g., resources) which may 
influence outcomes. 
Age 
Age in days. Older patients may suffer from 
illnesses other than liver disease. 
 
The most likely reason for a patient being removed from the waiting list is that 
the patient has become too ill to benefit from a transplant (i.e., their life 
expectancy is very low).  This implies that the outcomes of death and removal 
are closely related – both events occurring if the patient becomes very ill – and 
so the groups of patients experiencing each of these outcomes are likely to be 
very similar.  Three outcomes were therefore modelled and investigated: (1) 
death, (2) removal, and (3) death or removal.  This third outcome, and the 
reasons for considering it, are discussed in more detail in the segment below on 
Model Development.  Ultimately the decision to be made is whether these two 
events can be modelled as one, or if they need to be modelled separately. 
 
Model Development 
Basic descriptive analyses were utilised in identifying how the various attributes 
were distributed.  The clearest result from this was that, as expected, the 
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transition times for super urgent patients were far smaller than for patients 
waiting for a routine transplant (Table 4.9).  This suggests that separate models 
may be required to estimate the time to death and/or removal for these two 
groups of patients. 
 
Table 4.9 Average time (days) from joining the waiting list to the outcome 
experienced by the urgency of transplant. 
Urgency Death or Removal Transplantation 
Routine 90 79 
Super Urgent 5 3 
Overall 67 66 
 
Figure 4.3 depicts the hazard rate curves (as defined in Equation (2.8)) for the 
events to transplantation, to death, to removal, and to unknown event (as at the 
end of the observation period) for all patients who joined the waiting list.  The 
hazard rate curves for the events death and removal are similar and the hazard 
rate curve for transplant is significantly different.  Since the death and removal 
hazard rates are similar over time, this provides justification that these events 
may be combined, as they have a similar chance of occurring at any one point in 
time and are independent of cause.  For this reason, the combined event death or 
removal (censored at transplant) will be modelled instead of the two separate 
events death and removal. 
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Figure 4.3 Hazard Rates for all outcomes from the waiting list for all patients. 
 
Figures 4.4 and 4.5 show the hazard rates of (1) death or removal, (2) 
transplantation, and (3) unknown (censored) events, by the urgency of the 
required transplant.  Figure 4.4 shows that most super urgent patients will 
experience one of these outcomes within the first 5 days.  The hazard rates then 
level off, with very few patients remaining on the waiting list after this time.  
Figure 4.5 show similar patterns between the two curves, the hazard rates for 
death or removal, and transplantation declining at a similar rate.  This indicates 
that the two hazards are not independent of one another.  This implies that a CR 
model would be more suitable than a survival model.  A CR model was 
therefore developed as well as the survival model.  In addition to capturing death 
or removal event (as for survival model) it also captures Transplantation and 
censors the unknown events. 
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Figure 4.4 Hazard Rates for all outcomes from the waiting list for patients 
waiting for a super urgent transplant. 
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Figure 4.5 Hazard Rates for all outcomes from the waiting list for patients 
waiting for a routine transplant. 
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Log  Cumulative Hazard plots (Appendix J, Sections J.1 and J.1.3) confirm that 
the times to death or removal from the waiting list of routine patients satisfy the 
PHs assumption.  The Cumulative Hazard plot (Appendix J, Section J.1.2) 
confirms that an AFT model would be more appropriate for capturing the 
survival times of the super urgent patients.  The plots by outcome (Appendix J, 
Section J.1.6) confirm that an AFT CR model would be appropriate for 
modelling the times to death or removal, and to transplantation. 
 
Different parametric versions of the survival and competing risks models were 
next developed, and following goodness-of-fit analysis the most appropriate 
models were identified.  The two most appropriate models were: 
(1) Survival Models: 
– A log-logistic survival (AFT) model to capture the times to death or 
removal censored at all other events for patients requiring a super urgent 
transplant;  
– A Weibull (PH) model stratified by first transplant or not, to capture the 
times to death or removal censored at all other events for patients 
requiring a routine transplant. 
(2) Competing Risks Model:  
– A Weibull model (re-parameterised as AFT) stratified by first transplant 
or not, to capture the events death or removal, and transplantation 
censored at all other events. 
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The model development processes are summarised in Appendix J, and the 
goodness-of-fit analyses (plots of the Kaplan-Meier Estimates and the Weibull 
curves) conclude that the competing risks model captures the death or removal 
event more closely. 
 
Figures 4.6-4.7 show the overall fit of the competing risks Weibull model (for 
simplicity a null model is presented here), which was identified as the most 
appropriate from the goodness-of-fit analysis performed (Appendix J), and will 
be used within Hepatica.  It is interesting to see the shape of the fitted curves, 
however, we can not expect the same shape as the initial Kaplan-Meier curves, 
since the null model would represent an “average” person and the older patients 
may pull the curve down unrealistically.  Also, few actual deaths or removals 
will be recorded for the longer times (due to patients lost to follow-up etc.) and 
so the Kaplan-Meier curve will have larger confidence intervals (i.e., more 
uncertainty to the tail end of the graphs shown). 
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Figure 4.6 Weibull Competing Risks null model and Kaplan-Meier Estimate for 
the event Death or Removal for patients awaiting their first transplants. 
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Figure 4.7 Weibull Competing Risks null model and Kaplan-Meier Estimate for 
the event Death or Removal for patients awaiting their successive transplants. 
 
4.4.2 Final Model 
The Weibull competing risks model developed (Appendix J) captures the times 
to the outcomes, death or removal, and transplantation, from the point that the 
patient joins the waiting list.  However, it will only be required to estimate the 
times to death or removal within Hepatica, the decision about when to transplant 
a patient will be dependent on the allocation rules in place (as explained in 
Section 4.4.1).  From Figures 4.6 and 4.7 it can be seen that the competing risks 
model (which takes no account of explanatory variables) provides a reasonable 
approximation to the observed data (Kaplan-Meier Estimate), especially within 
the early days, when most of the events occur.  
 
The times estimated using the models will have no upper bound so in order to 
make them more realistic, when applying this sub-model to Hepatica, the 
estimated death or removal times will be truncated at 730 days from joining the 
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waiting list for patients requiring a routine transplant and 60 days from joining 
the waiting list for patients requiring a super urgent transplant.  Additionally, all 
patients progressing through the model are given a maximum life expectancy of 
95 years.  This constraint is more significant when determining post-transplant 
survival times (see Section 4.5.2) but could be of relevance for patients being re-
listed onto the waiting list.   
 
The formulae which will be used in generating the death or removal times 
(Equations (4.3) and (4.4)) are based on the general formula of the pth percentile 
value for the ith individual, for the Weibull model: 





 












 
 ii x
p
pt 
100
100
loglogexp)(   (4.2) 
where )( pt i  is the length of time after joining the waiting list that patient i
 will  
experience death or removal, 
p  is the percentile value, 
shape
1
 , 





 



expscale , 
  is the mean, 
  is a vector of coefficients of the explanatory variables, 
ix  is a vector of the explanatory variables for the i
th individual. 
Hence, the model fitted in Appendix J gives the following two equations ((4.3) 
and (4.4)) for generating the times to death or removal. 
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For patients joining the waiting list for their first liver transplant: 
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where f(txurg) represents the cut-off times for different urgencies of transplant. 
Table 4.10 details the explanatory variables in vector ix . 
 
For patients joining the waiting list for their successive liver transplants: 

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where the variables are as before. 
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Table 4.10 Explanatory Variables of the Weibull Competing Risks Waiting List 
Outcome Model. 
Explanatory 
Variables 
Corresponding Patient Characteristic 
iB  
1 if patient is from Centre B 
0 if patient is not from Centre B 
iC  
1 if patient is from Centre C 
0 if patient is not from Centre C 
iE  
1 if patient is from Centre E 
0 if patient is not from Centre E 
iAge  Patient age in days, at registration on to the waiting list 
iGender  
1 if a male patient 
0 if a female patient 
iUrgency  
1 if requiring a super urgent transplant 
0 if requiring a routine transplant 
iDisease1 sPatient'  
1 if patients primary liver disease is either primary 
biliary cirrhosis, autoimmune cirrhosis, or secondary 
biliary cirrhosis 
0 if a different primary liver disease 
iDisease3 sPatient'  
1 if patients primary liver disease is related to cancer 
0 if a different primary liver disease 
iDisease5 sPatient'  
1 if patients primary liver disease is diagnosed but falls 
into the “other” category 
0 if a different primary liver disease 
iDisease8 sPatient'  
1 if patients primary liver disease is Hepatitis B 
0 if a different primary liver disease 
iDisease12 sPatient'  
1 if patients primary liver disease was not reported 
0 if a different primary liver disease 
 
Equations (4.4) and (4.5) can be used to generate times by generating a random 
number for p  between 0 and 99. 
 
Interpretation and Evaluation of the Resultant Model 
The explanatory variables iB , iUrgency , iGender , iDisease3 sPatient' , 
iDisease8 sPatient' , and iDisease12 sPatient'  have negative coefficients.  This 
indicates that if a patient falls into any one of these groups (i.e., from centre B, 
super urgent patient, male patient, patients with liver cancer, patients with 
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Hepatitis B, and patients with non reported liver disease), then the time to death 
or removal once joining the waiting list, is shorter (i.e., they are worse off) than 
for a patient who does not have any of these characteristics.  iAge  also has a 
negative coefficient, which implies that the older the patient, the lower the pre-
transplant life expectancy. 
 
The explanatory variables which have positive coefficients are: iC , iE , 
iDisease1 sPatient' , and iDisease5 sPatient'  (i.e., from centre C, from centre E, 
patients with other cirrhotic diseases, and patients with other diagnosed disease), 
with patients from these groups the time between listing and death or removal is 
longer than for similar patients without these characteristics. 
 
The model is realistic since, the very large negative coefficient for urgency 
captures that super urgent patients will survive for a much shorter period than 
routine patients.  It also captures the effect of older patients surviving for a 
shorter period of time on the waiting list.  Centre effects are also captured, 
which will reflect how the different centres interpret the assessment guidelines 
and the variation in the patient mix joining the waiting list from each of the 
centres. 
 
This model will be used within Hepatica when a patient joins a waiting list.  
Within Hepatica a time will be sampled from the model to determine when the 
patient will experience death or removal from the waiting list (assuming that 
they do not receive a transplant in the meantime). 
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4.4.3 Overall Evaluation 
The model which has been developed can be sampled from within Hepatica, 
using a formula to determine death or removal from once a patient has joined the 
waiting list.  It allows for times to be generated for the whole range of liver 
diseases represented by patients that join the waiting list.  This avoids the use of 
detailed, disease specific models which have been implemented in previous liver 
transplant matching models (Eldabi et al. 2001). 
 
A CR approach allows for multiple events to be modelled simultaneously.  This 
is useful when there are several possible outcomes, and when the outcomes 
which require censoring are not independent of one another.  Here the time to 
transplantation and the time to unknown events, have different hazards (Figures 
4.3 to 4.5) and so a CR approach is applicable. 
 
Figures 4.6 and 4.7 show Kaplan-Meier plots with the null Weibull CR model 
curves.  These look like reasonable approximations, however will never be 
identical, due to the cohort not representing an “average” person.  The Kaplan-
Meier estimate and estimated curve (as presented in Appendix J) show that the 
fit is reasonable. 
 
  
Statistical Sub-Model Development 
 
164 
4.5 Post-Transplant Outcome Model 
4.5.1 Development 
The next set of models to be developed aim to capture the outcomes experienced 
by the patients after they have been transplanted with a new liver.  The possible 
outcomes which were considered after a patient receives a liver transplant were: 
graft failure, death and re-listing.  The key requirement for Hepatica is to 
determine which outcome a patient will experience, and when, based on the 
characteristics of the patient, donor, and the transplant operation performed (as 
outlined in Section 3.7.2), and summarised in Table 4.11.  
 
Many previous studies model the event of graft failure separately to death, 
however, once a patient’s liver graft fails, they generally die within 24 hours.  
Within the observed data, 99.5% of patients to experience graft failure (but not 
re-listed), died within 24 hours and the remainder within 48 hours.  Once a 
patient is re-listed onto the waiting list they are assumed to follow the outcomes 
as defined by the distributions developed in Section 4.4.  Therefore, we are only 
interested in modelling the two outcomes post-transplantation of (1) re-listing 
and (2) death or graft failure.  Since the majority of deaths which are observed 
within the data will ultimately be due to liver failure, the events death and graft 
failure can be combined and it is not required to distinguish if the deaths are due 
to other causes (Gunson 2004). 
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Table 4.11 Covariates considered for the Post-Transplant Outcome Model. 
Variable Appropriate Values Discussion 
Donor-Patient 
ABO match 
Identical, Compatible, 
Incompatible (as defined in 
Section B.1, Appendix B). 
Blood group match will 
influence early graft rejection. 
Cold ischaemic 
time 
> 12 hours or not. The time a liver spends outside 
of a body will influence how the 
liver functions post-transplant. 
Donor age 
> 65 years or not. Defines a characteristic of 
marginal livers, which are 
associated with shorter survival. 
Donor cause of 
death 
Donor cause of death groups 
outlined in Section A.2 
(Appendix A). 
Defines a characteristic of 
marginal livers, which are 
associated with shorter survival. 
Transplant 
Number 
First, Successive. The transplant number will 
influence both the severity of 
illness and issues such as 
recurring diseases. 
Completeness of 
liver used 
Whole, Reduced, Split. Defines a characteristic of 
marginal livers, which are 
associated with shorter survival. 
Primary liver 
disease at 
registration 
Disease groups as outlined in 
Section A.1.2 (Appendix A). 
Certain liver disease will have a 
greater chance to recurring post 
transplant. 
Patient Age at 
transplant 
Age in days. Older patients may suffer from 
illnesses other than liver 
disease. 
Recipient/Donor 
rhesus match 
Match, No Match. Rhesus match is known to effect 
other post-organ transplant 
survival. 
Transplant 
Urgency 
Routine, Super Urgent. The severity of illness before 
the transplant may influence 
how likely a patient is to recover 
from the operation. 
MELD score 
Both as a continuous value 
based on the original score, 
and as a factor variable as 
explained in A.3 (Appendix 
A). 
The severity of illness before 
the transplant may influence 
how likely a patient is to recover 
from the operation. 
Donor gender to 
Recipient 
Gender 
4 groups: male to male, male 
to female, female to male, 
female to female. 
Gender may influence the size 
and weight of an organ which 
may affect the overall outcome 
experienced. 
Donor weight 
minus Patient 
weight 
Continuous variable. Weight matching is considered 
important in the current system. 
Patient Body 
Mass Index 
Factor variable as defined in 
Section A.4 (Appendix A). 
Body mass index may influence 
the ability of recovering from 
the transplant. 
Patient Gender 
Male, Female. The prognosis for many diseases 
varies by gender. 
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Information about transplant operations and the outcomes of patients post-
transplant is kept by UK Transplant, and was obtained from them for this 
analysis (Section 3.7.1).  However, some outcomes will not be reported, as the 
patients will eventually go back to just seeing their general practitioners, who 
will monitor progress themselves. 
 
The dependent variables for this analysis were the outcomes experienced and the 
time at which these outcomes occur.  The independent variables (listed in Table 
4.11) considered were identified as potentially influencing the possible 
outcomes post-transplant, and included patient and donor attributes and MELD 
score which is based on clinical measures.  MELD score may influence the post-
transplant outcomes a patient experiences, since it can determine the severity of 
a patient’s illness and justify a decision to re-list or not. 
 
Model Development 
Basic descriptive analyses were utilised in identifying which distributions the 
various attributes took (e.g., shape of age/weight distributions). 
 
Figure 4.8 depicts the hazard rate curves (as defined in Equation (2.8)) for the 
events: (1) to re-listing, (2) to death or graft failure, and (3) to unknown eventual 
outcomes, post-transplantation.  It confirms that the hazard rate curves for the 
events re-listing, death or graft failure, and unknown events are different from 
one another (i.e., not independent of cause), and that the competing risks 
modelling approach may be more applicable. 
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Figure 4.8 Hazard Rates for all the outcomes post-transplantation for all 
patients. 
 
However, as for pre-transplant, both types of models (a survival model and a 
competing risks model) will be developed.  The survival model will consider the 
outcome death, graft failure, or re-list censored at unknown events.  While the 
competing risks model will consider the two outcomes death or graft failure, and 
re-listing censored at unknown outcomes.  From the methodology outlined in 
Sections 3.6.3 [A] and under the competing risks model development process 
section (and presented in Appendix K), it was determined that the log-logistic 
survival model which considered the event death, graft failure, or re-list 
censored at all other events, was the most appropriate for capturing the post-
transplant outcomes. 
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The competing risks modelling approach was found not to be applicable for the 
post-transplant outcomes, since the basic assumptions, of PH or AFT under 
competing risks, did not hold.  This is shown by the lines crossing in the plots of 
Log Cumulative Hazard by outcome (Appendix K Section K.1.5 Figure K.4) 
and Cumulative Hazard by outcome (Appendix K Section K.1.6 Figure K.5). 
 
Figure 4.9 shows that the overall fit of the null log-logistic survival model 
developed, with the Kaplan-Meier survival estimate. 
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Figure 4.9 Log-Logistic null survival model and Kaplan-Meier Estimate for the 
event Death/Graft Failure and Re-Listing post-transplant. 
 
4.5.2 Final Model 
The developed log-logistic survival model (Appendix K) captures the time to the 
outcomes death/graft failure or re-listing, from transplantation.  Figure 4.9 
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indicates that the null log-logistic model provides a reasonable fit to the 
observed survival Kaplan-Meier Estimate.  In order to ensure that realistic 
survival times are estimated, it will be assumed that patients will only live until 
they are 95 years old, and so the related survival times will be cut accordingly. 
 
For the log-logistic survival model, the pth percentile value for the ith individual 
is:  

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
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logexp)(    (4.5) 
where )( pt i  is the length of time after joining the waiting list that patient i
 will  
experience death or removal, 
p  is the percentile value, 




 , 


1
 , 
  and  represent the log logistic distribution parameters, 
  is the mean, 
  is a vector of coefficients of the explanatory variables, 
ix  is a vector of the explanatory variables for the i
th individual. 
 
This formula can be used to generate a death/graft failure/re-list time for the 
patients who have been transplanted.  The model fitted in Appendix K gives the 
following equation for generating these times: 
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where the variables are as before and where  
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 within developed model.  
Table 4.12 details the explanatory variables in vector ix . 
 
Equation (4.6) can be used to generate times from transplantation to a post-
transplant outcome by generating a random number for p  between 0 and 99. 
 
Interpretation and Evaluation of the Resultant Model 
The log-logistic survival curve implies that the hazard just after transplantation 
increases and then starts to decrease.  The risk of re-listing or death/graft failure 
is greatest straight after a transplant as this is when the immune system may 
reject a graft.  After this time the risk diminishes. 
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Table 4.12 Explanatory Variables of the Log-Logistic Survival for the Post-
Transplant Outcome Model. 
Explanatory Variables 
Corresponding Patient, Donor, or Transplant 
Characteristic 
iWhole  
1 if the patient was transplanted with a whole liver 
0 if the patient was not transplanted with a whole liver 
iDAge  
1 if the liver came from a donor aged over 65 years 
0 if the donor was less than 65 years old 
iDcod5  
1 the donor died due to an infection 
0 the donor did not die due to an infection 
iPWeightDWeight )(   The difference between the donor weight and patient weight 
iMeld3  
1 if MELD score at the time of transplant is in group 3 
0 if MELD score in another group 
iPAge  Patient age at the time of the transplant 
iDisease1  
1 if patient’s primary liver disease is either primary biliary 
cirrhosis, autoimmune cirrhosis, or secondary biliary 
cirrhosis 
0 if a different primary liver disease 
iDisease5  
1 if patient’s primary liver disease is diagnosed but falls into 
the “other” category 
0 if a different primary liver disease 
iDisease6  
1 if patient’s primary liver disease falls in the super 
urgent/acute disease group 
0 if primary liver disease does not fall in to the super 
urgent/acute disease group 
iDisease10  
1 if patient’s primary liver disease is alcoholic liver disease 
0 if primary liver disease is not alcoholic liver disease 
iIdentical  
1 if the patient’s blood group was identical to the donors 
blood group 
0 if blood groups were different 
 
The explanatory variables iDAge , iDcod5 , iMeld3 , iDisease5 , and iDisease6  
have negative coefficients.  This indicates that if a patient or their transplantation 
characteristics fall into any one of these groups, then the time from 
transplantation to death/graft failure or re-listing is shorter than for a patient who 
does not fall into any of these groups.  iPAge  also has a negative coefficient, 
which implies a reduction in the time to death/graft failure or re-listing from 
transplantation, for older patients.  A patient aged 10 years older than another 
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with the same characteristics will progress along the survival curve 1.45 times 
faster (based on the acceleration factor )exp(1 ix 
  = )100373.0exp(  ). 
 
The explanatory variables which have positive coefficients are: iWhole , 
iDisease1 , iDisease10 , and iIdentical , indicating that patients from these 
groups, experience a longer time between transplantation and Death/Graft 
Failure or Re-Listing, than similar patients who do not have these 
characteristics. 
 
The model seems realistic as it identifies that characteristics associated with 
marginal livers (donor age, donor cause of death, non-whole), significantly 
reduce the time to a post-transplant outcome.  As expected, it also identifies that 
as patient age increases the time to post-transplant outcome decreases.  The 
model also captures that identically matched blood groups give rise to longer 
times to post-transplant events.  This is realistic since patients with identically 
blood-matched livers are less likely to experience early graft rejection. 
 
4.5.3 Overall Evaluation 
The model which has been developed provides a formula which is easy to 
implement in the sampling of Death/Graft Failure or Re-Listing times, from 
once a patient has received a liver transplant.  It allows for times to be generated 
for the whole range of liver diseases represented by patients that join the waiting 
  
Statistical Sub-Model Development 
 
173 
list.  This avoids the use of detailed, disease specific models which have been 
implemented in previous liver transplant matching models (Eldabi et al. 2001). 
 
The log-logistic model developed also allows capture of the higher initial risk, 
soon after transplant, through the use of a non-monotonic hazard function. 
 
Figure 4.9 show Kaplan-Meier plots with the null log-logistic survival model 
curve.  This looks like a reasonable approximation, however it will never be 
identical, due to the cohort not representing an “average” person.  The Cox-Snell 
residuals (as presented in Appendix K) determine how well the model fits and 
Figure K.7 shows that the fit is reasonable. 
 
4.5.4 Further Validation 
A recent study (Barber et al. 2007) considered the survival of adult patients 
(patients aged 17 years or older at the time of transplantation) who had been 
transplanted with a new liver, in the UK, between 1 January 1985 and 31 
December 2003.  Barber et al. (2007) developed a parametric AFT model with 
an underlying Weibull distribution for the survival times.  Their calculations 
estimate that the median survival time of the liver allograft recipients was 22.2 
years (95% confidence interval 19.3-25.6 years). 
 
Using the post-transplant outcome model, summarised in Section 4.5.2, a similar 
calculation was performed.  The log-logistic survival model was used to 
calculate median survival times (time to either death, graft failure, or RL) for the 
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patients observed to have been transplanted in the UK after joining the waiting 
list between 1 January 1999 and 31 December 2002, by 6 October 2003.  An 
average of the median times was then calculated and this estimated that liver 
transplantation lengthens the life of a patient suffering from ESLD by 19.7 
years.  This estimate falls within the confidence limit which Barber et al. (2007) 
have estimated and is comparable to their result, when taking into account some 
inherent differences between calculations and study populations: 
(1) Barber et al. (2007) only estimate the survival benefits gained by patients 
who have survived for at least 6 months post-transplant, whereas our 
calculation considers all the transplanted patients; and 
(2) The mix of patients in both studies is slightly different to one another, as 
Barber et al. (2007) consider a proportion of patients transplanted between 1 
January 1985 and 31 December 2003, whereas we consider the patients who 
joined the waiting list between 1 January 1999 and 31 December 2002 and 
who were transplanted by 6 October 2003. 
 
4.6 Patient and Donor Arrivals and Assignment of 
Characteristics 
4.6.1 Arrival Rates 
After initial checks for erroneous data, Stat::fit (an add-in available to run within 
the software package Simul8 which statically fits data to the most useful 
analytical distribution (Stat::fit is developed by GEERMS)) was used to fit 
distributions to the patient and donor arrivals.   Stat::fit was used to determine 
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whether the arrival data resembled a Poisson process and hence decide whether 
the negative exponential distribution was appropriate for generating both patient 
and donor inter arrival times, (when interpreting the Chi-squared statistic, at the 
99.9% level of significance).  The arrival rates used within Hepatica were 
determined by the factors considered within Sections 3.3.1 and 3.3.2. 
 
4.6.2 Assignment of Characteristics 
When patients and donors arrive into the simulation model they are assigned 
characteristics which determine the patient to whom a liver transplant is 
allocated (based on the policy in place, as outlined in Section 3.3.4), and 
determine the patients’ eventual outcome (as defined through the models in 
Sections 4.4 and 4.5).  Therefore, the characteristics assigned are based on the 
information which is required for the allocation of the liver transplants and the 
information required in estimating survival times.  Appendix L looks at the 
characteristics required and summarises any dependencies (e.g., a higher 
proportion of the Super Urgent/Acute disease group will require a super urgent 
transplant, than the other disease groups).   
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Table 4.13 Dependencies Found Between Characteristics to be Assigned. 
 Dependencies Between 
Patient Characteristics 
Disease group and Transplant urgency 
Disease group and First transplant 
Disease group and Transplant centre 
Disease group and Patient gender 
Disease group and MELD group 
Transplant urgency and First transplant 
Transplant urgency and Patient gender 
Transplant urgency and MELD group 
First transplant and MELD group 
Transplant centre and MELD group 
Transplant centre and Blood group 
Patient weight and Patient gender 
Donor Characteristics 
Whole liver and Donor cause of death 
Whole liver and Transplant centre 
Donor cause of death and Transplant centre 
Donor age and Whole liver 
Donor age and Donor cause of death 
The analysis reported several dependencies, which are summarised in Table 
4.13.   
 
4.7 Summary 
This chapter summarised the development of the statistical sub-models which 
will be used within Hepatica, as well as explaining the main assumptions made.  
Statistical modelling techniques were employed, using a variety of software 
packages. 
 
Three main models are developed, to capture outcomes from (1) assessment, (2) 
the waiting list, and (3) post-transplantation.  Dependencies between attributes 
values were also tested for, to ensure correct assignments were made to the 
donors and the patients. 
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A logistic regression model captured the assessment decisions (of whether or not 
to list patients onto the waiting list) in one liver unit.  The analysis found the 
following patient attributes significant in determining which patients are listed: 
transplant urgency, age, disease group, and MELD score.  However, due to data 
limitations (as discussed in Section 4.3.3), this analysis led to a revision of the 
simulation model to be built and the simulation model will now not explicitly 
model the assessment phase. 
 
A Weibull Competing Risks model captured the waiting outcomes (to death or 
removal and to transplantation).  The patient attributes which were significant in 
predicting the time to an outcome from the waiting list, are: liver transplant 
number, centre, age, gender, transplant urgency, and disease group.  The 
competing risks model was found to be more accurate than a survival model, as 
it can explicitly model the outcome of transplantation while the survival model 
would have to censor these times. 
 
A log-logistic Survival model captured the post-transplant outcomes (to death, 
graft failure, or re-list).  The attributes found to be significant are: transplant 
urgency, disease group, patient age, MELD group 3, donor weight minus patient 
weight, and attributes which describe a marginal liver (whole, donor age greater 
than 65 years, and donor cause of death due to infection).  The log-logistic 
model indicates that there is a higher initial risk of death, graft failure, or re-list, 
which would be expected as the patient’s body adjusts to the new liver, and 
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immunosuppression treatment.  The post-transplant model has been validated 
using the results from a recently published study (Barber et al. 2007). 
 
Overall interpretation of the sub-models suggested that as patient age increases, 
patients are less likely to be transplanted and more likely to die, or if 
transplanted, to experience graft failure or death quicker.  This could be since 
patients are less likely to be listed or allocated a transplant if they are older and 
also that older patients often suffer from more complications than younger 
patients. 
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Chapter 5 
 
Simulation Design, Verification and Validation 
 
5.1 Introduction 
This chapter details the various assumptions that have been made when 
designing and implementing the simulation experiments and explains why these 
assumptions are valid.  The chapter reports the analysis performed in verifying 
and validating the base model.  Verification is required in order to check that 
Hepatica has been coded correctly and is discussed in Section 5.4.  Validation is 
necessary in order to establish if Hepatica is an accurate representation of the 
real system, and is reported on in Section 5.6. 
 
5.2 Simulation Design 
This section describes the decisions made in designing the simulation 
experiments, including the length of the warm-up period, and the number of runs 
(replications) to be analysed for each scenario.  The analysis which supports the 
decisions made is based on the base scenario as described in Section 5.3. 
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5.2.1 A Terminating or Non-Terminating System? 
The liver transplant allocation system has been identified as a non-terminating 
system, since there is no time at which the waiting list is cleared, and since 
patient and donor arrivals follow Poisson arrival rates (so may arrive at any time 
of the day). 
 
However, the number of patients within the system (or the total time the patients 
spend in the system) will not reach a steady state for a number of years, if at all.  
This is due to the increasing number of patients that could potentially be re-
listed onto the waiting list, as more transplants take place (resulting in a greater 
stock of patients potentially requiring a re-transplant). 
 
5.2.2 Simulation Initialisation & Determining the Warm Up 
Period 
Cold systems can lead to biased results.  There are three ways in which a non-
terminating system may be “warmed up”:  
(1) Using starting conditions (by populating the activities and queues with 
patients recorded from the real system); 
(2) Using a warm up period (running the simulation model and not recording 
any results, until the model contains a realistic number of patients in each 
activity/queue); or  
(3) A combination of the above two approaches. 
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For this model both a warm-up period and the use of starting conditions are 
required.  Data are easily obtained for the number of patients waiting for a 
transplant at any point in time.  However, data relating to patients who received 
their transplants a few years ago, is not easily attainable.  This is because a few 
years after the transplantation date a patient will no longer be seen by the liver 
unit and instead care will be provided by their local general practitioner.  These 
patients may however require another transplant in the future and if they do, 
they will go back to the liver unit.  Therefore, a warm-up period is required to 
obtain a stock of patients which can be re-listed on to the waiting list. 
 
A warm-up period by itself is not adequate since the simulation would start with 
no patients on the waiting list.  If very few patients are on the waiting list when a 
donor liver arrives, then the rules implemented may lead to unrealistic 
allocations.  Also, a decision would be required as to when to start the arrival of 
donated livers, since if the donated livers arrived at the start when no patients 
were on the waiting list, this may mean that donated livers are initially wasted 
and the waiting list may never build up with a realistic number of patients. 
 
After the base scenario model had been verified (as reported in Section 5.4), 20 
replications were performed to identify a suitable duration for the warm-up 
period.  Figure 5.1 confirms that the rate of increase in the proportion of patients 
who are on the waiting list and are waiting for their second or greater liver 
transplant, slows right down after around 730 days.  Therefore, for all the 
analysis a warm-up of 3 years (1,095 days) will be used.  This is in line with the 
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10% of patients who were joining the waiting list for their second or successive 
liver transplant between 1999 and 2002. 
 
(Note: the percentage of patients waiting for a successive transplant is expected 
to increase for a number of years, as more patients will be transplanted and 
therefore potentially re-listed.  In the real system this is controlled by the 
decisions made by the liver consultants). 
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Figure 5.1 The percentage of re-listed patients on the waiting list. 
 
It is important for the percentage of re-listed patients to be steady as this 
confirms that there are a steady stream of patients re-joining the waiting list, and 
that the system has “warmed-up”, enough.  As noted previously, the system my 
never actually be truly stable (Section 5.2.1). 
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5.2.3 Number of Replications 
The Confidence Interval Method was used to determine the number of 
replications required to obtain a 95% confidence in the value obtained for the 
mean time spent by patients on the waiting list (Robinson 2004). 
 
The only time within Hepatica which is not sampled from a known distribution 
is the time from joining the waiting list to receiving a transplant.  The times 
observed to death or removal from the waiting list will depend on whether a 
patient has received a transplant.  So the mean time spent on the waiting list is 
an important value which Hepatica should seek to estimate accurately. 
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Figure 5.2 Determining the number of replications required (using the 
Confidence Interval Method). 
 
From Figure 5.3 we can see that the overall mean time patients are on the 
waiting list levels off from about 7-8 replications.  Most of the benefit is gained 
from 7-8 runs and additional replications do not reduce the size of the 
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confidence interval (CI) greatly, and the confidence interval is reasonably small 
(95% CI % deviation 9-10%).  As a result of this analysis it was decided that 10 
replications would be observed for each alternative scenario that was run – this 
caters for possible difference between scenarios. 
 
5.2.4 Random Number Seeds 
For experimentation purposes 10 sets11 of random number seeds have been 
generated.  These will be implemented in each of the scenarios considered.  This 
will be done so that, as far as possible, we are comparing like for like between 
the scenarios (i.e., the same patient and donor arrival times and attributes will be 
generated across the particular demand and supply scenario). 
 
5.3 Base Scenario 
This chapter concentrates on the first base scenario, which implements the 
allocation rules in place at the time the data from UKT were gathered.  It 
corresponds to the allocation rules L1 outlined in Section 3.3.4 and assumes a 
constant patient mix (A1 Section 3.3.3), a constant supply of liver donations (S1 
Section 3.3.2), and a constant demand for liver transplants (D1 Section 3.3.1).   
 
The activity flow diagram below (Figure 5.3) outlines the basic structure of 
Hepatica developed to capture the main outcomes experienced by patients that 
join the UK liver transplant waiting list.  This outlines the flows considered 
                                                 
11 Each set consists of six seeds, since this is the number required in Witness. 
  
Simulation Design, Verification and Validation 
 
185 
within the base scenario and the alternative scenarios (as outlined in Section 
3.3). 
 
Figure 5.3 Activity Flow Diagram of Hepatica 
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Starting Conditions and Patient Arrivals on to the Waiting List 
The simulation initially starts with 107 patients on the waiting list.  This equates 
to the number of adult patients that were observed to be on the waiting list on 1st 
January 2003. 
 
Once the patients arrive in the system they are directed straight on to the waiting 
list where they wait until either they receive a liver transplant (i.e., a donor is 
matched to a patient as described below) or until they reach the time of their 
death or removal.  Patients experiencing this latter outcome are then directed out 
of the system via a dummy queue (which has been built in to help with data 
collection purposes) and are immediately taken out of the simulation.  
 
Both starting patients and future patient arrivals have attributes that are assigned 
based on the overall distributions defined in Section 4.6 and each patient death 
or removal time is determined by sampling from the competing risk model 
(Section 4.4.2). 
 
Arrivals of Donated Livers 
The donor interarrival times were determined from the observed donor arrival 
rates as recorded by UKT.  Their attributes were also determined from sampling 
from the distributions identified in Section 4.6.  On the arrival of a donor, the 
matching algorithm determines if there is a suitable patient waiting on the 
waiting list (following the rule L1 in Section 3.3.4) and if a suitable patient 
exists then the patient and donor advance to the “Transplant Allocation” activity.  
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If there is no suitable patient within a day of the donor liver arriving then the 
donated liver is wasted and directed to the wasted liver queue.  A donated liver 
which has been wasted spends zero time in the wasted liver queue (which exists 
for data collection purposes) and is then taken out of the simulation. 
 
Transplant Allocation 
The transplant allocation activity is the state in which a transplant takes place.  
This activity combines the donated liver and patient entities into a new 
“transplanted patient entity”, which retains the attributes of both the patient and 
the donor. 
 
The transplant allocation activity takes zero time, after which the patient moves 
to a transplanted queue where they are allocated a death/graft failure/re-list time 
by sampling from the survival distribution (described in Section 4.4.2).  An 
outcome flag is also created which determines which of these outcomes the 
patient will experience.  The outcome flag is allocated at random, according to a 
set distribution, as no difference was found between the attributes of patients and 
the death/graft failure or re-list outcomes. 
 
The patients are then directed to the functioning graft activity which routes them 
either back on to the waiting list queue (at the time of a re-list) or to the death or 
graft failure queue.  The functioning graft activity takes zero time for patients 
who die and takes the amount of time to re-listing for the patients who are re-
listed.   
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Re-Listing 
The re-listed patients follow the same paths as the original patients (once they 
are placed back on the waiting list) and the following attributes are updated just 
before the patient leaves the functioning graft activity to be re-listed;  
(1) Liver transplant number is increased by one; 
(2) Patient age is recalculated; and  
(3) Disease group and urgency are updated to follow distributions observed for 
second or more transplants, as identified using UK Transplant data 
(Appendix L). 
 
This base scenario has been verified and validated using the analysis described 
and reported in Sections 5.4 and 5.6. 
 
5.3.1 Base Scenario - Model Runtime 
The time taken to run one replication of the base scenario in Witness was 
roughly 5 minutes.  The processor used was an Intel (R), Pentium (R) D CPU 
2.80 GHz 2.79GHz, with 0.99 GB of RAM. 
 
5.4 DES Base Model Verification 
Several tests were performed during the development of the base scenario, to 
verify that the model was coded correctly.  Comparisons were made between the 
output from the model and the assumptions that had been made in its 
development, as discussed in detail in Chapter 4.  The checks were either 
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performed on one run (for verifying the simulation flows) of the base model or 
ten runs (for verifying the times generated), depending on the analysis required.  
Sections 5.4.1 to 5.4.7 give a detailed account of the verification checks that 
were performed for the base scenario.  Additional checks were also performed to 
make sure that the aspects which were altered under the various alternative 
scenarios in Section 3.3, were also coded correctly and these are summarised in 
Section 5.5. 
 
5.4.1 Calculation of Death/Removal and Death/Graft 
Failure/Re-List times 
Several times were determined within Hepatica and these were dependent on 
patient, donor and transplant attributes.  These were the time to death or removal 
from the waiting list (which was based on the competing risk model developed 
in Section 4.4) and the time to death, graft failure or re-listing (which was 
determined using the survival model developed in Section 4.5). 
 
The survival times were verified to check if the formulae for death/removal and 
death/graft failure/re-list times were accurately coded into Witness and a check 
was performed within Excel.  The checks used the formulae as presented in 
Equations (4.3), (4.4) and (4.6); the value of p (where p is the percentile value) 
was determined at random using an in-built Witness function and this value, 
along with the relevant attributes, were output by Witness.  Then a calculation 
was carried out to determine whether any of the times were incorrect.  The 
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checks resulted in no difference being seen in any of the times generated by 
Witness and the times calculated using the formulae in Excel. 
 
5.4.2 Distribution of Death/Removal times 
The death/removal times were verified by plotting the cumulative distribution 
functions of the values assigned in Hepatica and those obtained from the null 
competing risk model (Section 4.4.1).  Figure 5.4 shows that both distributions 
are similar.  They will not be exactly the same as the “average” characteristics 
used in the competing risks model will not precisely resemble the sampled 
characteristics of all the patients in the simulation (as discussed in detail in 
Section 4.4.1). 
 
From Figure 5.4 we can see that the cumulative distribution function of the 
times assigned are all within 730 days, this is because the model was coded to 
make sure that all the patients requiring a routine transplant, died within this 
time, in order to resemble the criteria for listing (Section 1.3.4).  Also, the curve 
jumps at around 60 days - this will be due to the limit set on the time to death of 
patients awaiting super urgent transplants. 
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Figure 5.4 Comparison of the Death/Removal times assigned in the simulation 
and the Competing Risks null Model. 
 
5.4.3 Realisation of Death/Removal and Death/Graft 
Failure/Re-List times 
Checks were performed to ensure that the patient outcomes experienced within 
Hepatica - of pre-transplant death or removal from the waiting list or post-
transplant death, graft failure or re-listing - took place at the correct times.  The 
information recorded from Hepatica included the time at which the event had 
occurred, the time at which the patient had joined the waiting list or had been 
transplanted (i.e., the times of origin, as listed in Section 2.4), and the length of 
time to the particular event (as generated by the distributions checked in Section 
5.4.1).  A calculation was then performed in Excel for each of the outcomes to 
check if the outcome had occurred at the correct time.  No differences were 
found between the times the events occurred in the simulation and the times 
calculated in Excel. 
  
Simulation Design, Verification and Validation 
 
192 
5.4.4 Implementation of Allocation Rules 
To verify the allocation rules in place, the simulation was run for 150 days with 
the following output from Witness: 
- A list of all the patients registered on to the waiting list, the attributes of 
these patients, the time at which they joined the waiting list and the time at 
which they were scheduled to die or be removed from the waiting list; 
- A list of all the donated livers with all donor attributes and the time at which 
they were donated; and 
- A list of the transplanted patients with the associated donor and transplant 
attributes. 
 
The list of donated livers was then checked, one by one.  Each time a liver was 
donated, the waiting list was manually searched using the allocation criteria (for 
the base scenario this is based on patient and donor criteria as outlined in L1 
Section 3.3.4) to find the appropriate patient to be transplanted.  This 
information was then cross-checked to verify whether or not the correct patient 
had been transplanted within Hepatica.  These checks found that the correct 
patients were being transplanted as according to the base scenario (L1) rules. 
 
These checks also ensured that no transplants were being performed on patients 
who had already died, or been removed from the waiting list. 
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5.4.5 Updating Patient Ages  
Patient age is updated at two stages within Hepatica.  The death/removal time 
generated is dependent on the patient’s age on registration to the waiting list, 
while the death/graft failure/re-listing time is dependent on the patient’s age at 
the point they receive a transplant   In order for these times to be estimated 
accurately, the patient age must be updated before they can be generated.  
Therefore, the two stages at which the age is updated, are:  
(1) Once a patient is transplanted, and before they are allocated a post transplant 
outcome (so that the patient’s age can be updated according to the length of 
time they were on the waiting list); and  
(2) Just before a patient is re-listed back onto the waiting list (so that the 
patient’s age can be updated to incorporate the time between transplant and 
their eventual re-listing). 
 
To check that the ages were being updated correctly two checks were performed.  
Once a patient has been transplanted, their old age (the age at which they joined 
the waiting list), their new age (at transplant) and the time between them joining 
the waiting list and their transplant were all output from Witness.  Then using 
Excel a calculation was performed to determine whether the new age 
corresponded to the old age plus the time between them joining the waiting list 
and their transplant.  The second check considered the patients just before they 
were placed back on to the waiting list.  Here the output from Witness included 
the old age (the age at which the patient had been transplanted), the new age (at 
re-list), the time at which the patient had been transplanted, and the current time 
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(i.e., the time of re-list).  Then in Excel a check was made to make sure that the 
new patient age equalled the old age plus the time between the transplant and re-
listing. 
 
Both of these verification checks concluded that the patient ages were being 
updated correctly. 
 
5.4.6 Routing of Patients, Post Transplant 
To check whether the patients were directed to the correct activities/queues after 
receiving a transplant, several files were output from Witness and analysed in 
Excel.  One “overall” file was output from the “transplanted” queue listing all 
the patients that were transplanted with the post transplant outcome they were 
assigned (either death/graft failure or re-list). 
 
For the patients who were re-listed another file which contained the post 
transplant outcome indicator and patient identification number was output.  This 
file was compared to the overall file to check that the correct patients had been 
re-listed.  A similar check was carried out to ensure that the correct patients 
experienced death/graft failure post-transplant. 
 
All the checks confirmed that the patients were being re-listed or directed to 
death/graft failure correctly. 
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5.4.7 Routing of Wasted Livers 
To check whether or not the livers that were not used for transplantation within 
one day after arriving into the simulated system were correctly counted as 
“wasted” livers, files containing information regarding the liver arrival time, the 
liver transplant time, the liver identification number and the liver wasted time 
were output from Witness.  One run of the base scenario was then considered to 
check that all livers were used within a day of arriving.  Since no livers are 
wasted in the base scenario, a dummy scenario which contained fewer patient 
arrivals was used to check if the livers were deemed wasted after a day of 
arriving.  In Excel a calculation was made to find the differences between, 
firstly, the time the livers were used in transplants and the time at which they 
arrived, and, secondly, the time the livers were “wasted” and the time at which 
they arrived.  The first check returned times which were all less than a day and 
the second returned times which were all equal to a day, so confirming that the 
model was correctly recording wasted livers. 
 
5.5 Verification of Alternative Scenarios 
The additional checks which were performed on the alternative scenarios, where 
the simulation factors were changed by one factor (demand, supply, assessment 
rule, or demand rule) are briefly described next.  All the checks preformed 
confirmed that the coding was correct for the various scenarios. 
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5.5.1 Alternative Demand Scenarios 
The demand is altered as described in Section 3.3.1.  To check that the demand 
factors were coded correctly, a yearly count for the number of patients arriving 
onto the waiting list and the list of these patients broken down by disease group 
was considered. 
 
5.5.2 Alternative Supply Scenarios 
The supply is altered as described in Section 3.3.2.  To check that the correct 
numbers of donated livers were entering the system, an overall figure for the 
number of donations every year was considered. 
 
5.5.3 Alternative Assessment Rules 
The assessment rules are altered through changing patient prognosis as 
described in Section 3.3.3.  To check if the prognosis without transplantation 
was either worse or better, a check similar to that outlined in Section 5.4.1 was 
performed, to make sure that the death/removal times were being calculated 
correctly within Hepatica. 
 
5.5.4 Alternative Allocation Rules 
For each set of allocation rules (as outlined in Section 3.3.4) the verification 
check outlined in Section 5.4.4 was performed, to make sure that the correct 
patients received a transplant. 
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5.6 DES Base Model Validation 
Several tests were performed once the base scenario was verified to help validate 
the model against information contained within the UK Transplant data.  The 
checks performed interpreted information from ten runs of the base model.   
Each run recorded data for a period of 1,460 days (4 years) with an initial period 
of warm up of 1,095 days (3 years).  The models were run for 4 years for a 
number of reasons:  
(1) The data used from UK Transplant covered a 4 year period; 
(2) Four years should be long enough to demonstrate the effect of a changing the 
policy, demand, or supply; and  
(3) Four years is a realistic time period over which policies may last or be re-
assessed after. 
Sections 5.6.1 to 5.6.3 give the results obtained from the validation checks 
performed. 
 
5.6.1 Time to Death/Removal 
The times to death/removal from the waiting list observed in the base scenario 
were compared with those recorded within the UK Transplant dataset.  Note that 
the death/removal times experienced by patients in Hepatica will be affected by 
both the simulated survival time and whatever allocation decisions were being 
made.  For this reason it would not be surprising to see differences between UK 
Transplant and the simulation results.   
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Figure 5.5 Comparison of the time to death/removal to occur in the simulation 
and the time to death/removal observed in the UKT data. 
 
Figure 5.5 shows the cumulative distribution functions of the times to 
death/removal from the waiting list, as observed in the UK Transplant data and 
also within the base scenario simulation runs.  The curves show that the 
distributions of times are similar, however the distribution observed within 
Hepatica shows that time times to death or removal were generally longer.  This 
is the effect of more super urgent patients receiving transplants which leads to 
routine patients having to wait longer.  This discrepancy is discussed further in 
Section 5.6.2. 
 
5.6.2 Time to Transplant 
The times to transplant from joining the waiting list observed in the base 
scenario were compared with those observed in the UK Transplant dataset.  Note 
that the time to transplant experienced by patients in Hepatica is not explicitly 
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modelled, and is purely dependent on the allocation decisions were being made.  
Any differences observed could be caused by a variety of factors, rather than one 
specific element of the model. 
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Figure 5.6 Comparison of the time to Transplant to occur in the simulation and 
the time to Transplant observed in the UKT data 
 
Figure 5.6 presents the cumulative distribution function of the times to 
transplant from joining the waiting list as observed in the UK Transplant data 
and within the base scenario simulation runs.  The curves are not identical; 
further investigation determined that this is because a greater proportion of super 
urgent patients are being transplanted within the simulation than observed in the 
UK Transplant data.  Tables 5.1 and 5.2 indicate that roughly 10% more super 
urgent patients, and 4% fewer routine patients, received a transplant in the base 
case simulation.   
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Table 5.1 Observed and Simulated Outcomes from the Waiting List for Super 
Urgent Patients (UK Transplant 2004e). 
Super Urgent Patients UKT Data Simulated 
Transplanted (%) 76.8% 87.5% 
Average Time to Transplant 3.2 days 1.2 days 
Average Time to Death/Removal 4.7 days 1.2 days 
 
Table 5.2 Observed and Simulated Outcomes from the Waiting List for Routine 
Patients (UK Transplant 2004e). 
Routine Patients UKT Data Simulated 
Transplanted (%) 85.7% 81.4% 
Average Time to Transplant 78.6 days 163.6 days 
Average Time to Death/Removal 89.7 days 96.6 days 
 
In addition, the time to transplant for these super urgent patients is on average 
greater within the UK Transplant data (3.2 days), than within Hepatica (1.2 
days).  This indicates that super urgent patients are obtaining liver transplants 
quicker in the simulation, meaning that routine patients are having to wait longer 
for a transplant, often missing out completely.  The discrepancy observed in 
Figure 5.6 demonstrates the net effect of this with routine patients (82% of all 
patients who join the waiting list) spending much longer on the waiting list 
before they are transplanted.  At the start of the curve there is a sharper increase, 
which would represent the super urgent patients receiving transplants early on. 
 
In Section 5.4.4 it was concluded that the allocation rules were being 
implemented correctly; so when a donated liver arrives into the system, this is 
being allocated according to the policy in place.  The implication of this is that 
there is some key operational factor(s) regarding the transplant of super urgent 
patients which has not been documented in the literature or captured within 
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Hepatica.  Further investigation would be required to resolve this, probably in 
consultation with clinicians, as discussed further in Section 7.5.3. 
 
5.6.3 Time to Death/Graft Failure/Re-List 
The times to death/graft failure/re-listing post transplantation as observed in the 
base scenario were compared with those observed in the UKT dataset.  Note that 
the death/graft failure/re-listing times experienced by patients in Hepatica will 
be affected by both the simulated survival time and whatever allocation 
decisions were made.  For this reason it would not be surprising to see 
differences between UKT and the simulation results. 
 
0
0.2
0.4
0.6
0.8
1
0 100 200 300 400 500 600 700 800 900 1000
Time to Death\Graft Failure\Re-Listing (Days)
C
u
m
u
la
ti
v
e
 D
is
tr
ib
u
ti
o
n
 F
u
n
c
ti
o
n
Simulation Output UKT (observed)
 
Figure 5.7 Comparison of the time to death/graft failure or re-listing to occur in 
the simulation and the time to death/graft failure  or re-list observed in the UKT 
data 
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Figure 5.7 shows the cumulative distribution functions of the observed times to 
death/graft failure or re-list post-transplantation as observed in the UK 
Transplant data and within the base scenario simulation runs (i.e., the events that 
actually took place within the study observation period).  Figure 5.8 displays the 
Kaplan-Meier Estimates for the times assigned to all transplanted patients within 
the simulation model and the times observed within the UK Transplant data set.  
The two curves are very similar, indicating that the survival model is suitable to 
use.  The discrepancy after 3 years (1,095 days) results from fewer events being 
observed after this length of time, within the UK Transplant data.  This would be 
due to issues, such as, patients being lost to follow-up. 
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Figure 5.8 Kaplan-Meier Estimates for the Post Transplant Outcome Times 
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5.7 Summary 
This chapter outlined the basic experimental set-up required.  It determined that 
a 3 year (1,095 day) warm up period is necessary, and that 10 replications lead 
to a reasonable confidence in the accuracy of the results. 
 
Also reported are the overall the verification and validation tests which confirm 
that the simulation model developed is a good representation (is both coded 
correctly and provides an accurate representation of the UK liver transplant 
system) to what is observed within the UK Transplant dataset. 
 
Hepatica was found to allocate transplants to a higher proportion of patients 
requiring a super urgent transplant, and this may bias any results obtained using 
this model.  It is likely that some aspect of the process of allocating transplants 
to super urgent patients has not been modelled fully, and requires further 
analysis.  However, the experimentation carried out using the model (and 
presented in Chapter 6) is still valid, since relative comparisons are made 
between the various scenarios, all of which are influenced by this effect. 
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Chapter 6 
 
Experimentation 
 
6.1 Introduction 
This chapter reports the results from running various scenarios in Hepatica.  It 
starts by detailing the base scenario, equity measures, and utility measures used 
in comparing the various scenarios. 
 
The scenarios considered are based on the experimental design explained in 
Section 3.7.  The main findings from the analyses are summarised, with several 
key aspects are discussed, which require considering when/if the policies are 
changed. 
 
6.2 Set Up of Experiments 
6.2.1 Base Scenario 
Two base scenarios were developed.  The first scenario (B1) (as described in 
Section 5.3) was used for validation purposes and implemented the allocation 
rules in place at the time the data was collected.  The second scenario (B2) uses 
the updated allocation rules (introduced in July 2006), with which all 
experimental scenarios are compared.  The only difference between the two 
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scenarios is that B1 implements the allocation rules L1, while B2 implements 
the allocation rules L2.  The main difference between the two allocation rules 
and the reasons for this are explained in detail in Section 3.4.4. 
 
The base scenario (B2) assumes the allocation rules L2, a constant demand 
through time D1, a constant supply through time S1, and a similar patient mix 
joining the waiting list as between 1999-2002 A1 (all these factors are discussed 
in more detail in Section 3.3).  All the scenarios simulated were run for a period 
of 7 years: 3 warm-up years and 4 years over which data were collected. 
 
6.2.2 Weightings Used to Determine Improvements In Outcomes 
The equity and utility measures recorded in Hepatica are detailed Section 3.4.  
The rest of this section identifies the key measures which were evaluated to give 
an overall picture of each scenario compared against the base scenario.  Tables 
6.1 and 6.4 outline the weightings that were used for calculating the overall 
equity and utility points derived for each scenario (as described in Section 
3.4.3).  These will be used to evaluate how the alternative scenarios affect equity 
and utility within the liver transplant system, compared to the base scenario.  A 
number of different weightings were tested but all gave the same overall results 
and so the weightings below were implemented. 
 
Equity 
The two main equity measures which are analysed to obtain the overall impact 
of the scenarios, are: 
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(EM1) Difference in Numbers to be Transplanted Across Groups - this 
measure captures the extent to which a policy is allocating liver 
transplants fairly across different patient groups.  Since there are only 
two outcomes from once a patient joins the waiting list 
(Death/Removal or Transplantation) only one outcome requires 
observation.  This measure is assessed by summing up the differences 
between the expected and the observed number of patients to be 
transplanted from each group.  The smaller the value obtained, the 
fairer the allocation of liver transplants has been.  The patient groups 
considered are: centre, blood group, transplant number, primary liver 
disease group, weight, age, and gender.  Once a value was calculated 
for an alternative scenario it was compared to the base scenario value.  
Then equity points were allocated based on whether the alternative 
scenario performed better, the same, or worse than the base scenario 
(as outlined further in Section 3.4.3). 
(EM2) Difference in Numbers to Experience Death/Graft Failure Across 
Groups - this measure captures the differences in the proportion of 
patients from different groups experiencing the two post transplant 
outcomes of Death/Graft Failure and Re-Listing.  Again, since there 
are only two outcomes from once a patient receives a transplant, only 
one outcome requires observation.  This measure is assessed by 
summing up the differences between the expected and the observed 
number of patients to experience death/graft failure.  The smaller the 
value obtained, the fairer the allocation policy has been in terms of 
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post-transplant survival chances.  The patient groups considered are: 
centre, blood group, transplant number, primary liver disease group, 
weight, age, and gender.  Once a value was calculated for an alternative 
scenario it was compared to the base scenario value.  Then equity 
points were allocated based on whether the alternative scenario 
performed better, the same, or worse than the base scenario (as 
outlined further in Section 3.4.3). 
Both EM1 and EM2 contribute to the overall assessment of equity (as presented 
in Sections 6.3-6.5).  Table 6.1 shows that points obtained through the measure 
EM1 receive a higher weight than the points obtained through the measure EM2 
when calculating the overall equity points; this is because the policy changes 
within the different scenarios and will directly impact on who is transplanted.  
The post transplant events will be a consequence of this. 
 
Table 6.1 Equity Point Weightings. 
Equity Measure Weighting 
(EM1) Waiting List Outcome 2 
(EM2) Post Transplant Outcome 1 
 
Tables 6.2 and 6.3 give example calculations for the measures (EM1) and (EM2) 
for the base scenario. 
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Table 6.2 Calculation of Difference in Numbers to be Transplanted Across 
Groups (EM1) for the Base Scenario, B2. 
Patient Group 
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B
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  (1) (2) 
Abs 
{(1)-(2)} 
  
All 28044 23055     
Centre A 1911 1512 1571 59 - 
Centre B 4765 3759 3917 158 - 
Centre C 2928 2504 2407 97 + 
Centre D 2700 2213 2220 7 - 
Centre E 7016 5946 5768 178 + 
Centre F 5948 4823 4890 67 - 
Centre G 2776 2298 2282 16 
582 
+ 
Blood Group O 12863 11878 10575 1303 + 
Blood Group A 11097 8367 9123 756 - 
Blood Group B 2931 1870 2410 540 - 
Blood Group AB 1153 940 948 8 
2607 
- 
First Transplant 24599 20342 20223 119 + 
Successive 
Transplant 3445 2713 2832 119 
238 
- 
All Other Diseases 8864 7231 7287 56 - 
Other Cirrhotic 5028 4349 4134 215 + 
Cancer 667 478 548 70 - 
Other Diagnosed 1645 1457 1352 105 + 
Super Urgent/Acute 5398 4537 4438 99 + 
Hepatitis B 941 732 774 42 - 
Alcoholic Disease 4827 3884 3968 84 - 
Not Reported 674 387 554 167 
839 
- 
Weight <=50kg 1571 1311 1292 19 + 
Weight 51-65kg 8137 6753 6689 64 + 
Weight 66-80kg 10303 8410 8470 60 - 
Weight 81-99kg 6273 5138 5157 19 - 
Weight 100kg and 
over 1760 1443 1447 4 
166 
- 
Age <=25 years 1865 1626 1533 93 + 
Age 25-35 2658 2299 2185 114 + 
Age 36-45 5126 4308 4214 94 + 
Age 46-55 8528 6985 7011 26 - 
Age 56-65 8097 6455 6657 202 - 
Age 66 and over 1770 1382 1455 73 
601 
- 
Male 15358 12396 12626 230 - 
Female 12686 10659 10429 230 
460 
+ 
EM1 (i.e., total) 5492  
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Table 6.3 Calculation of Difference in Numbers to Experience Death/Graft 
Failure Across Groups (EM2) for the  Base Scenario, B2. 
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  (1) (2) 
Abs 
{(1)-(2)} 
  
All 23055 16984     
Centre A 1512 1100 1114 14 - 
Centre B 3759 2814 2769 45 + 
Centre C 2504 1800 1845 45 - 
Centre D 2213 1691 1630 61 + 
Centre E 5946 4377 4380 3 - 
Centre F 4823 3514 3553 39 - 
Centre G 2298 1688 1693 5 
211 
- 
Blood Group O 11878 8712 8750 38 - 
Blood Group A 8367 6219 6164 55 + 
Blood Group B 1870 1383 1378 5 + 
Blood Group AB 940 670 692 22 
121 
- 
First Transplant 20342 14996 14985 11 + 
Successive 
Transplant 2713 1988 1999 11 
21 
- 
All Other Diseases 7231 5341 5327 14 + 
Other Cirrhotic 4349 3188 3204 16 - 
Cancer 478 359 352 7 + 
Other Diagnosed 1457 1054 1073 19 - 
Super Urgent/Acute 4537 3340 3342 2 - 
Hepatitis B 732 543 539 4 + 
Alcoholic Disease 3884 2857 2861 4 - 
Not Reported 387 302 285 17 
83 
+ 
Weight <=50kg 1311 981 966 15 + 
Weight 51-65kg 6753 4960 4975 15 - 
Weight 66-80kg 8410 6241 6195 46 + 
Weight 81-99kg 5138 3726 3785 59 - 
Weight 100kg and 
over 1443 1076 1063 13 
148 
+ 
Age <=25 years 1626 1201 1198 3 + 
Age 25-35 2299 1677 1694 17 - 
Age 36-45 4308 3163 3174 11 - 
Age 46-55 6985 5168 5146 22 + 
Age 56-65 6455 4767 4755 12 + 
Age 66 and over 1382 1008 1018 10 
75 
- 
Male 12396 9129 9132 3 - 
Female 10659 7855 7852 3 
6 
+ 
EM2 (i.e., total) 665  
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Utility 
As discussed in Section 2.3.2, it is important to gauge utility at all parts of the 
liver transplantation system, since we ideally want policies which create an 
effective system overall.  The objective is essentially to make the best decisions 
in terms of providing the greatest good for the greatest number of patients. 
 
Several measures were considered when evaluating utility (as discussed in 
Sections 3.4 and 3.4.2 and reported in Sections 6.3-6.5), however only the most 
important five measures contribute to the overall utility aspect considered in 
Hepatica.  Table 6.4 summarises the weightings given to each of the aspects 
when calculating the overall utility points for a particular policy.  All 
comparisons were made against the base scenario, as explained in Section 3.3.4. 
 
Table 6.4 Utility Point Weightings. 
Utility Measure Weighting 
UM1 Life Years in System per patient 1 
UM2 Life Years Gained per Transplant 1 
UM3 Number of Wasted Livers 1 
UM4 % Death/Removals from waiting list 0.5 
UM5 % Death/Graft Failure within 1 year of transplantation 0.5 
 
The aspects considering life year in the system and life years gained ((UM1) and 
(UM2)) are important as they portray how effective the decision to transplant, or 
not to transplant particular patients, is.  Another key measure is the number of 
livers wasted (UM3).  This is used on the basis that if livers are wasted, then this 
implies that there are inefficiencies in the system.  The percentage of patients to 
experience death or removal from the waiting list (UM4) and the percentage of 
patients to experience death or graft failure within one year of transplantation 
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(UM5) are also required as any utilitarian system should be looking to minimise 
the number of patients who experience these outcomes.  These measures are 
given slightly less weight, since the main aim of liver transplantation is to 
improve the overall measures of patient survival. 
 
6.3 Analysis of Outputs from Changing one Factor 
This section reports on the results obtained from the ‘one factor’ changes as 
outlined in Sections 3.3.1-3.3.4.  It uses the methodology outlined in Sections 
3.4.3 and 6.2 to compare the equity and utility measures obtained with the 
results observed from the base scenario.  
 
6.3.1 Demand Factors 
The demand factors consider the effect of an increasing, or of a constant demand 
for liver transplantations, as detailed in Section 3.3.1.  For the base scenario the 
average number of arrivals each year (excluding the number of patients re-listed) 
613 (2,452 in total)  The total number of extra arrivals over the 4 years 
simulated for the demand factors D2, D3, and D4, were 122, 193, and 146, 
respectively. 
 
From Tables 6.5 and 6.6 it can be seen that when the demand for liver 
transplantation is increased and all other experimental factors are kept the same, 
the allocation system becomes less fair and the utility measures are also 
adversely affected. 
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Table 6.5 Utility Outputs from Demand Scenarios. 
Demand 
Scenario 
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B2 Base case 23.9 26.4 5.20 14.40 17.80  
D2 
Demand 
Increasing (122 
extra patients 
over 4 years) 23.5 26.2 4.90 14.40 18.50 
-0.5 
D3 
Demand 
Increasing (193 
extra patients 
over 4 years) 23.4 26.3 5.20 14.50 18.90 
-0.5 
D4 
Demand 
Increasing (146 
extra patients 
over 4 years) 23.5 26.3 5.19 14.33 18.55 
-0.5 
Note: The Number of Wasted Livers is not presented in this table, since all the policies 
considered had 0 wasted livers, over the 4 years which were simulated. 
 
Table 6.6 Equity Outputs from Demand Scenarios. 
Demand 
Scenario 
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B2 Base case 5492 665   
D2 
Demand Increasing  
(122 extra patients over 4 years) 5996 627 
-1 
D3 
Demand Increasing  
(193 extra patients over 4 years) 6185 814 
-3 
D4 
Demand Increasing  
(146 extra patients over 4 years) 6687 778 
-3 
 
Over the 4 years simulated, significant differences were observed in the 
percentage of patients experiencing death or removal from the waiting list.  As 
expected, this has arisen because the increase in demand has meant that a 
smaller proportion of patients are able to receive a transplant. 
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For the waiting list and post transplant equity outcomes, there was an overall 
negative bias in the patient groups transplanted, however there were no dramatic 
changes, and no particular losers or gainers amongst the patient groups.  The 
effect of increasing the demand was simply to increase the biases present in the 
base scenario.  In both cases, the patient groups who received priority – super 
urgent patients and those with blood group O – fared much better than other 
patients.  As demand increases, this discrepancy was observed to become more 
pronounced. 
 
Figure 6.1 shows the average number of patients on the waiting list over the 10 
simulation runs, by simulated time, for the 4 demand factors.  The size of the 
waiting list at the end of the 4 simulated years, are: 256, 276, 293, and 283, for 
the factors D1, D2, D3, and D4, respectively.  Given that supply is insufficient 
(and constant) it is logical that the number of patients waiting for a transplant 
should increase as the demand for liver transplantation increases. 
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Figure 6.1 Size of Waiting List by time for the Demand Scenarios. 
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No significant changes were observed for the other measures, in particular, for 
the life year calculations only small decreases are observed.  It is likely that the 
simulations performed have only started to see the effect of increasing the 
demand, and running the models for a longer period would result in more 
aspects becoming significant. 
 
6.3.2 Supply Factors 
The supply factors consider the affect of an increasing, a decreasing, or a 
constant supply of liver transplants, as detailed in Section 3.3.2.  For the base 
scenarios the average number of donations per year was 561 (2,244 in total).  
The change in total number of liver donations over the 4 years simulated for the 
supply factors S2, S3, and S4, were a decrease of 398, an increase of 558, and an 
increase of 205, respectively. 
 
From Tables 6.7 and 6.8 it can be seen that when the supply of liver transplants 
is decreased and all other experimental factors are kept the same, the allocation 
system becomes less fair and the utility measures are adversely affected.  
Conversely, the equity and utility of the system is significantly improved if the 
supply of livers is increased. 
 
As the supply is increased, the number of patients receiving a transplant 
increases, hence there is a reduction in the proportion of patients experiencing 
death or removal from the waiting list and the number of life years in the system 
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increases (Table 6.7). The opposite is observed when the supply of livers 
decreases. 
 
Table 6.7 Utility Outputs from Supply Scenarios. 
Supply 
Scenario 
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B2 Base case 23.9 26.4 5.20 14.40 17.80  
S2 
Declining 
donations (398 
fewer over 4 
years) 21.9 26.3 5.20 14.30 24.60 
-1.5 
S3 
Increasing 
donations (558 
more over 4 
years) 24.6 26.0 5.10 14.30 14.00 
1 
S4 
Increasing 
donations (205 
more over 4 
years) 23.8 26.2 5.00 14.20 17.20 
0 
Note: The Number of Wasted Livers is not presented in this table, since all the policies 
considered had 0 wasted livers, over the 4 years which were simulated. 
 
Table 6.8 Equity Outputs from Supply Scenarios. 
Supply 
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B2 Base case 5492 665   
S2 
Declining donations  
(398 fewer over 4 years) 7102 591 
-1 
S3 
Increasing donations  
(558 more over 4 years) 4344 563 
3 
S4 
Increasing donations  
(205 more over 4 years) 5112 642 
2 
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When the supply is decreased the bias on the outcomes from the waiting list 
grew in magnitude and when the supply is increased the bias decreases (Table 
6.8).  The attribute which is affected the most is urgency of the transplant (Table 
6.9).  Super urgent patients receive priority over donated livers, so when the 
supply decreases routine patients will have less chance of receiving a transplant, 
but when the supply of donated livers increases their chances are greatly 
improved and the equity also improves. 
 
Table 6.9 Outcome Differences for Transplant Urgency Status, from Supply 
Scenarios. 
Urgency EM1 EM2 
B2 341 31 
S2 731 6 
S3 236 11 
S4 22 53 
 
Figure 6.2 shows the average number of patients on the waiting list over the 10 
simulation runs, by simulated time, for the 4 supply factors.  The size of the 
waiting list at the end of the 4 simulated years, are: 256, 439, 72, and 202, for 
the factors S1, S2, S3, and S4, respectively.  The number of patients waiting for 
a transplant increases as the supply of liver transplants decreases. 
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Figure 6.2 Size of Waiting List by time for the Supply Scenarios. 
 
No significant changes were observed in the post transplant utility measures.  
This implies that the patient mix to be transplanted is similar across the four 
supply factors – at least in terms of the factors which impact on post-transplant 
survival. 
 
6.3.3 Assessment Rule Factors 
The assessment factors consider the effect of restricting the pre-transplant 
prognosis of patients who join the waiting list, as detailed in Section 3.3.3.  The 
total number of patient and donor arrivals remains constant in all three scenarios.  
The only aspect altered is how long the patient is expected to live if they do not 
receive a transplant.  Factor A2 reduces the times by 10% and factor A3 
increases the times by 10%. 
 
From Tables 6.10 and 6.11 it can be seen that as the pre-transplant prognosis 
worsens, the allocation system becomes less fair and the utility measures are 
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adversely affected.  As the pre-transplant prognosis improves, the allocation 
system again becomes less fair, but the utility measures are improved. 
 
As the pre-transplant prognosis worsens, the proportion of patients experiencing 
death or removal from the waiting list increases and the number of life years in 
the system decreases (Table 6.10), and vice versa when the pre-transplant 
prognoses of patients is better.  When the pre-transplant prognosis of patients 
joining the waiting list is much lower, many more will die before a liver 
becomes available to them.  A secondary result is that as more patients die, the 
size of the waiting list reduces.  Ultimately this means that a number of livers 
are wasted as there are no suitable patients on the waiting list when the donated 
liver becomes available.  There was no significant impact on post-transplant 
survival, implying that the characteristics of patients receiving a transplant is not 
affected that much. 
 
Table 6.10 Utility Outputs from Assessment Scenarios. 
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B2 Base case 23.9 26.4 5.20 14.40 17.80  
A2 
10% poorer 
initial prognosis 22.5 26.5 5.10 14.30 20.40 
-2.5 
A3 
10% better 
initial prognosis 24.9 26.0 5.30 14.30 14.40 
1.5 
Note: The Number of Wasted Livers is not presented in this table; B2 and A3 had 0 
livers wasted, while A2 had 51 livers wasted per year, over the years simulated. 
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Table 6.11 Equity Outputs from Assessment Scenarios. 
Assessment 
Scenario 
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B2 Base case 5492 665   
A2 10% poorer initial prognosis 6501 691 -2 
A3 10% better initial prognosis 6104 744 -3 
 
Table 6.2 indicated that the base case scenario favours blood group O patients 
over patients with other blood types, as it gives them priority over any blood 
group O donations.  There is currently a poorer supply of blood group A, B, and 
AB livers (Appendix B, Table B.2) and this is not sufficient to meet the demand 
of all patients with these blood groups.  This shortfall can only be met by using 
organs donated by people with blood group O.  The positive bias of transplants 
to blood group O patients is not noted under A2, which assumes the same 
allocation priorities as the base scenario.  This is because there are fewer patients 
waiting (since patients die earlier) and therefore priority by blood group is not as 
important and patients with blood groups A, B, and AB do better.  Similarly, 
patients requiring a routine transplant benefit under factor A2, since there are 
fewer patients on the waiting list, and so the fact that super urgent patients 
normally receive priority, becomes less important. 
 
Figure 6.3 shows the average number of patients on the waiting list over the 10 
simulation runs, by simulated time, for the 3 assessment factors.  The size of the 
waiting list at the end of the 4 simulated years, are: 256, 14, and 680, for the 
factors A1, A2, and A3, respectively.  The size of the waiting list is smaller for 
the scenarios where the prognosis of patients joining the waiting list is worse. 
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Figure 6.3 Size of Waiting List by time for the Assessment Scenarios. 
 
6.3.4 Allocation Rule Factors 
The allocation factors consider the affect of implementing various allocation 
rules, as detailed in Section 3.3.4.  Changes were made to the allocation rules to 
influence seven main aspects:  
(1) Blood group matching and equity among blood groups; 
(2) Centre matching; 
(3) Liver transplant number 
(4) Patient age; 
(5) Time spent waiting for a transplant; 
(6) Patient weight compared to donor weight; and  
(7) Pre-/post-transplant prognosis and utility. 
Tables 6.12 and 6.13 summarise the utility and equity outcomes recorded from 
the simulation.  The findings from each aspect are summarised after the tables. 
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Table 6.12 Utility Outputs from Allocation Scenarios. 
Allocation Priority To 
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B2  Base case 23.9 26.4 5.20 14.40 17.80   
L3 Compatible Blood Groups 23.4 25.8 5.40 15.20 17.70 -2.5 
L4 Identical Blood Groups 23.9 26.4 5.00 14.00 17.60 0 
L5 Local Patients 23.6 26.1 5.00 14.00 18.10 0 
L6 National Patients 23.9 26.3 5.20 14.20 17.40 0 
L7 First Transplants 23.5 26.2 4.80 13.50 18.80 0 
L8 Successive Transplants 23.6 26.3 4.70 13.60 18.20 0.5 
L9 Younger Patients 24.6 27.5 5.00 13.80 18.80 2 
L10 Older Patients 22.2 24.7 5.00 14.00 18.60 -2.5 
L11 
Those waiting the shortest 
time 23.4 26.0 5.20 14.40 18.70 -2.5 
L12 
Those waiting the longest 
time 23.7 26.3 4.70 13.20 18.20 0.5 
L13 
Patients where the absolute 
difference between donor 
and patient weight is 
minimised 23.6 26.2 4.80 13.50 18.30 -1 
L14 
Patients with the soonest 
death or removal time (i.e., 
worst pre-transplant 
prognosis) 24.6 26.7 5.00 14.10 15.40 1.5 
L15 
Patients with the best post-
transplant prognosis 29.4 33.3 3.60 10.50 18.10 2.5 
L16 
Patients with best prognosis 
compared to expected 
prognosis without a 
transplant 30.8 35.1 3.80 11.00 17.90 2.5 
L17 
An adaptive policy which 
attempts to make allocation 
decisions through keeping 
track of equity measures, 
for groups not fairly 
transplanted across, within 
the other allocation policies 23.7 26.1 5.20 14.70 17.60 0 
Note: The Number of Wasted Livers is not presented in this table, since all the policies 
considered had 0 wasted livers, over the 4 years which were simulated. 
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Table 6.13 Equity Outputs from Allocation Scenarios. 
Allocation Priority To 
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B2 Base case 5492 665   
L3 Compatible Blood Groups 4972 665 2 
L4 Identical Blood Groups 5071 747 1 
L5 Local Patients 4690 797 1 
L6 National Patients 5893 584 -1 
L7 First Transplants 11232 642 -2 
L8 Successive Transplants 9961 762 -3 
L9 Younger Patients 5760 614 1 
L10 Older Patients 13305 745 -3 
L11 Those waiting the shortest time 5222 632 1 
L12 Those waiting the longest time 10561 755 -3 
L13 
Patients where the absolute difference 
between donor and patient weight is 
minimised 9488 569 
-1 
L14 
Patients with the soonest death or 
removal time (i.e., worst pre-transplant 
prognosis) 5324 1043 
-1 
L15 
Patients with the best post-transplant 
prognosis 9393 645 
-2 
L16 
Patients with best prognosis compared 
to expected prognosis without a 
transplant 9458 620 
-1 
L17 
An adaptive policy which attempts to 
make allocation decisions through 
keeping track of equity measures, for 
groups not fairly transplanted across, 
within the other allocation policies 3376 697 
2 
 
(1) Blood Group Matching and Equity (B2, L3, L4, L17) 
The number of life years in the system will be affected by changes in the number 
of patients experiencing death or removal from the waiting list, and also by 
changes in post transplant survival times.  In factor L3 the number of life years 
gained was seen to significantly decrease and from Table 6.12 it would seem 
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that this happened because a significantly larger proportion of transplanted 
patients experienced post-transplant survival times shorter than one year. 
 
Factor L3 imposes less stringent rules on blood group matching and hence a 
smaller percentage of transplants took place where there was an identical match 
between donor and patient blood groups when compared with the base scenario 
(as shown in Table 6.14).  Hepatica uses identical blood group as a factor when 
generating post transplant survival times (Equation 4.6 Section 4.5.2) - because 
rejection is less likely when there is an identical match between blood groups.  
This would therefore explain the results observed for L3. 
 
Table 6.14 Percentage of Transplants with Identical Donor and Patient Blood 
Groups. 
 Percentage of 
Identical Matches 
Identical blood 
matches 
Total transplants 
B2 97.7 2,253 2,306 
L3 87.7 2,028 2,312 
L4 99.7 2,299 2,306 
L17 90.4 2,090 2,311 
 
Policies which enforce identical donor and patient blood group matching more 
stringently will lead to an increase in the total gain in life years (e.g., policy L4).  
Table 6.14 shows the proportion of transplants which took place where there 
was an identical match between the blood types of the patient and donor.  The 
extra life years gained under L4 is not actually significant, as the base scenario 
already had a very high proportion of transplants where the blood groups were 
identically matched. 
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L17 gives priority to patients from the blood group which has currently received 
the fewest number of transplants relative to size of this group (assuming that that 
the blood groups of donor and patient are compatible).  This policy significantly 
improves the equity of the system pre-transplant and does not affect the other 
outcomes greatly.  The patients who miss out the greatest under this policy 
(compared to the base scenario) are those with blood group O.  Overall this 
policy allocates more fairly than the base scenario, across the four blood groups. 
 
(2) Centre Matching (B2, L5, L6) 
The base scenario (B2) allocates livers to super urgent patients on a national 
basis and to routine patients initially within the retrieving centre.  If no 
compatible match exists then they allocate nationally.  L5 employs more 
stringent rules and allocates the donated livers locally within the retrieval centre 
first and then if no match is found, allocates nationally.  L6 uses a more relaxed 
process and allocates all donated livers nationally. 
 
Under the more stringent policy (L5) super urgent patients miss out on 
transplantation in favour of routine patients.  This leads to greater equity in the 
system with regard to transplant centre and transplant urgency, but also leads to 
more super urgent patients dying or being removed from the waiting list.  L5 
also allocates more fairly across blood groups at the expense of blood group O 
patients. 
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L6 is similar to the base scenario in terms of its treatment of super urgent 
patients, however, biases increase in the treatment of routine patients, 
particularly between patients with different blood types.   
 
(3) Transplant Number (B2, L7, L8) 
L7 and L8 give priority to patients waiting for their first (L7) or successive liver 
transplant (L8).  These policies both improve the equity in the system across 
blood groups when compared to the base scenario, albeit at the expense of 
patients with blood group O. 
 
L7 leads to an increase in the number of routine patients receiving a transplant 
and exaggerates the bias in favour of patients waiting for their first transplant.  
This results in the policy being less fair pre-transplant.  Under L7, more patients 
died from the waiting list but a significant improvement in post-transplant 
survival times was observed.  The groups likely to suffer the most are those 
super urgent patients requiring a re-transplant, while the post-transplant survival 
times are likely to have benefited from the implicit bias towards younger and 
routine patients – who are expected to live longer post-transplant (Equation (4.6) 
Section 4.5.2). 
 
By allocating to patients waiting for a successive transplant (L8), the bias 
changes direction towards patients waiting for a successive transplant, generally 
favouring older patients.  This reduces the equity in the system, particularly 
across different patient age groups. 
  
Experimentation 
 
226 
(4) Patient Age (B2, L9, L10) 
L9 gives priority to younger patients, while L10 gives priority to older patients; 
with livers being allocated to the youngest (or eldest) patients on the waiting list. 
 
In both scenarios, super urgent patients no longer have priority over routine 
patients, meaning that routine patients experience better outcomes when 
compared to the base scenario.  This has a direct effect on the number of deaths 
of super urgent patients pre-transplant (Table 6.12).  L9 results in a fairer system 
for patients waiting for their first transplant, but patients waiting for a successive 
transplant (generally super urgent patients) are put at a disadvantage.   
 
Allocating to younger patients results in better overall post-transplant survival 
times, but the opposite is true when priority is given to older patients.  This is 
consistent with the post-transplant survival model created, in which the age of 
the patient was found to be a significant factor. 
 
Understandably, under L9 the bias against older patients is exaggerated, while 
under L10 the bias switches so that older patients receive more transplants. 
 
(5) Time Spent Waiting for a Transplant (B2, L11, L12) 
Allocating to patients either based on the shortest waiting times (L11) or the 
longest waiting times (L12) results in more routine patients being transplanted.  
This finding is intuitive for L12, for L11 it requires a bit more explanation.  
Firstly, super urgent patients will no longer have priority ahead of routine 
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patients that have recently been placed on the waiting list; indeed, there are far 
more routine patients than super urgent patients, so they will now receive a 
larger proportion of the livers available.  Secondly, as more patients die or are 
removed from the waiting list, the list will reduce in size, giving routine patients 
more chance of receiving a donated liver.  Super urgent patients, who are likely 
to die after a couple of days, are not so fortunate.  Allocating to those patients 
who have been waiting the shortest time leads to a significant decrease in the 
number of life years gained and a decrease in the number of life years in the 
system.  This is primarily because many more patients are experiencing death or 
removal from the waiting list. 
 
(6) Patient Weight Compared to Donor Weight (B2, L13) 
L13 allocates a donated liver by determining the patient whose weight is most 
closely matched with the donor’s weight.  The result of this is that the number of 
life years in the system significantly decreases as a consequence of a greater 
number of patients experiencing death or removal from the waiting list.  The 
increase in death/removal from the waiting list is most likely to be due to the 
additional weight criteria having a negative impact on the number of super 
urgent patients receiving transplants.  There are fewer super urgent patients and 
so it will be more likely that a routine patient will be a better match in terms of 
weight.  As a result of weight matching, significantly better post transplant 
outcomes are experienced. 
 
 
  
Experimentation 
 
228 
(7) Pre-/post-transplant prognosis and utility (B2, L14, L15, L16) 
L14 allocates the donated livers by giving priority to patients with the worst pre-
transplant prognosis.  This significantly increases the number of life years in the 
system, and reduces the percentage of patients to experience death or removal 
from the waiting list.  Table 6.15 shows how the number of patients on the 
waiting list significantly increases under this policy, as a result of fewer 
deaths/removals.  Under this policy older patients gain as they are likely to have 
a worse pre-transplant prognosis (Equation (4.3) Section 4.4.2), this causes a 
great reduction in post transplant equity. 
 
L15 and L16 both consider the likely survival chances of patients post 
transplant.  L15 just looks to maximise this expected post transplant survival 
time, while L16 looks at maximising the difference between post-transplant and 
pre-transplant prognoses.  Both policies result in significantly improving the life 
years in the system, the life years gained from transplant, and all post transplant 
outcome times. 
 
However, both policies also result in overall biases increasing.  The bias 
becomes greater against older patients and patients with smaller weights.  These 
factors are all present in the formula which predicts post transplant outcome 
times (Equation (4.6) Section 4.5.2), and are all associated with shorter post-
transplant survival times. 
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Routine patients receive more transplants under both L15 and L16.  However, 
under L16 the bias towards routine patients is not as great as under L15.  This is 
due to L16 seeking to maximise the life years gained from transplantation and 
therefore favouring super urgent patients who are expected to die very soon, but 
who also have a reasonable survival time post transplant, while L15 only 
considers who will have the best post transplant prognosis, which is shorter for 
super urgent patients (Equation (4.6) Section 4.5.2). 
 
Table 6.15 Start and End Waiting List Size for all Allocation Factors. 
 Allocation Priority to 
Year 0  
(1095 days) 
Year 4  
(2555 days) 
B2 Base case 214 256 
L3 Compatible Blood Groups 224 267 
L4 Identical Blood Groups 204 243 
L5 Local Patients 205 259 
L6 National Patients 82 96 
L7 First Transplants 90 104 
L8 Successive Transplants 78 81 
L9 Younger Patients 146 147 
L10 Older Patients 101 101 
L11 Those waiting the shortest time 136 139 
L12 Those waiting the longest time 70 76 
L13 Patients where the absolute difference 
between donor and patient weight is 
minimised 
112 114 
L14 Patients with the soonest death or 
removal time (i.e., worst pre-
transplant prognosis) 
441 598 
L15 Patients with the best post-transplant 
prognosis 
230 229 
L16 Patients with best prognosis 
compared to expected prognosis 
without a transplant 
194 238 
L17 An adaptive policy which attempts to 
make allocation decisions through 
keeping track of equity measures, for 
groups not fairly transplanted across, 
within the other allocation policies 
214 259 
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From Table 6.15 it can be seen that the waiting list size increases dramatically 
under L14.  This is not unexpected as the policy attempts to allocate livers to 
patients who have the shortest time to death or removal, while the current policy 
in use does not consider this when allocating a liver to a routine patient.  As a 
result of this, patients who have longer death or removal times will remain on 
the waiting list and fewer patients will die, so the waiting list size will increase.  
It is expected that eventually the number of patients on the waiting list would 
stabilise, as a steady stream of routine patients would die from the waiting list.  
Before the waiting list stabilised, there might be a critical point when the 
benefits of the policy are reduced.  Two allocation policies result in much 
shorter waiting list sizes at the end of the four years, than all the other policies.  
These are allocation to patients requiring successive transplants (L8) and 
allocation to patients waiting the longest time (L12).  Allocating to those waiting 
for their successive transplant or to patients who have been waiting the longest 
time, results in allocating few transplants to super urgent patients.  This results 
in more deaths and removals from the waiting list, which in turn reduces the size 
of the waiting list. 
 
Overall Equity and Utility - Allocation Rule Scenarios 
From Figure 6.4 we can see that the only alternative allocation rule which, when 
compared with the current policy, improves both equity and utility within the 
liver transplantation system is L9 (giving priority to younger patients).   
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The allocation rules which improve the overall equity within the system, without 
adversely affecting the utility measures, are: 
– L4 (priority to patients with identical blood group to the donor), 
– L5 (priority to patients in the same centre as where the donor is retrieved, 
and  
– L17 allocating maintaining compatible blood groups (i.e., to patients of the 
blood groups with proportionally the fewest transplants). 
L15 and L16 increase utility most, but at the expense of equity within the 
system.  Allowing allocation to any patient with a compatible blood group,  (L3) 
does improve equity within the system, but to the detriment of the utility 
measures.  Giving priority to older patients (L10) results in particularly bad 
outcomes with regard to both equity and utility.  Allocating to patients who have 
most recently joined the waiting list (L11) improves equity, as in effect the liver 
transplants are being allocated to patients at random, but produces a far less 
effective system.  Conversely, L12, which allocates to patients who have been 
on the waiting list the longest, is less equitable since patients with certain 
attributes will be more likely to benefit, as they can survive for longer before 
requiring a transplant.  
 
The most promising policies (L4, L5 and L9) are considered further in Sections 
6.4 and 6.5.  L17 is not considered, as this policy is not practicable, however, it 
has been useful to demonstrate the potential impact of a policy which attempts to 
increase equity within the system. 
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Figure 6.4 Equity Points Against Utility Points for the Allocation Scenarios. 
 
6.3.5 Discussion of Findings 
As the demand for liver transplantation increases, both equity and utility in the 
liver transplantation system are adversely affected.  Utility is affected because 
the imbalance between supply and demand is increased, meaning that a greater 
proportion of patients experience negative outcomes.  Equity is also affected as 
the system in place gives priority to super urgent patients and patients with 
blood type O.  As demand increases, patients with other characteristics become 
even less likely to receive a transplant.  Essentially, the biases present in the 
base scenario are exaggerated as the imbalance between supply and demand 
increases. 
 
Similarly, a declining supply of livers results in a much greater bias towards 
super urgent patients being transplanted.  As supply is increased many more 
routine patients were transplanted, and vice versa.  The same pattern is observed 
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between patients with blood type O and with patients from other blood groups.  
It was found that as the supply of donated livers increases, it will still take 
approximately two years before the size of the waiting list begins to fall.  
 
The overall effect of restricting the assessment criteria, so that only patients with 
worse prognosis are allowed onto the waiting list, is to decrease the number of 
life years in the system.  In these scenarios, the pre-transplant prognoses of 
patients are worse, meaning that they will die earlier, and are less likely to 
receive a transplant in the meantime.  As a secondary consequence, a number of 
livers would be wasted as there could be no suitable patients on the waiting list.  
As the assessment criteria is restricted to only allowing patients with better 
prognosis onto the waiting list, the number of life years in the system increases.  
Both policies are biased in terms of which patient groups benefit from 
transplantation. 
 
One desirable feature of the base scenario is that by giving priority to blood 
group O patients (when a blood group O liver is donated) it does encourage 
identical blood group matching.  However, due to the mismatch between donor 
blood groups and patient blood groups (Table B.2 Appendix B), enforcing only 
identical blood group matched transplants (L4), does significantly disadvantage 
blood groups AB, B, and A. 
 
A more stringent centre matching policy leads to super urgent patients missing 
out on a transplant but increases equity amongst patient blood groups.  This is 
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because when a liver is donated, it will be allocated first to a compatible patient 
within the centre, irrespective of whether a super urgent patient is waiting 
elsewhere.  Local populations of donors and patients will have similar ethnicity 
and so similar blood groups, and so it is likely that this helps to improve the 
equity amongst the different blood groups. 
 
Implementing policies which give priority to patients waiting for either their first 
transplant or a successive transplant, affected the proportions of patients 
transplanted by urgency.  For the policy which gave priority to patients waiting 
for their first transplant, fewer super urgent patients were transplanted.  The pre-
transplant survival times are then dominated by these super urgent patients, who 
die sooner, hence the proportion to death/removal from the waiting list 
increases.  The post-transplant survival times are dominated by the routine 
patients and so the number of deaths/graft failures (within 1 year of 
transplantation) and re-lists (within 1 year of transplantation) were seen to 
decrease.  Similar effects were noted from giving younger or older patients 
priority for transplantation. 
 
Allocating livers according to the time (shorter or longer) a patient has spent on 
the waiting list results in better outcomes for the routine patients and worse 
outcomes for super urgent patients, with more deaths and removals from the 
waiting list.  Allocating to those who have spent a shorter time on the waiting 
list leads to fewer life years in the system and life years gained from transplant, 
and better post transplant equity.  Allocating transplants to minimise the weight 
  
Experimentation 
 
235 
difference between the patient and donor also disadvantages super urgent 
patients. 
 
Allocating transplants to the patient with the worst pre-transplant prognosis at 
the time when a liver is donated has the effect of reducing the number of patients 
who die from the waiting list and increasing the overall life years in the system, 
as well as reducing some of the bias present in the base scenario.  The policies 
which use post-transplant prognosis improve all utility measures except the 
proportion of patients who die/are removed from the waiting list, which worsens 
slightly.  These policies also lead to the system becoming more biased towards 
younger, routine, male patients who will remain alive for longer post transplant, 
and patients who are heavier. 
 
6.4 Analysis of Outputs from New Allocation Rules 
As identified in Sections 6.3.4 and 6.3.5, the most promising allocation policies 
identified are: L4 (priority to patients with an identical blood group to the 
donor’s), L5 (priority to patients from the same centre as the donor), and L9 
(priority to younger patients).  Since these allocation rules can be combined 
(e.g., (L4) and (L9) combined would give priority to younger patients with 
identical blood groups) several new rules were devised and these were used in 
further simulation runs.  The factors that received priority were always the ones 
which had performed better initially, as reported in Section 6.3.4.  The new rules 
considered were: L4L5, L4L9, L5L9, and L4L5L9. 
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6.4.1 New Allocation Scenarios 
Tables 6.16, 6.17 and Figure 6.5 show that when these allocation factors are 
combined, the resulting policy negatively impacts on both the utility and equity 
within the liver transplantation system.  In particular, all of the new allocation 
policies resulted in worse outcomes for super urgent patients.  This will have 
arisen because no priority is given to super urgent patients and because the 
additional criteria imposed make it more likely for a routine patient to be 
allocated a donated liver over a super urgent patient.  As there are a greater 
number of routine patients on the waiting list, it is more likely that they will 
satisfy the criteria ahead of any super urgent patients on the list. 
 
Table 6.16 Utility Outputs from the New Allocation Scenarios. 
New Allocation 
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B2 Base case 23.9 26.4 5.20 14.40 17.80   
L4L5 
Identical blood 
groups and 
local centre 22.8 25.3 4.97 13.74 18.22 -2 
L4L9 
Identical blood 
groups and 
youngest 23.3 26.0 5.01 14.01 18.80 -1.5 
L5L9 
Local centre 
and youngest 23.0 25.7 4.97 13.77 18.65 -2 
L4L5L9 
Identical blood 
group, local 
centre and 
youngest 23.3 25.9 4.84 13.65 18.65 -1.5 
Note: The Number of Wasted Livers is not presented in this table, since all the policies 
considered had 0 wasted livers, over the 4 years which were simulated. 
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Table 6.17 Equity Outputs from the New Allocation Scenarios. 
New Allocation 
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B2 Base case 5492 665   
L4L5 
Identical blood groups and local 
centre 5789 694 -2 
L4L9 Identical blood groups and youngest 7190 672 -3 
L5L9 Local centre and youngest 6539 603 -1 
L4L5L9 
Identical blood group, local centre 
and youngest 7504 864 -3 
 
All factors which give younger patients priority for receiving a transplant (i.e., 
L4L9, L5L9, and L4L5L9) increase the bias towards younger patients being 
transplanted. 
 
L4L5
L5L9
L9
B2
L4L9
L4L5L9
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1
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Figure 6.5 Equity Points Against Utility Points for the New Allocation 
Scenarios. 
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6.4.2 Discussion of Findings 
All combinations were found to improve post transplant survival, albeit at the 
expense of more patients dying from the waiting list.  Overall, therefore, the 
utility of the system is lower than the base scenario.  Equity within the system is 
worse for all scenarios and indicates that the allocation rules favour certain 
groups of patients over others.  This suggests that within the liver transplantation 
system there is no real advantage to developing complicated allocation policies – 
simple policies are likely to be at least as effective. 
 
6.5 Analysis of Outputs from Full Factorial Experiments 
The next stage of the analysis is to look at how these individual factors interact 
with each other.  These full factorial experiments were constructed using the 
assessment rules, demand and supply factors which portrayed the situations that 
are considered to be the most realistic.  The allocation rule factors which were 
chosen were identified as the most promising rules, from the analysis presented 
in Sections 6.3.4 and 6.3.5, at improving equity and utility within the liver 
transplantation system. 
 
The factors considered for the full factorial experiment, are: 
 Demand 
– A constant demand (D1); and 
– An increasing demand (D4). 
 Supply 
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– A constant supply (S1); and 
– A declining supply (S2). 
 Assessment 
– Current assessment criteria (A1). 
 Allocation 
– Base priority rules (B2); 
– Priority to patients with an identical blood group to the donor’s (L4); 
– Priority to patients from the same centre as the donor (L5); and 
– Priority to younger patients (L9). 
Since Section 6.4 shows that combining the allocation factors adversely affects 
the overall outcome measures.  These combinations were not considered within 
the full factorial experiment. 
 
6.5.1 Full Factorial Experiments 
Table 6.18 outlines the scenarios considered in the full factorial experiments. 
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Table 6.18 Utility Outputs of Full Factorial Scenarios. 
Key Demand Supply Allocation 
B2 Constant over time Constant over time Base case rules 
L4 
Constant over time Constant over time Priority to Identical 
Blood Groups 
L5 
Constant over time Constant over time Priority to Same 
Centre 
L9 
Constant over time Constant over time Priority to Younger 
Patients 
D4 
Demand Increasing 
(146 extra patients over 
4 years) 
Constant over time 
Base case rules 
L4D4 
Demand Increasing 
(146 extra patients over 
4 years) 
Constant over time 
Priority to Identical 
Blood Groups 
L5D4 
Demand Increasing 
(146 extra patients over 
4 years) 
Constant over time 
Priority to Same 
Centre 
L9D4 
Demand Increasing 
(146 extra patients over 
4 years) 
Constant over time 
Priority to Younger 
Patients 
S2 
Constant over time Declining donations 
(398 fewer over 4 
years) Base case rules 
L4S2 
Constant over time Declining donations 
(398 fewer over 4 
years) 
Priority to Identical 
Blood Groups 
L5S2 
Constant over time Declining donations 
(398 fewer over 4 
years) 
Priority to Same 
Centre 
L9S2 
Constant over time Declining donations 
(398 fewer over 4 
years) 
Priority to Younger 
Patients 
D4S2 
Demand Increasing 
(146 extra patients over 
4 years) 
Declining donations 
(398 fewer over 4 
years) Base case rules 
L4D4S2 
Demand Increasing 
(146 extra patients over 
4 years) 
Declining donations 
(398 fewer over 4 
years) 
Priority to Identical 
Blood Groups 
L5D4S2 
Demand Increasing 
(146 extra patients over 
4 years) 
Declining donations 
(398 fewer over 4 
years) 
Priority to Same 
Centre 
L9D4S2 
Demand Increasing 
(146 extra patients over 
4 years) 
Declining donations 
(398 fewer over 4 
years) 
Priority to Younger 
Patients 
  
 
From Tables 6.19 and 6.20 (and as discussed in detail in Sections 6.3.4 and 
6.3.5), the three allocation factors L4, L5, and L9 improve the overall equity, 
without adversely affecting the overall utility. 
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Table 6.19 Utility Outputs of Full Factorial Scenarios, which assume a Constant 
Demand and Supply. 
Full Factorial 
Scenarios 
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B2 23.9 26.4 5.20 14.40 17.80 
L4 23.9 26.4 5.00 14.00 17.60 
L5 23.6 26.1 5.00 14.00 18.10 
L9 24.6 27.5 5.00 13.80 18.80 
 
Table 6.20 Equity Outputs of Full Factorial Scenarios, which assume a Constant 
Demand and Supply. 
Full Factorial 
Scenarios 
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B2 5492 665 
L4 5071 747 
L5 4690 797 
L9 5760 614 
 
Table 6.21 Utility Outputs of Full Factorial Scenarios, which assume an 
Increasing Demand and a Constant Supply. 
Full Factorial 
Scenarios 
L
if
e 
Y
ea
rs
 i
n
 
S
y
st
em
 p
er
 P
a
ti
en
t 
L
if
e 
Y
ea
rs
 G
a
in
ed
 
p
er
 T
ra
n
sp
la
n
t 
%
 R
e-
L
is
te
d
 w
it
h
in
 
1
 y
r 
%
 D
ea
th
/G
ra
ft
 
F
a
il
u
re
 w
it
h
in
 1
 y
r 
%
 D
ea
th
\R
em
o
v
a
l 
fr
o
m
 W
L
 
D4 23.5 26.3 5.19 14.33 18.55 
L4D4 23.6 26.4 5.04 14.19 18.62 
L5D4 22.5 25.1 4.97 13.92 18.94 
L9D4 24.2 27.6 5.09 13.81 20.09 
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Table 6.22 Equity Outputs of Full Factorial Scenarios, which assume an 
Increasing Demand and a Constant Supply. 
Full Factorial 
Scenarios 
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D4 6687 778 
L4D4 5633 679 
L5D4 4712 739 
L9D4 8975 489 
 
Tables 6.21 and 6.22 give the results from all the scenarios which consider an 
increasing demand.  When there is a greater demand, it was found that: 
- Prioritising identically matched transplants no longer improves any aspects 
of utility, however, does improve on post transplant equity; 
- Allocating to patients from the same centre, results in a negative impact on 
the number of life years gained per patient and per transplant, but again 
improves on post-transplant equity; and 
- Allocating to younger patients results in a negative impact on the equity 
achieved from the waiting list. 
 
Table 6.23 Utility Outputs of Full Factorial Scenarios, which assume a Constant 
Demand and a Declining Supply. 
Full Factorial 
Scenarios 
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S2 21.9 26.3 5.20 14.30 24.60 
L4S2 21.9 26.4 5.02 14.19 24.55 
L5S2 20.8 24.9 5.04 13.77 24.27 
L9S2 22.1 28.6 4.90 13.68 29.70 
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Table 6.24 Equity Outputs of Full Factorial Scenarios, which assume a Constant 
Demand and a Declining Supply. 
Full Factorial 
Scenarios 
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S2 7102 591 
L4S2 5446 601 
L5S2 5421 854 
L9S2 8372 490 
 
Tables 6.23 and 6.24 give the results from all the scenarios which consider an 
declining supply.  When there is a smaller supply, it was found that: 
- Prioritising identically matched transplants no longer improves any aspects 
of utility, however, does continue to improve waiting list outcome equity; 
- Allocating to patients from the same centre, results in a negative impact on 
the number of life years gained per patient and per transplant; and 
- Allocating to younger patients results in a negative impact on the equity 
achieved from the waiting list. 
 
Table 6.25 Utility Outputs of Full Factorial Scenario s, which assume an 
Increasing Demand and a Declining Supply. 
Full Factorial 
Scenarios 
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D4S2 21.5 26.3 5.25 14.50 25.69 
L4D4S2 21.7 26.5 5.14 14.17 25.38 
L5D4S2 20.3 24.7 5.13 13.66 25.33 
L9D4S2 21.9 28.9 4.98 13.70 30.93 
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Table 6.26 Equity Outputs of Full Factorial Scenarios, which assume an 
Increasing Demand and a Declining Supply. 
Full Factorial 
Scenarios 
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D4S2 6273 516 
L4D4S2 5633 632 
L5D4S2 5256 836 
L9D4S2 8975 695 
 
Tables 6.25 and 6.26 give the results from all the scenarios which consider both 
an increasing demand and a decreasing supply.  Under this situation, it was 
found that: 
- Prioritising identically matched transplants no longer improves any aspects 
of utility; 
- Allocating to patients from the same centre, results in a negative impact on 
the number of life years gained per patient and per transplant; and 
- Allocating to younger patients results in a negative impact on the equity 
achieved from the waiting list. 
 
Overall, under the various demand and supply scenarios, it was found that 
allocating to identically matched patients did not improve on utility as before, 
allocating to younger patients maintained better utility and allocating to patients 
at the same centre negatively impacted on the overall utility.  Allocating to 
younger patients had a negative impact on equity, while equity improved or 
remained the same when allocating to patients at the same centre or which 
identical blood groups to the donors. 
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6.5.2 Discussion of Findings 
The results from the full factorial experiments identified that the allocation rule 
that performs the best in terms of utility under all the supply and demand 
scenarios is allocating to younger patients (L9).  L9 also performs the worst in 
terms of equity, since it greatly exaggerates the biases against older patients. 
 
Under each of the demand and supply scenarios, the waiting list size reaches an 
equilibrium after 2 years. 
 
Increasing supply does not result in a drastic improvements to equity due to  
inherent biases within the allocation policies. 
 
Due to the dynamics involved within equity and utility outcomes, if supply goes 
down or demand increases then it becomes increasingly hard to design a policy 
which is both equitable and maximises utility, while acknowledging the priority 
that should be allocated to patients requiring super urgent transplants. 
 
6.6 Summary 
This chapter summarised the results obtained from experimentation carried out 
using Hepatica.  The results from changes in the demand, supply, assessment 
rules, and allocation rules are reported.  New allocation rules were created based 
on the initial ‘one factor’ changes which improved both utility and equity 
outcomes.  The most likely demand, supply and assessment factors and 
allocation factors which improve the system outcomes were then used in a full 
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factorial experiment.  Under each of the demand and supply scenarios, the 
waiting list size reached equilibrium after roughly two years. 
 
Overall the utility of donated livers is easier to improve than the overall equity 
in the system, under any policy which attempts to prioritise patients for liver 
transplantation.  The biggest gains for both equity and utility resulted from the 
scenarios in which the patients expected to survive longer receive priority for 
transplantation (L4: identically matched blood groups, L5: routine patients, 
gained over super urgent, L9: younger and first transplant patients gained).  
However, when changing the future supply of liver transplants and the future 
demand for liver transplantation, this limits the overall impact of the allocation 
scenarios. 
 
Several effects were found, in particular, when the overall supply increased at a 
greater rate than demand, the routine patients benefit, but when the overall 
supply decreases, routine patients lose out even more since there are fewer 
transplants and the super urgent patients receive priority for these.  Similarly, 
when the overall supply decreased at a greater rate than demand, patients with 
blood groups A, B and AB missed out, as blood group O patients receive 
priority over any livers available.  When supply increases, patients with different 
blood types have a more even chance of receiving a transplant. 
 
All combinations (of policies L4, L5 and L9) improve post transplant survival.  
However, this is at the expense of more patients dying from the waiting list, 
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therefore the overall affect on utility is negative when compared to the base 
scenario.  Equity is worse for all these scenarios and this implies that the 
allocation rules favour certain groups of patients over others.  This suggests that 
within the liver transplantation system it is best to keep liver transplant 
allocation rules simple. 
 
The key points to emerge from the analysis are that it is important to keep rules 
simple in order not to introduce too much bias into the system.  Due to the 
inherent need to prioritise by transplant urgency there is a limit as to the 
improvements which can be gained within the equity and utility measures. 
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Chapter 7 
 
Conclusions 
 
7.1 Introduction 
This chapter summarises the work performed in this thesis.  It outlines the 
methodology that was used to meet the objectives of the work, the conclusions 
reached for the research questions posed, the limitations of the work and 
identifies areas of further work.  This chapter also summarises some general 
conclusions and reports what was learnt from the work. 
 
7.2 Problem Situation and Literature Review 
When a person falls ill with end stage liver disease the only effective treatment 
that is currently available is a liver transplant.  Although alternative treatments 
are being developed, in most cases the livers are provided from cadaveric 
donors.  The prevalence of liver-related diseases is on the increase and the 
amount of unmet demand is unknown.  Chapter 1 discusses this shortage in 
supply compared to the number of patients who require the operation, and 
explains that this shortfall is  expected to worsen in the near future. 
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There are many conflicting opinions about which patients are suitable for 
transplant and how donated livers should be allocated.  This, and the current 
shortage of donors, means that it is important to understand how various policies 
affect the outcomes experienced by the patients with end stage liver disease.  
There are two key stages within the liver transplantation process at which 
changes in policy can affect who joins the waiting list (assessment stage) and 
which patients receive a transplants (allocation stage).  The policies chosen will 
determine the outcomes that individual patients will experience, as well as the 
overall effectiveness and fairness of the system. 
 
There is a large amount of literature on Transplant Matching Models, but 
relatively few published studies which consider the UK Liver Transplant 
System.  This literature was discussed in Chapter 2 and several limitations of the 
previous models were identified.  While there have been several detailed 
transplant matching studies in the USA, the set up of the liver transplantation 
system in the USA is inherently different to the liver transplantation system in 
the UK. 
 
Most previous models make little attempt to consider future changes in demand 
and supply for liver transplantation.  However, due to the likely increasing gap 
between future need and future donations, it is necessary to understand whether 
different policies would be more appropriate in different situations. 
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Many of the previous models adopt a utilitarian approach when determining 
which patient should receive a liver transplant from all those on the waiting list.  
By focusing solely on the benefit gained from a potential transplant, it is likely 
that certain groups of patients will be disadvantaged if their survival chances 
post-transplant are relatively low.  This is particularly likely to be true of older 
patients and patients with diseases that are liable to recur. 
 
The sole UK model (Eldabi et al. 2001) just considers the cost-effectiveness of 
alternative allocation policies, and only concentrates on two disease groups.  As 
such, it is limited on its ability to assess the equity of the system under these 
different policies.  Significantly, it also does not include super urgent patients in 
the model.  As these patients receive priority for any liver that is donated, their 
inclusion is crucial to be able to accurately model the liver transplant system.  
 
The literature review identified some gaps in previous research which the work 
within this thesis aims to fill.  These are the need to:  
– Incorporate supply and demand;  
– Monitor all patient groups;  
– Balance the outcome measures equity and utility; and  
– Consider assessment criteria restrictions, in the UK liver transplant system. 
These are the main contributions this thesis makes to transplant matching 
studies. 
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From the literature three main aspects were identified which require 
consideration when building a model to represent the liver transplantation 
system; these are: 
(1) The identification of suitable measures for comparison between policies;  
(2) The identification of techniques by which to estimate the time a patient 
remains in a particular state; and 
(3) The identification of a methodology by which to model patient progression 
through the system. 
 
7.3 Research Objectives and Methodology Implemented 
This section reports on the methodology which has been implemented and to 
what extent the analysis performed has met the research objectives stated in 
Chapter 2. 
 
7.3.1 Suitable Measures to Enable Comparison Between Policies 
The identification of suitable measures  to enable comparison between policies. 
 
The overall aim of the analysis was to identify scenarios where all patients had 
an equal chance of receiving a liver transplant at the same time as maximising 
the effectiveness provided by the scarce liver transplants.  Thus, equity and 
utility measures were used to look at the fairness and effectiveness of various 
scenarios.  The equity and utility measures considered in the Discrete Event 
Simulation (DES) model were those from once a patient joins the waiting list. 
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The utility measures considered are:  
– Life years in the system per patient;  
– Life years gained per transplant;  
– Percentage of patients re-listed within 1 year of receiving a transplant;  
– Percentage of patients to experience death or graft failure within 1 year of 
receiving a transplant; and  
– Percentage of patients to experience death or removal from the waiting list, 
and the number of livers wasted. 
 
The level of equity within the system was also considered by looking at the 
outcomes that different patients experienced following their arrival onto the 
waiting list, and post-transplant.  Ideally, the chances of experiencing these 
outcomes would be independent of: 
– The transplant centre; 
– The patient’s blood group; 
– The number of previous transplants the patient had received; 
– The disease type that the patients was suffering from; and 
– The patient’s age, weight and gender. 
The differences by transplant urgency status were also analysed, but did not 
contribute to the overall equity measures. 
 
The individual utility and equity measures were then weighted and combined to 
give the overall equity and utility of the system, and plots were created to 
compare changes in these measures across different allocation policies.   
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7.3.2 Estimating Events and Survival 
The identification of a technique by which to estimate the time a patient will stay 
in a particular state (events and survival). 
  
A logistic regression model was developed to take into account patient attributes 
for capturing the decision made of whether patients should join the waiting list, 
or not.  It was decided not to use this model within the final DES model due to 
concerns about the validity of the results it produced.  In particular, the model 
developed only captures the assessment decisions within one particular liver 
transplant centre.  The characteristics of patients treated by this centre were 
shown to be significantly different to patients from other transplant centres, and 
the assessment rules are also thought to be interpreted differently by different 
centres.  For these reasons it was decided not to rely on the logistic model 
created, and instead patients would be modelled from their arrival onto the 
waiting list.  Changes to the assessment criteria were instead simulated by 
changing the prognosis of patients joining the waiting list.   
 
The time until patients experienced death or removal from the waiting list was 
modelled using parametric competing risk models.  The time until patients 
experienced death, graft-failure or re-listing following their transplant was 
modelled using parametric survival models.  These models were then 
incorporated within the DES model, using Monte Carlo sampling techniques to 
determine how long a particular patient spent in a particular state.  The main 
advantage of the survival techniques used is that the models can take into 
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account censored information resulting from the restrictions on the study period 
used. 
 
The competing risks model enabled the modelling of times to the two main 
events from once a patient joins the waiting list:  
(1) Death or Removal; and  
(2) Transplantation.   
The chosen method resolves the basic limitation of Survival Analysis that all 
censored event times should be independent of a cause, i.e. uninformative.  The 
distributions developed for the Death/Removal outcome were then used within 
Hepatica.   
 
All of the models were created using patient, donor and transplant risk factors 
that were easily attainable for all cases, taking into account the outcomes of all 
adult patients who joined the liver transplant waiting list within the study period.  
A detailed analysis of disease progression was not required due to the short 
times patients are expected to spend on the waiting list.  As a result, only the 
main clinical measures were used in the analysis. 
 
7.3.3 Patient Progression 
The identification of a methodology by which to model patient progression 
through the system. 
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A Discrete Event Simulation was built to model the UK Liver Transplantation 
system, with a view to assessing whether alternative assessment rules and 
alternative transplant allocation policies improve upon the current rules and 
policies in place.  DES was chosen to model patient progression over other 
methods.  The main advantages that this technique offers is that it can allow for 
the modelling of patient- and donor-level interactions, it can capture the 
variation within the system, and allows for previous patient, donor and 
transplant characteristics to all aid in determining the transition times in future 
states (i.e., it can retain patient disease history). 
 
The DES model was designed to output the equity and utility measures required 
to compare alternative scenarios.  Statistical sub-models were developed and 
sampled from to estimate the times patients spent in particular states within the 
DES model. 
 
Different scenarios were run to assess the impact on the equity and utility 
measures of changes to future demand and supply, and to the assessment and 
allocation policies in place.  Expectations of future demand and supply were 
identified from published work, the new assessment criteria restricted the type of 
patients eligible for transplantation, and the allocation policies were identified as 
those which could feasibly be implemented and also those which were designed 
to improve either equity or utility within the system. 
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7.4 Research Questions and Key Findings  
This section considers the research questions posed at the end of Chapter 2 and 
summarises the key findings of the work performed. 
 
7.4.1 Suitable Measures to Enable Comparison Between Policies 
‘Can we get a better understanding of whether alternative allocation policies 
can improve both equity and utility, simultaneously?’ 
 
The equity analysis of the base scenario presented in Chapter 6, confirmed that 
the base scenario is not equitable, with differences in outcomes observed across 
patient characteristics (blood group, disease group, age, centre) which determine 
how a donated liver is currently allocated to a particular patient on the waiting 
list. 
 
Hepatica was used to model various scenarios and analyse how alternative 
allocation policies impacted on the equity and utility of the system, given the 
current level of supply and demand and the assessment criteria in place.  Three 
allocation policies were found to improve on either the equity or utility of the 
system, without adversely affecting the other.  These were policies which aim 
to: 
(1) Allocate to patients with an identical blood group to the donor; 
(2) Allocate to younger patients; and  
(3) Allocate to patients who were at the same centre that the liver was retrieved. 
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An additional policy was designed to address the main inequality in the system – 
patient blood group.  This policy gave priority to the blood groups which 
proportionally had received the fewest number of transplants so far, ensuring 
that all transplants took place between patients and donors with compatible 
blood groups.  This policy succeeded at improving the equity within the system, 
but at the expense of adversely affecting the utility of the system. 
 
A further policy was designed to try and obtain the maximum utility of the 
system.  This policy allocated each liver to the patient who would receive the 
largest benefit from that transplant – in terms of life expectancy.  This policy 
succeeded at improving the utility of the system, but at the expense of adversely 
affecting the equity within the system.   
 
‘Does the complexity of the allocation rules affect the equity and utility 
outcomes?’ 
The allocation rules which improved both equity and utility were combined to 
try and create an even better policy.  The resulting allocation rules adversely 
affected both equity and utility, as a result of introducing more biases within the 
system.  This suggests that for the examples considered it was a mistake to 
combine the allocation rules (making them more complicated), and that it may 
be better to keep allocation rules quite simple. 
 
 
 
  
Conclusions 
 
258 
‘Do the policies which improve equity and/or utility, continue to do so as 
demand and supply change?’ 
The base scenario allocation rules and the allocation rules which improved both 
the equity and utility were then used in scenarios in which demand and supply 
changed over time.  The analysis performed indicated that it is hard to balance 
both equity and utility over the long term.  Over time the patient mix will 
change, as will the number of donations and patients requiring transplants.  Any 
allocation policy which needs to prioritise patients, will inherently impose biases 
within the system, and due to changes in the patient mix, the magnitude and 
direction of the biases will be affected.  The life years gained will implicitly be 
affected by the direction and extent of the biases, as many patient characteristics 
determine the eventual timings and outcomes the patients experience.  Thus, the 
policy which provides the most benefits is dependent both on supply, demand, 
and the mix of patients requiring a liver transplant. 
 
7.4.2 Estimating Events and Survival 
‘Can we find a parametric distribution using statistical techniques that can be 
sampled from within a DES?’ 
 
It was possible to develop statistical models to capture the outcomes: from 
assessment, from the waiting list, and from transplantation.  To capture the times 
to events from the waiting list and post transplantation, it was necessary to used 
very specialised techniques, to incorporate censored data and multiple risks.  As 
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a result, distributions which captured the outcomes and times were complex, but 
it was then possible to use these distributions within the DES model. 
 
The models developed help to show which patient characteristics affect their 
progression through the system, and the likely outcomes that they will 
experience.  
 
Patient age was found to be significant at all stages in the transplant system.  
Older patients were less likely to initially be placed on to the waiting list.  They 
were also modelled to experience death or removal from the waiting and 
death/graft failure/re-listing outcomes sooner than younger patients. 
 
Transplant urgency is another factor which unsurprisingly has an affect on the 
outcomes that a patient experience.  As super urgent patients have very low pre-
transplant life expectancy they were found to be much more likely to be listed 
onto the waiting list, and are given priority over livers that are donated.  As well 
as having a very low pre-transplant life expectancy, they were also found to have 
to experience death/graft failure/re-listing following a transplant sooner than 
routine patients.  
 
The Model for End stage Liver Disease (MELD) score is significant in 
determining who is listed for transplant, and the patients recovery post 
transplant.  However, MELD does not appear significant in the waiting list 
outcome model.  This may be unexpected as the MELD score is used in the 
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USA to determine how ill a patient is when on the waiting list.  The main 
limitation of the MELD score in this study is that we could only capture it at the 
stage at which patients were either assessed at Birmingham Liver Unit or at the 
time of transplant.  MELD score is a clinical measure which will change over 
time and so for any definite conclusions we would need to monitor it at more 
observation points (e.g., daily or weekly intervals), and capture how the MELD 
score changes over time. 
 
Patients with liver disease due to unknown causes, Cryptogenic cirrhosis, 
alcoholic cirrhosis, and the Hepatitis C Virus, were less likely to be placed on 
the waiting list initially.  On the whole, alcoholic liver disease patients were 
found to experience longer survival times post transplant.  Liver diseases due to 
cancer, Hepatitis B, or a missing diagnosis were seen to experience shorter times 
to death or removal once on the waiting list, but were not significantly different 
within the post transplant survival times.  Patients suffering from other cirrhotic 
diseases (primary biliary cirrhosis, autoimmune cirrhosis or secondary biliary 
cirrhosis) experienced significantly longer survival times both while on the 
waiting list and post transplant,   while patients in the category “other diagnosed 
liver disease” were seen to do well on the waiting list and have significantly 
shorter times to post transplant outcomes. 
 
Other factors which were significant in the waiting list outcome model included 
the centre at which a patient was registered and patient gender.  The transplant 
centre will affect the outcome partly as a result of how different centres interpret 
  
Conclusions 
 
261 
the assessment guidelines and partly due to the initial mix of patients that are 
referred to them; which will again influence the decisions they make in view of 
the assessment guidelines.  Males were seen to experience death or removal 
sooner than females. 
 
Several other patient, donor and transplant attributes were also significant in the 
post transplant model.  Marginal livers used in transplantation (Section 1.5.3) 
are defined to be split or reduced livers, donors aged over 65 years old, and 
where the donor died due to infection.  All these factors caused the times to post 
transplant events to be shorter.  Identically matched donor and patient blood 
groups significantly improved post transplant survival, as did the covariate 
patient weight minus donor weight, implying that the patients who are heavier 
are more likely to experience better post transplant outcomes.  This would be 
due to the heavier patients, actually being “healthier” than the lighter patients, 
due to the nature of liver diseases – in the latter stages of which, patients can 
lose a lot of weight. 
 
7.4.3 Patient Progression 
‘Can a simulation answer questions in the UK context about equity and utility 
within the transplant allocation and assessment process?’ 
 
It was possible to use Hepatica to capture and evaluate how different policies 
within the assessment and allocation processes affect the equity and utility 
within the liver transplantation system. 
  
Conclusions 
 
262 
For evaluating the changes in the assessment rules, it was not possible to capture 
the patients that would join the waiting list as a direct result of changing the 
assessment rules, due to data limitations.  However, changes in the assessment 
policies were mimicked by altering the pre-transplant prognosis of all the 
patients joining the waiting list.  This in effect altered the patient mix joining the 
waiting list and thus the assessment rules in place. 
 
The allocation rules were modelled directly in the simulation, by searching the 
waiting list for the most appropriate patient (according to the allocation rules in 
place), to identify the patient who should obtain the liver transplant. 
 
The model is able to assess system equity and utility, resulting from various 
demand, supply, assessment rule, and allocation rule factors.  This has helped to 
increase understanding of how various changes to assessment and allocation 
policies would affect the liver transplant system.  By incorporating all patient 
groups, in particular super urgent patients, Hepatica is a more comprehensive 
model of the UK liver transplantation system than has previously been created. 
 
7.5 Limitations and Further Work 
Longer term it would be beneficial to develop an interface to make the 
simulation model more user friendly so that UK Transplant and the Liver 
Transplant Units can use it for testing various policies they may implement.  
More specific areas of further work are discussed below, which take forward the 
issues and limitations raised in Sections 7.3 and 7.4. 
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7.5.1 Suitable Measures to Enable Comparison Between Policies 
Ranking and Balancing Outcome Measures 
It became evident that there is no clear way in which to balance and rank the 
equity and utility measures against one another.  The need for this is accentuated 
because when the demand for liver transplants is greater than the supply of livers 
there is no policy which optimises both the utility and equity within the system; 
either one can be improved, but generally only at the expense of the other.  
There is therefore a need for further development in determining the most 
appropriate equity and utility measures to use, and also the techniques used to 
rank and balance them. 
 
The general public and doctors both have a high power and high interest in the 
liver transplant system, for example, the public have the power to refuse to 
donate, while the doctors have power in determining which patients should 
receive the donated livers.  In order to develop the equity and utility measures 
further, input would be required from all the stakeholders in the liver 
transplantation process.  Several studies have concluded that the general public 
have different views from doctors about the importance of equity and utility and 
how they should influence the allocation of liver transplants.  Therefore, any 
approach which seeks to identify the core measures to consider, needs to involve 
the points of views of all sides. 
 
There are many additional measures which could be used to assess the equity 
and utility of the system.  Some of these were recorded from Hepatica, but only 
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a few key measures were used to compare different scenarios.  There is scope to 
further develop how the scenarios are ranked which would allow the inclusion of 
additional measures.  Multi-Criteria Decision Analysis could be employed here 
to rank equity and utility measures by importance (as defined by meeting with 
the various stakeholders), and then determine which policies result in the best 
outcomes. 
 
Additional Outcome Measures 
There are some measures commonly used within the healthcare setting which 
would aid the assessment and allocation decision processes.  These include 
quality of life measures and the costs involved.  There is also an ongoing debate 
about preventable diseases - should a more hard-line approach be taken, as the 
NHS shifts its focus towards preventing diseases and promotes leading healthier 
lifestyles. 
 
An important utility measure commonly used in healthcare is Quality Adjusted 
Life Years (QALYs).  To assess the overall gains in QALYs, the Quality of Life 
(QoL) patients experience will need evaluating at three stages:  
(1) On the waiting list;  
(2) Once transplanted; and  
(3) When the liver graft is rejected, and when a patients die due to other causes. 
One of the measures that the NHS considers is the cost per QALY.  This allows 
some comparison to be made between different treatments and provides a basis 
from which to prioritise treatments for different conditions (e.g., drug treatment 
  
Conclusions 
 
265 
for high blood pressure or screening for cancer).  The main limitation in the 
current liver transplant system is the shortage in the number of donors, and if a 
liver is donated then it will be used in transplantation.  However, if a treatment is 
developed for end stage liver disease or the supply of donated livers increases, 
then costs will become more important (both the cost-effectiveness of liver 
transplants and the additional QALYs gained from a transplant). 
 
Definition of Equity 
The output from the simulation model showed that in general it is much harder 
to obtain equity in the system.  The base scenario and alternative scenarios are 
biased towards or biased against transplanting certain patient groups.  In 
particular, polices which prioritise super urgent patients give a much greater bias 
against routine patients.  This is perfectly understandable and should be the case, 
as super urgent patients have a very short life expectancy without one.  During 
the experimentation phase, one policy was developed to try and maximise equity 
within the system.  Super urgent patients were no longer given priority and so a 
smaller number of them received a transplant, with the utility of the system 
undermined as a result.  As further work it would be useful to change the 
definition of equity so that policies are allowed to allocate to super urgent 
patients where possible and then identify any biases against other patient groups 
(excluding the monitoring of all characteristics of super urgent patients).   
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Implications of New Developments 
Healthcare in the UK is constantly evolving as a result of new developments and 
innovations, for example, the wider use of living liver transplants for adults on 
the NHS on the costs for and supply of liver transplants.  Analytical methods 
need to be developed in order to capture their likely effect.  If the use of living 
donors becomes more prevalent, any change in the donor’s health would also 
need to be monitored when assessing the value of this alternative treatment.  
Cost-benefit analysis and the life years gained by the patient and any potential 
life years lost by the donor would be required. 
 
Other future work may arise pending further technological developments.  In 
particular, one study is showing promising signs in lengthening the time a liver 
can survive outside a human body (Gross 2007).  This study could lead to 
further understanding of how the liver functions and therefore to new treatments 
of liver failure, similar to dialysis for kidney failure. 
 
There is also some work to be done on establishing if education (on the causes 
of liver diseases and the likely outcomes, as well as, ways in which to prevent 
certain types of liver disease) is an effective means to reduce the number of end 
stage liver disease sufferers.  This aspect is important due to the limited number 
of livers available. 
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Hepatica could easily be extended to incorporate these aspects, or could be used 
to give an early indication of the likely impact of any changes to demand and/or 
supply. 
 
7.5.2 Estimating Events and Survival 
Data Limitations 
In order to improve the competing risks and survival models created it would be 
useful to be able to analyse data from a longer observation period.  This would 
aid in confirming how patient survival changes over a longer period of time, 
especially important for estimating the long term benefits of a liver transplant.  
The models could also be calibrated with more recent data than for the years 
1999-2002. 
 
The logistic regression model developed to predict whether or not a patient joins 
the waiting list needs further development in order to be able to fully incorporate 
the assessment phase into the simulation model.  To do this, further data needs 
to be collected from all the liver transplant units in the UK.  This work would 
also need to capture how different decisions were made at the different liver 
transplant centres (i.e., how the fairly subjective assessment criteria and 
allocation rules are interpreted).  This could be done by presenting several 
different patient waiting list and donation scenarios, from which it could be 
determined whether centres are likely to make the same decisions if they have 
similar patients mixes, or whether centres weight their decisions favouring either 
equity or utility. 
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As discussed in Section 7.4.2, the MELD score associated with the patients did 
not appear to be significant to the outcomes observed from the waiting list.  The 
MELD score in our data set is only recorded at the time a patient joins the 
waiting list, however, the score is based on clinical measures which will change 
over time (as the disease progresses).  Therefore, monitoring how the MELD 
score changes over time would help establish how ill a patient is, more 
accurately. 
 
Models - Methodology and Assumptions 
It was difficult to evaluate how well the survival and competing risks models fit 
the original data, since the models had many covariates.  Taking the average 
values for the covariates leads to resulting distributions which would never 
occur.  Notably, a number of binary variables are used which can only take the 
values 0 or 1.  The “average” value that these variables took may be around 0.2 
– which is meaningless.  Separating the models by each combination of 
covariates, meant that very few data points existed to compare against.  Another 
way to determine if the models are suitable would be by using re-sampling 
techniques to sample values from the models in the proportions based on the 
observed patient, donor and transplant characteristics, and comparing a Kaplan-
Meier survival plot for the sampled cases with a Kaplan-Meier plot based on the 
original data. 
 
There is also some work to be performed to identify whether the more complex 
competing risks model provides a better approximation to death or removal 
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outcomes than a simpler survival model would.  Extra analysis would seek to 
confirm whether the extra effort in developing the more complicated model is 
justified (i.e., is able to capture the events and times more accurately). 
 
7.5.3 Patient Progression 
Assessment 
There is a great deal of modelling work that could be done regarding the 
assessment process.  One of the major areas of work would be to identify how 
the national assessment criteria  are interpreted by the local liver transplant units. 
 
Pre-Assessment Modelling 
The model developed is limited to what is required for measuring the outcomes 
and meeting the objectives for modelling.  Therefore, some aspects (in 
particular, prior to referral to the liver unit) were not modelled and the equity 
and utility measures are only considered in detail from when a patient joins the 
waiting list.  However, as identified in Section 2.3.1, it is important that the 
system is equitable at all points in the system where decisions influence the 
progression of the patient to the next state.  Geographical equity measures were 
analysed as patients joined the waiting list and are they received a transplant 
(Appendix G), however other patient attributes also require monitoring for 
equity purposes if a truly equitable system is to be identified. 
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Super Urgent Patients 
In Chapter 5 we observed that a larger proportion of super urgent patients are 
transplanted within the base scenario in Hepatica, compared to the observed 
proportion within UK Transplant data. As a result, routine patients were having 
to wait longer for a transplant, with a greater number dying or being removed 
from the waiting list as a result. 
 
The survival time analyses, for both pre- and post-transplant outcomes, did find 
significant differences between super urgent and routine patients, and this was 
captured within the covariates of the overall prediction model.  However, the 
subsequent analysis performed within the simulation shows that the two groups 
of patients should be modelled separately. 
 
More detailed information about the process of receiving and allocating a 
donated liver is required.  Specifically, this needs to explore any factors (perhaps 
time or location) which prevent livers being allocated to a super urgent patient.  
It may be that additional states or assumptions are required within Hepatica to 
capture the progression of super urgent patients more accurately.   
 
Optimal Timing 
If utility became the most important aspect to consider then there would be a 
need to develop a model which identified the optimal time during the 
progression of a patient’s disease at which to transplant.  Much more work 
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would also be necessary to identify differences between the various diseases, 
and to identify the accuracy of the predictions. 
 
7.6 Summary 
The work presented in this thesis has illustrated the use of several different 
Operational Research and Statistical techniques for use in the modelling of the 
UK Liver Transplantation System.  The techniques have aided in the further 
understanding of the assessment and allocation system currently implemented, 
and how changes to the current system may influence the overall equity and 
utility measures. 
 
Hepatica includes new aspects which have either not been considered within the 
UK context and/or the various US models.  These are: 
- Modelling of both system equity and utility; 
- The incorporation of super urgent patients; and 
- Implementing a competing risks model to capture times to events from 
the waiting list. 
 
Many of the limitations in the modelling are a result of the need to balance 
several aspects, common when modelling:  
(1) The level of detail to include in the model,  
(2) The complexity of the modelling technique implemented; and  
(3) Data limitations.   
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Thus, many ideas for further work have been generated.  One important aspect 
in generalising the model so that the different liver transplant units may use it, 
would be to understand in more detail the decisions made at the different centres 
and the different patient mixes at each of the centres. 
 
There are also many insights which have been gained into decision making 
within the UK Liver Transplantation System, which have been observed through 
the analysis performed.  Firstly, there is a need to implement simple rules, and 
rules which change over time, to obtain the best equity and utility output 
measures.  Secondly, it is easier to improve the overall utility in the system than 
the equity, due to the implications of prioritisation.  
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Appendix A 
 
Patient and Donor Attribute Grouping 
A.1 Disease Categories 
A.1.1 UKT Disease Categories 
The liver diseases which are recorded onto the UK Transplant database when a 
patient is registered onto the waiting list are listed in Table A.1 below. 
 
Table A.1 Primary Liver Disease Codes as Recorded by UK Transplant. 
Primary liver disease codes (at registration) 
400 Liver disease unknown 438 Drug (non-paracetamol)/toxin induced 
410 Chronic liver failure cause unknown 439 FHF - other please specify 
411 Primary biliary cirrhosis 440 Malignancy (ca) not classifiable 
412 Autoimmune cirrhosis    441 Hepatocellular carcinoma non-cirrhotic 
413 Post hepatitis b cirrhosis 442 Hepatocellular carcinoma cirrhotic 
414 Sclerosing cholangitis 443 Cholangiocarcinoma 
415 Alpha-1-antitrypsin deficiency 444 Primary liver sarcoma 
416 Budd-chiari 445 Secondary liver tumour 
417 Cryptogenic cirrhosis 446 Other mesenchymal tumours 
418 Secondary biliary cirrhosis 447 Other hepatic malignancies 
419 Alcoholic cirrhosis 448 Benign liver tumour 
420 Biliary atresia 450 Metabolic disease 
421 CLF - congenital hepatic fibrosis 460 Polycystic disease 
422 Chronic Wilsons disease    461 Haemochromatosis 
423 Congenital biliary disease 471 Acute rejection 
424 Post hepatitis c cirrhosis 472 Chronic rejection 
425 Cholestatic disease (paed) 473 Primary non-function 
430 Acute hepatitis - unknown 474 Acute vascular occlusion 
431 FHF - viral 475 Non thrombotic infarction 
432 FHF - drug induced 476 Ductopenic rejection 
433 FHF - toxin induced 477 Recurrent disease 
434 Acute wilsons disease 478 Biliary complications 
435 Acute hepatitis a 498 Other 
436 Acute hepatitis b 499 Liver disease unknown 
437 Drug induced - paracetamol 888 Not reported 
  
A.1.2 Adjusted LAG Groupings 
A study conducted by the Liver Advisory Group (Hudson et al. 2005), 
determined a set of disease groups which were relevant to combine.  These LAG 
groupings were adjusted for this study, to help make the disease groups similar 
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in size and to maintain heterogeneous groups and are shown in Table A.2 below.  
Advice was taken from a Liver Disease Epidemiologist (Roderick 2004). 
 
Table A.2 Disease Groupings Used within the Thesis. 
Disease Grouping Diseases Categories within the Grouping 
1 Other Cirrhotic Diseases  
(see categories 8 to 11) 
- Primary biliary cirrhosis 
- Autoimmune cirrhosis    
- Secondary biliary cirrhosis 
2 Cholestatic Liver Disease - Sclerosing cholangitis 
- Biliary atresia  
- Congenital biliary disease 
- Cholestatic disease (paed) 
3 Cancer - Malignancy (ca) not 
classifiable 
- Hepatocellular carcinoma 
non-cirrhotic 
- Hepatocellular carcinoma 
cirrhotic 
- Cholangiocarcinoma 
- Primary liver sarcoma 
- Secondary liver tumour 
- Other mesenchymal tumours 
- Other hepatic malignancies 
4 Metabolic Liver Disease - Alpha-1-antitrypsin 
deficiency  
- Chronic wilsons disease    
- Metabolic disease 
- Haemochromatosis 
5 Other Diagnosed Disease - CLF - congenital hepatic 
fibrosis 
- Other 
- Polycystic disease 
- Benign liver tumour 
6 Super Urgent/Acute Liver 
Disease 
- Budd-chiari 
- Acute hepatitis - unknown 
- FHF - viral 
- FHF - drug induced 
- FHF - toxin induced 
- Acute Wilsons disease 
- Acute hepatitis a 
- Acute hepatitis b 
- Drug induced - paracetamol 
- Drug (non-
paracetamol)/toxin induced 
- FHF - other please specify 
- Acute rejection 
- Chronic rejection 
- Primary non-function 
- Acute vascular occlusion 
- Non thrombotic infarction 
- Ductopenic rejection 
- Recurrent disease 
- Biliary complications 
7 Unknown Liver Disease Chronic liver failure cause 
unknown 
- Liver disease unknown 
8 Hepatitis B - Post hepatitis b cirrhosis 
9 Cryptogenic Liver 
Disease 
- Cryptogenic cirrhosis 
10 Alcoholic Liver Disease - Alcoholic cirrhosis 
11 Hepatitis C - Post hepatitis c cirrhosis 
12 Not Reported - Not Reported - Missing entries 
  
A.2 Donor Cause of Death Groupings 
Table A.3 below depicts how the donor causes of death were grouped, so that 
indicator variables could be created and used within the analysis.  The groupings 
were made based on the advice from a Senior Lecturer of Public Health 
Medicine and Epidemiologist (Roderick 2004). 
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Table A.3 Donor Cause of Death Groupings Used within the Thesis. 
Cause of Death Grouping Causes of Death within the Grouping (as recorded by UK 
Transplant) 
1 Intracranial Intracranial Haemorrhage 
Intracranial Thrombosis 
Brain Tumour 
Hypoxic Brain Damage - All causes 
Intracranial - Type unclassified (CVA) 
2 Trauma Trauma - RTA - Car 
Trauma - RTA - Motorbike 
Trauma - RTA - Pushbike 
Trauma - RTA - Pedestrian 
Trauma - RTA - Unknown type 
Other Trauma - Suicide 
Other Trauma - Accident 
Other Trauma - Unknown cause 
Cardiac Arrest 
3 Cardiovascular Myocardial Infarction 
Aneurysm 
Ischaemic Heart Disease 
Cardiovascular - Type unclassified 
4 Respiratory Failure Pulmonary Embolism 
Pneumonia 
Asthma 
Respiratory Failure 
5 Infections Meningitis 
Septicaemia 
Infections - Type Unclassified 
6 Other Carbon Monoxide Poisoning 
Respiratory - Type Unclassified (Inc. Smoke Inhalation) 
Cancer, Other than Brain Tumour 
Paracetamol Overdose 
Other Drug Overdose (please specify) 
Other 
Unknown 
  
A.3 Patient Model for End Stage Liver Disease (MELD) Score 
Groupings 
The MELD score uses a mathematical formula based on serum creatinine, 
bilirubin, and INR. MELD scores can range from 6 (less ill) to 40 (gravely ill).  
MELD scores greater than 40 are all grouped together and receive a score of 40 
(California Pacific Medical Centre).  The individual score determines how 
urgently a patient needs a liver transplant within the next three months, for 
patients suffering from a chronic liver disease and is used in the USA to 
prioritise patients, as well as aiding in determining how frequently laboratory 
tests should be done.  Table A.4 shows the values used to create the MELD 
score groups. 
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Table A.4 MELD Score Groupings Used within the Thesis. 
MELD Grouping Range of MELD Score Frequency of Laboratory Test 
1   25 Every 7 days 
2 19-24 Every 30 days 
3 11-18 Every 90 days 
4  10 Every year 
  
A.4 Patient Body Mass Index (BMI) Groupings 
The Body Mass Index (BMI) is calculated using the following formula: 
2(m))(height 
(kg)weight 
BMI  
Table A.5 shows how the patient BMI values were grouped in the analysis, 
using common definitions (World Health Organisation) of underweight, normal 
range, overweight and obese. 
 
Table A.5 BMI Score Groupings Used within the Thesis. 
BMI Grouping Range of BMI Score 
1 Underweight < 18.50 
2 Normal Range 18.50 - 24.99 
3 Overweight 25.00 - 29.99 
4 Obese   30.00 
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Appendix B 
 
Definition of ABO-Compatibility 
B.1 Definition 
Once patients are on the waiting list they are in competition for the livers 
available.  In the UK, a patient must have a compatible blood type (as depicted 
in Table B.1 below) to the donors (UKT Liver Advisory Group 1999). 
 
Table B.1 ABO Blood Group Compatibility. 
Donor Blood Type 
 
O A B AB 
O     
A     
B     
Patient Blood Type 
AB     
  
B.2 Patient and Donor Blood Group Distributions 
Table B.2 shows the percentage by blood group: (1) of patients requiring liver 
transplant, and (2) of donors allocated to adult patients, between 1 January 1999 
and 31 December 2002 (UK Transplant 1999-2002). 
 
Table B.2 Proportions of Patients and Donors by Blood Group. 
 Patients (%) Donors (%) 
O 45 52 
A 40 38 
B 11 8 
AB 4 2 
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Appendix C 
 
Coverage of UK Liver Transplant Units and UK 
Liver Units 
Figure C.1 depicts the location of all the liver transplant units in the UK and the 
areas that each of the liver units retrieves livers from, as designated in 1993 
(King’s College Hospital).  It can be observed that the South West of England 
does not have any liver transplant units.  Patients and donors from this region are 
mainly the responsibility of Kings; however, other units including Birmingham 
may receive patients from this region for transplantation.  There are a number of 
liver units (Table C.1) within the South West which can monitor patients, but 
these units are not able to provide liver transplant operations (British Liver 
Trust). 
 
 
Figure C.1 Liver Retrieval Zones in the United Kingdom and Ireland.  
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Table C.1 Liver Units in the UK by Region (hospitals with liver transplant units 
are marked in bold). 
Region Hospital 
East Anglia Addenbrooke’s, Cambridge 
Mersey Royal Liverpool Hospital, Liverpool 
Mersey University Hospital, Liverpool 
N E Thames Royal Free Hospital, London 
N E Thames Royal London Hospital, London 
N E Thames University College Hospital, London 
N W Thames St Mary’s Hospital, London 
Northern Freeman Hospital, Newcastle Upon Tyne 
North West Manchester Royal Infirmary, Manchester 
Oxford John Radcliffe Hospital, Oxford 
Oxford Royal Berkshire Hospital, Reading 
S E Thames King’s College Hospital, London 
South West Bristol Royal Infirmary, Bristol 
South West Derriford Hospital,  Derriford Road, Plymouth 
S W Thames St George’s Hospital, London 
Trent Royal Hallamshire Hospital, Sheffield 
Trent 
Queens Medical Centre, University Hospital, 
Nottingham 
Wessex Southampton General Hospital, Southampton 
West Midlands Queen Elizabeth Hospital, Birmingham 
Yorkshire St James’ Hospital, Leeds 
Aberdeen & Northern Aberdeen Royal Infirmary, Aberdeen 
Aberdeen & Northern Ninewells Hospital, Dundee 
Edinburgh & Lothian Edinburgh Royal Infirmary, Edinburgh 
Glasgow & W Scotland Southern General Hospital, Glasgow 
Glasgow & W Scotland Glasgow Royal Infirmary, Glasgow 
Glasgow & W Scotland Gartnaval Hospital, Glasgow 
Cardiff 
Cardiff  Liver Unit, University Hospital of 
Wales, Cardiff 
Belfast Royal Victoria Hospital, Belfast 
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Appendix D 
 
The Kaplan-Meier Estimate 
The Kaplan-Meier estimate (which provides a non-parametric estimate of the 
survival function) is normally used to analyse censored survival data.  To obtain 
the Kaplan-Meier estimate a series of time intervals is constructed such that one 
death, D, is contained in a particular time interval and this death is taken to 
occur at the start of the interval.  For example, suppose that t(1), t(2) and t(3) are 3 
observed survival times, where t(1) < t(2) < t(3), and C is a censored survival time 
between t(1) and t(2).  The intervals begin at t(1), t(2) and t(3).  Note: more than one 
death may occur at the start of a particular interval. 
 
 
Figure D.1 Constructing intervals, for deriving the Kaplan-Meier Estimate. 
t(0) t(1) t(2) t(3) time 
D 
D C D 
D 
D 
D 
 
 
The Kaplan-Meier estimate of the survival function is given by: 









 

k
j j
jj
n
dn
tS
1
)(ˆ  
where  nj = the number of individuals who are alive just before time t(j)  
(including those who are about to die at time t(j)), 
 dj = the number who die at time t(j), 
k = the number of intervals. 
 
The estimate is updated at the start of each of the intervals. 
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Example 
Table D.1 gives the Kaplan-Meier estimates for the example depicted in Figure 
D.1. 
 
Table D.1 Example of Calculating the Kaplan-Meier Estimate.  
Time jn  jd  )(ˆ tS  
t(0) 7 0 1 
t(1) 7 2 714.0
7
27


 
t(2) 4 1 536.0
4
14
7
27




 
t(3) 3 3 0
3
33
4
14
7
27






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Appendix E 
 
Different Forms of Survival Function 
Table E.1 Properties of Survival Functions with Different Underlying Hazards. 
Hazard Function 
Model 
(Type) Model Assumptions 
Modelled 
parametrically 
or non-
parametrically? 
Monotonic or 
non-
monotonic 
functions 
Computing 
Processing 
Time 
Cox 
Regression 
(PH) 
Hazard functions are 
proportional, e.g. 
patient A will always 
be   times more 
likely to die than 
patient B. 
Baseline hazard 
function modelled 
non-
parametrically. 
Any, as defined 
non-
parametrically 
(not restricted 
to unimodal). 
Non-parametric 
distributions 
require greater 
computer 
processing time. 
Exponential 
(PH) 
Hazard functions are 
proportional, e.g. 
patient A will always 
be   times more 
likely to die than 
patient B. 
Exponential 
distribution used 
to model baseline 
hazard. 
Monotonic 
Function. 
Parametric 
therefore less 
computer 
processing time. 
Weibull 
(PH) 
Hazard functions are 
proportional, e.g. 
patient A will always 
be   times more 
likely to die than 
patient B. 
[Can be re-
parameterised as an 
AFT model]. 
Weibull 
distribution used 
to model baseline 
hazard. 
Monotonic 
Function. 
Parametric 
therefore less 
computer 
processing time. 
Log-Logistic 
(AFT) 
The shape of the 
survival curve is the 
same for all patients, 
but they move along 
it faster or slower 
according to the value 
of their covariates. 
Log-Logistic 
distribution used 
to model baseline 
hazard. 
Unimodal. 
  
Parametric 
therefore less 
computer 
processing time. 
Lognormal 
(AFT) 
The shape of the 
survival curve is the 
same for all patients, 
but they move along 
it faster or slower 
according to the value 
of their covariates. 
Lognormal 
distribution used 
to model baseline 
hazard. 
Unimodal. Similar to log-
logistic but its 
usefulness is 
limited as it can 
only be 
expressed in 
terms of 
integrals.  
Therefore, 
requires greater 
computer 
processing 
time/more 
complex 
calculation 
algorithm. 
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Appendix F 
 
Allocation Rule Details 
L1 Old Base Allocation Rules 
Base Scenario (in operation until July 2006). 
1] local compatible SU patient 
 O  O, B   A  A, AB  B  B, AB  AB  AB 
2] national compatible SU patient 
 O  O, B  A  A, AB  B  B, AB  AB  AB 
3] local compatible routine patient 
 O  O, B  A  A, AB  B  B, AB  AB  AB 
4] national compatible routine patient 
 O  O, B  A  A, AB  B  B, AB  AB  AB 
5] local compatible SU patient (O  A, AB) 
6] national compatible SU patient (O  A, AB) 
7] local compatible routine patient (O  A, AB) 
8] national compatible routine patient (O  A, AB) 
9] local non compatible 
10] national non compatible  
 
L2 Current Base Allocation Rules 
Current Scenario (in operation from July 2006) - based on the information 
presented by Hamilton and O’Neill (2006), as explained further in Section 3.3.4. 
1] local compatible SU patient 
 O  O   A  A, AB  B  B, AB  AB  AB 
2] national compatible SU patient 
 O  O   A  A, AB  B  B, AB  AB  AB 
3] local compatible routine patient 
 O  O   A  A, AB  B  B, AB  AB  AB 
4] national compatible routine patient 
 O  O   A  A, AB  B  B, AB  AB  AB 
5] local compatible SU patient (O  A, B, AB) 
6] national compatible SU patient (O  A, B, AB) 
7] local compatible routine patient (O  A, B, AB) 
8] national compatible routine patient (O  A, B, AB) 
9] local non compatible 
10] national non compatible  
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L3 Priority Given to Patients with any Compatible Blood Group 
to the Donor 
Factor L3 will follow the same rules as before in that the priority order will be to 
allocate to patients with a compatible blood group to the donors’, to super urgent 
patients and to patients from the centre associated to the retrieval area in which 
the donor fell.  However, unlike the compatibility rules in place currently, 
patients with blood group O will not be given priority for livers donated by 
blood group O donors. 
1] local compatible SU patient 
 O  O, A, B, AB A  A, AB  B  B, AB  AB  AB 
2] national compatible SU patient 
 O  O, A, B, AB A  A, AB  B  B, AB  AB  AB 
3] local compatible routine patient 
 O  O, A, B, AB A  A, AB  B  B, AB  AB  AB 
4] national compatible routine patient 
 O  O, A, B, AB A  A, AB  B  B, AB  AB  AB 
5] local non compatible 
6] national non compatible  
 
L4 Priority Given to Patients with an Identical Blood Group to 
the Donor 
Factor L4 will allocate first to patients with identical blood groups to the donor, 
then to patients with compatible blood groups to the donor.  It will also prioritise 
by transplant urgency and retrieval centre. 
1] local identical SU patient 
 O  O A  A  B  B  AB  AB 
2] national identical SU patient 
 O  O A  A  B  B  AB  AB 
3] local identical routine patient 
 O  O A  A  B  B  AB  AB 
4] national identical routine patient 
 O  O A  A  B  B  AB  AB 
5] local compatible SU patient 
 O  A, B, AB A  AB  B  AB 
6] national compatible SU patient 
 O  A, B, AB A  AB  B  AB 
7] local compatible routine patient 
 O  A, B, AB A  AB  B  AB 
8] national compatible routine patient 
 O  A, B, AB A  AB  B  AB 
9] local non compatible 
10] national non compatible  
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L5 Priority Given to Patients in the Same Centre Where 
Donated Liver is Retrieved 
Factor L5 will assume the same blood group compatibility rules as the current 
allocation rules.  It will then give priority to patients within the same centre as 
where the donated liver is retrieved, then to SU patients. 
1] local compatible SU patient 
 O  O   A  A, AB  B  B, AB  AB  AB 
2] local compatible routine patient 
 O  O   A  A, AB  B  B, AB  AB  AB 
3] local compatible SU patient (O  A, B, AB) 
4] local compatible routine patient (O  A, B, AB) 
5] national compatible SU patient 
 O  O   A  A, AB  B  B, AB  AB  AB 
6] national compatible routine patient 
 O  O   A  A, AB  B  B, AB  AB  AB 
7] national compatible SU patient (O  A, B, AB) 
8] national compatible routine patient (O  A, B, AB) 
9] local non compatible 
10] national non compatible  
 
L6 No Priority Given to Patients from the Retrieving Centre 
Factor L6 considers all allocations on a national basis, i.e., does not factor in a 
priority for the retrieving centre. 
1] compatible SU patient 
 O  O   A  A, AB  B  B, AB  AB  AB 
2] compatible routine patient 
 O  O   A  A, AB  B  B, AB  AB  AB 
3] compatible SU patient (O  A, B, AB) 
4] compatible routine patient (O  A, B, AB) 
5] non compatible  
 
L7 Priority Given to Patients registered for their first transplant 
Factor L7 will use the current compatibility rules and then prioritise patients 
who are waiting for their first liver transplant above those not waiting for their 
first liver transplant. 
1] compatible requiring a first transplant 
 O  O   A  A, AB  B  B, AB  AB  AB 
2] compatible requiring a first transplant (O  A, B, AB) 
3] compatible not requiring a first transplant 
 O  O   A  A, AB  B  B, AB  AB  AB 
4] compatible not requiring a first transplant (O  A, B, AB) 
5] non compatible requiring a first transplant 
6] non compatible not requiring a first transplant  
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L8 Priority Given to Patients registered for a successive 
transplant 
Factor L8 will use the current compatibility rules and then prioritise patients 
who are waiting for their successive liver transplant above those that are waiting 
for their first liver transplant. 
1] compatible not requiring a first transplant 
 O  O   A  A, AB  B  B, AB  AB  AB 
2] compatible not requiring a first transplant (O  A, B, AB) 
3] compatible requiring a first transplant 
 O  O   A  A, AB  B  B, AB  AB  AB 
4] compatible requiring a first transplant (O  A, B, AB) 
5] non compatible not requiting a first transplant 
6] non compatible requiring a first transplant  
 
L9 Priority Given to Younger Patients 
Factor L9 will give priority to the youngest patients with compatible blood 
groups. 
1] youngest compatible patient 
 O  O   A  A, AB  B  B, AB  AB  AB 
2] youngest compatible patient (O  A, B, AB) 
3] youngest non compatible  
 
L10 Priority Given to Older Patients 
Factor L10 will give priority to the oldest patients with compatible blood groups. 
1] eldest compatible patient 
 O  O   A  A, AB  B  B, AB  AB  AB 
2] eldest compatible patient (O  A, B, AB) 
3] eldest non compatible  
L11 Priority Given to Patients who have been waiting the 
shortest time 
Factor L11 will give priority to the patients who have compatible blood groups 
to the donor and have been waiting the shortest time. 
1] waiting the shortest time and compatible 
 O  O   A  A, AB  B  B, AB  AB  AB 
2] waiting the shortest time and compatible (O  A, B, AB) 
3] non compatible waiting the shortest time  
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L12 Priority Given to Patients who have been waiting the 
longest time 
Factor L12 will give priority to the patients who have compatible blood groups 
to the donor and have been waiting the longest time. 
1] waiting the longest time and compatible 
 O  O   A  A, AB  B  B, AB  AB  AB 
2] waiting the longest time and compatible (O  A, B, AB) 
3] non compatible waiting the longest time  
 
L13 Priority Given to Patients where the absolute difference 
between donor and patient weight is minimised 
Factor L13 will give priority to patients with compatible blood groups to the 
donor and where the absolute difference between donor weight and patient 
weight is minimised. 
 
1] min(absolute(donor weight-recipient weight)) and compatible 
 O  O   A  A, AB  B  B, AB  AB  AB 
2] min(absolute(donor weight-recipient weight)) and compatible (O  A, B, AB) 
3] min(absolute(donor weight-recipient weight)) and non compatible  
 
L14 Priority Given to Patients with the soonest Death or 
Removal time (i.e., worst pre-transplant prognosis) 
Factor L14 will give priority to patients with compatible blood groups to the 
donor and by the patient who will next die or be removed from the waiting list. 
1] next DR time and compatible 
 O  O   A  A, AB  B  B, AB  AB  AB 
2] next DR time and compatible (O  A, B, AB) 
3] next DR time and non compatible  
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L15 Priority Given to Patients with the best prognosis post 
transplant 
Factor L15 will give priority to patients with compatible blood groups to the 
donor and by the patient who will gain the most days post transplant, if they 
were to be transplanted with the current liver. 
1] furthest DGFRL time and compatible 
 O  O   A  A, AB  B  B, AB  AB  AB 
2] furthest DGFRL time and compatible (O  A, B, AB) 
3] furthest DGFRL time and non compatible  
 
L16 Priority Given to Patients with best prognosis compared 
to expected prognosis without a transplant 
Factor L16 will give priority to patients with compatible blood groups to the 
donor and by the patient who will gain the most days post transplant compared 
to how long they are currently expected to live, if they were to be transplanted 
with the current liver. 
1] max(DGFRL time - DR time) and compatible 
 O  O   A  A, AB  B  B, AB  AB  AB 
2] max(DGFRL time - DR time) and compatible (O  A, B, AB) 
3] max(DGFRL time - DR time) and non compatible  
 
L17 An adaptive policy which attempts to make allocation 
decisions through keeping track of equity measures, for 
groups not fairly transplanted across, within the other 
allocation policies 
Factor L17 will aim to give the fairest equity measures and hence decide on a 
transplant by means to assessing the current equity figures.  It will also make 
sure that only compatible transplants can take place. 
1] compatible patient and when % transplant in a particular group is lower than rest 
 O  O , A, B, AB A  A, AB  B  B, AB  AB  AB 
2] non compatible patient and when % transplant in a particular group is lower than 
rest  
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Appendix G 
 
Geographical Equity Results 
This appendix summarises the results from two studies which consider the 
geographical equity between different patient groups requiring liver 
transplantation.  The first (Section G.1) performed by Suchi Patel considered all 
the patients that were referred to Birmingham Liver Unit for potential 
assessment for liver transplantation (with an initial appointment at Birmingham 
Liver Unit (BLU) between 1/1/99 and 31/12/02, and outcomes as recorded by 
July 2004).  The second (Section G.2) was performed by Dr Paul Roderick and 
considered the patients that joined the UKT waiting list from 1/1/00 to 31/12/02, 
and the outcomes as recorded on the National Transplant Database as at 7/7/03.  
These analyses helped to assess if certain areas of the UK were accessing 
significantly fewer liver transplants than they should be (equity by location). 
 
G.1 Geographic Comparisons of Referrals to BLU 
Figure G.1 summarises the eventual outcomes of all 765 patients referred to 
BLU. 
 
Figure G.1 A tree diagram to represent the decision based outcomes that were 
experienced, after referral to Birmingham Liver Unit. 
Referred to Birmingham Liver Unit (765) 
Transplanted (395) 
Listed (460) 
Considered/Assessed for 
Transplant (673) 
Not Transplanted (65) 
Not Listed (213) 
Not Considered/Assessed 
for Transplant (92) 
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The patients that are in the referred category but are not considered for 
transplant, were inpatients that visited Birmingham and had a diagnosis that 
could have potentially benefited from transplant (identified by matching the 
patient diagnoses with the list of transplantable disease, as in Table A.1 
Appendix A). 
 
G.1.1 Methodology 
Sections G.1.2-G.1.12 present the findings of the analysis which considered 
geographical equity for the outcomes: (1) to assessment, and (2) to listing, 
across the patients groups: (1) transplant urgency, (2) age at first visit, and (3) 
primary liver disease.  Analysis is also performed to assess if there are 
differences between the time a patient comes for their first visit to the liver unit: 
(1) to the time of their assessment, and (2) to the time of listing on to the waiting 
list. 
 
The patient’s location was defined as within the Birmingham Retrieval Area and 
outside of the Birmingham Retrieval Area.  The chi-squared statistic is 
calculated to identify differences within the numbers (as presented in Sections 
G.1.2-G.1.12).  A map of the English Strategic Health Authorities (post April 
2002), Health Authorities of Wales, Scotland and Northern Ireland was also 
created using data obtained from the Edina website, UKBorders (Edina), and 
this map is used to present various rates by Strategic Health Authorities (SHA) 
and Health Authorities (HA), as present in 2001.  All the analysis is performed 
and presented using ArcGIS, MS Excel, and Jasc Paint Shop Pro software.  The 
grey areas on the maps show regions from where no referrals were made to 
Birmingham liver unit for the purposes of liver transplantation, between 
01/01/99 and 31/12/02 (UK Transplant 1999-2002). 
 
Annex 1 shows the number of referrals from and the population of each region, 
and the referral rates per 1,000,000 population.  Note that the population figures 
(General Register Office for Scotland (2003); Isle of Man Government (2001); 
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Northern Ireland Statistics and Research Agency (2002); Office for National 
Statistics (2002); States of Jersey (2002); Welsh Assembly Government 
(Llywodraeth Cynulliad Cymrn) (2001)) had to come from various different 
sources and that a referral rate for the “Abroad” grouping was not attained since 
it was deemed incomparable. 
 
G.1.2 Referral Rates by location 
Table G.1 Referral rates to BLU by retrieval area 
 Birmingham 
Region 
Outside the 
Birmingham Region 
Total Population 10,068,618 32,143,970 
Number of Referrals 421 344 
Expected Number of Referrals under H0 175 559 
Chi-squared test P value <0.01 
  
By comparing Figure G.2 
with Figure C.1 in Appendix 
C, it can be seen that, as 
would be expected, the 
higher referring units are 
within the area Birmingham 
serves.  The numbers were 
statistically significantly 
different (Table G.1). 
Northern Ireland (which is 
within the area covered by 
BLU) seems to have fewer 
referrals than might be 
expected, when comparing 
to the other regions that 
BLU serves.  The numbers  
Figure G.2 Referral rates to 
BLU for each of the SHAs of 
England, and HAs of Wales, 
Northern Ireland and 
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Scotland, per 1,000,000 residents 
G.1.3 Assessed (of Referrals) by location 
Table G.2 Number of Patients Assessed of Those Referred to BLU by retrieval 
area. 
 Birmingham 
Region 
Outside the 
Birmingham 
Region 
Number of Referrals 421 344 
Number Assessed 366 307 
Expected Number to be Assessed under H0 370 303 
Chi-squared test P value 0.73 
  
 
The map indicates that for many 
regions outside of the 
Birmingham Liver Unit area had 
100% of referrals, assessed for 
transplantation.  However, the 
regions within the Birmingham 
Liver Unit area had 91-100% of 
their referrals assessed. 
Statistically the difference is not 
significant (Table G.2). 
 
Figure G.3 Percentage of patients referred to Birmingham Liver Unit that were 
assessed, by the SHAs of England, and HAs of Wales, Northern Ireland and 
Scotland 
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G.1.4 Listed (of Referrals) by location 
Table G.3 Number of Patients Listed of Those Referred to BLU by retrieval 
area. 
 Birmingham 
Region 
Outside the 
Birmingham 
Region 
Number of Referrals 421 344 
Number Listed 250 210 
Expected Number to be listed under H0 253 207 
Chi-squared test P value 0.77 
  
 
From Figure G.4 we can 
see that the SHAs and 
HAs which border 
“Birmingham and the 
Black Country” have a 
slightly smaller proportion 
of referrals placed on the 
waiting list.  However, 
this was not significant 
(Table G.3). 
 
 
 
 
 
 
 
 
 
Figure G.4 Percentages of those referred to Birmingham Liver Unit that were 
placed on the waiting list, by the SHAs of England, and HAs of Wales, Northern 
Ireland and Scotland  
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G.1.5 Listed (of Assessed) by location 
Table G.4 Number of Patients Listed of Those Assessed at BLU by retrieval 
area. 
 Birmingham 
Region 
Outside the 
Birmingham 
Region 
Number Assessed 366 307 
Number Listed 250 210 
Expected Number to be Listed under H0 250 210 
Chi-squared test P value 0.99 
  
 
From Figure G.5 we cannot 
see a pattern emerging for the 
proportions of those assessed 
that were placed on to the 
waiting list, and the tests in 
Table G.4 confirm that there 
are no differences in the 
chance of being listed. 
 
 
 
 
 
 
 
 
 
 
 
Figure G.5 Percentage of patients assessed at Birmingham Liver Unit that were 
placed on the WL, by the SHAs of England, and HAs of Wales, Northern Ireland 
and Scotland 
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G.1.6 Referrals by Transplant Urgency and location 
Table G.5 Number of Referrals by Transplant Urgency and retrieval area. 
 Birmingham 
Region 
Outside the 
Birmingham 
Region 
Number Listed 250 210 
Number Super Urgent 44 22 
Expected Number of Super Urgent 
patients under H0 
36 30 
Chi-squared test P value 0.04 
  
 
 
From Figure G.6 it can be 
seen that greater proportions 
of super urgent patients were 
referred from the regions 
around Birmingham, than the 
proportions referred from 
further away, and this is 
found to be statistically 
significant (Table G.5). 
 
 
 
 
 
 
 
 
 
Figure G.6 Percentage of patients referred to Birmingham Liver Unit that were 
of super urgent status when assessed, by the SHAs of England, and HAs of 
Wales, Northern Ireland and Scotland  
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G.1.7 Referrals by Patient Age and location 
Table G.6 Number of Referrals by Patient Age and retrieval area. 
 Birmingham 
Region 
Outside the 
Birmingham 
Region 
Number of Referrals 421 344 
Number greater than 65 years old 31 25 
Expected Number of patients greater 
than 65 years old under H0 
31 25 
Chi-squared test P value 0.96 
  
The map shows little 
difference between the 
proportion of patients aged 66 
and older referred from the 
regions around Birmingham, 
and the proportion referred 
from further away.  Statistical 
tests also demonstrate no 
significant difference (Table 
G.6). 
 
 
 
 
 
 
 
 
 
 
Figure G.7 Percentage of patients referred to Birmingham Liver Unit that were 
between 66 years or older at their first appointment, by the SHAs of England, 
and HAs of Wales, Northern Ireland and Scotland 
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G.1.8 Referrals by Disease and Location 
The LAG disease groupings (Hudson et al. 2004) were used to evaluate whether 
the mix of patient diseases differed by region. 
 
Table G.7 Number of referrals and disease diagnoses by region. 
Region 
Number of 
Referrals 
Number of different 
disease diagnoses 
Abroad 31 8 
Birmingham and IoM (B & IoM) 421 37 
Cambridge (C) 80 21 
Edinburgh (E & AB) 2 2 
Kings and Jersey (K & J) 172 20 
Leeds (L) 34 10 
Newcastle (N) 22 11 
Royal Free (RF) 3 2 
  
Table G.7 shows that the variety of diseases that are referred from the local 
region is greater than from further away.  However, this will be due partly to the 
larger number of cases referred from nearby. 
 
Table G.8 Contingency table of all regions by all LAG groupings. 
 B & 
IoM 
C E & 
AB 
K & 
J 
L N RF Grand 
Total 
Cirrhotic 285 52 30 123 25 16 3 534 
Cholestatic 29 6 1 25 3 2  66 
Cancers 1 1      2 
Metabolics 9   3 2   14 
Others/Not 
Reported/Unknown 
76 13 1 19 1 3  107 
Super-Urgent/Acute 21 8 1 2 3 1  36 
 421 80 33 172 34 22 3 765 
  
A Chi-Squared test performed on a grouped version of Table G.8 (to account for 
any cells with expected values less than 5) returned a p-value of 0.000041.  This 
means that the disease groups that are referred to Birmingham from the various 
areas are significantly different in their distribution. 
 
  
Appendices 
 
298 
G.1.9 Time from First Visit to Assessment by Location 
Table G.9 Time from first visit to assessment 
 Time to assessment 
Birmingham Area 
Mean time 114 
N 366 
Variance 58111 
Not Birmingham Area 
Mean time 103 
N 307 
Variance 47997 
Difference between means test 
Z value 0.6197 
P value 0.2324 
  
The results in Table G.9 show that there is no significant difference between the 
time from the first appointment to the time of the assessment, between the 
groups Birmingham and Not Birmingham. 
 
G.1.10 Time from first visit to listing by location 
Table G.10 Time from first visit to listing 
 Time to listing 
Birmingham Area 
Mean time 167 
N 250 
Variance 70266 
Not Birmingham Area 
Mean time 167 
N 210 
Variance 75089 
Difference between means test 
Z value 0 
P value 0.5 
  
The results in Table G.10 show that there is no significant difference between 
the time from the first appointment to the time of listing on to the waiting list, 
between the groups Birmingham and Not Birmingham. 
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G.1.11 Reasons for Patients not being Listed 
This section identifies that there were no differences by location in the reasons 
why patients were not listed.  Three reasons are considered: the patient was too 
well (Table G.11), the patient was too ill or died during assessment (Table 
G.12), and the patient would not recover post transplant (Table G.13). 
 
Table G.11 Results from testing the hypothesis that no difference exists between 
the proportions of patients considered too well for transplantation, within the 
Birmingham area and outside this area. 
 Birmingham 
Region 
Outside the 
Birmingham 
Region 
Number  not listed 146 123 
Number too well 28 23 
Expected Number of patients too 
well for transplant under H0 28 23 
Chi-squared test P value 0.93 
  
Table G.12 Results from testing the hypothesis that no difference exists between 
the proportions of patients considered too ill or that died during assessment, 
within the Birmingham area and outside this area. 
 Birmingham 
Region 
Outside the 
Birmingham 
Region 
Number  not listed 146 123 
Number too ill/died during 
assessment 43 36 
Expected Number of patients too 
ill/died during assessment for 
transplant under H0 43 36 
Chi-squared test P value 0.98 
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Table G.13 Results from testing the hypothesis that no difference exists between 
the proportions of patients considered too high risk for transplant, within the 
Birmingham area and outside this area. 
 Birmingham 
Region 
Outside the 
Birmingham 
Region 
Number  not listed 146 123 
Number too considered high risk for 
transplant 7 7 
Expected Number patients 
considered too high risk for 
transplant under H0 8 6 
Chi-squared test P value 0.75 
  
G.1.12 Conclusions and Limitations 
Conclusions 
The main findings of the analysis presented are that once patients are referred to 
Birmingham Liver Unit, location is not a factor in whether a patient is placed 
onto the waiting list or not; the attributes age and urgency status by location also 
do not affect a patients’ chances of obtaining a liver transplant once referred. 
 
It has also been shown that more referrals come from within the Birmingham 
Retrieval Zone which is to be expected since patients farther away will be 
referred to other Liver Units.  There is also a tendency for a higher proportion of 
super urgent patients to be referred from within the Birmingham Retrieval Zone. 
 
More disease types are represented by the referrals from within the Birmingham 
area.  Fewer types of disease diagnoses are represented from regions further 
away. 
 
This implies that location equity is met and that patients are equally likely to 
progress through the stages at Birmingham Liver Unit, wherever they are 
referred from. 
 
Limitations 
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The main limitation of this analysis is that the data considered is from only one 
liver unit.  This means that none of the hypothesis can be generalised across all 
the liver transplant units. 
 
Also, it was very difficult to find a single reference which gave the population 
figures for all regions considered at one single time point.  Instead several 
references had to be consulted and the figures range from 2001 to 2003.  This 
does not quite match the time period of the Birmingham data, which went from 
1999 to 2002. 
 
G.2 Equity of Listing by Geography 
Roderick’s (2003) analysis considered all the patients who joined the UK 
Transplant waiting list.  Tests were performed to identify if the registration rates 
were significantly different by age band, gender, and location (SHA).  The 
analysis showed no significant differences in the number of referrals from the 
different regions, or the other factors.  However, this analysis does assume that 
there will be a similar mix of patients requiring liver transplants, across the UK. 
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Annex 1 to Appendix G 
A list of all the regions, with the number of referrals, population, and the 
referral rate per 1,000,000 population. 
Region 
Number 
of  
referrals 
Total 
population 
Referrals 
per  
1,000,000 
population 
English Strategic Health Authorities    
Avon, Gloucestershire and Wiltshire 64 2145000 30 
Birmingham and the Black Country 110 2253000 49 
Cheshire & Merseyside 68 2343000 29 
Coventry, Warwickshire, Herefordshire and 
Worcester 80 1522000 53 
Cumbria and Lancashire 21 1900000 11 
Dorset and Somerset 20 1184000 17 
Essex 1 1612000 1 
Greater Manchester 22 2482000 9 
Hampshire and Isle of Wight 28 1749000 16 
Leicestershire, Northamptonshire and Rutland 42 1550000 27 
Norfolk, Suffolk and Cambridgeshire 1 2138000 0 
North Central London 1 1179000 1 
North West London 1 1729000 1 
Northumberland, Tyne & Wear 1 1382000 1 
Shropshire and Staffordshire 55 1482000 37 
South West Peninsula 25 1562000 16 
South Yorkshire 11 1265000 9 
Surrey and Sussex 3 2548000 1 
Thames Valley 31 2076000 15 
Trent 37 2611000 14 
West Yorkshire 1 2078000 0 
Northern Ireland    
Eastern Northern Ireland 5 665726 8 
Western Northern Ireland 7 284877 25 
Scotland    
Greater Glasgow 2 866370 2 
Wales    
Bro Taf 22 366800 60 
Dyfed Powys 18 236300 76 
Gwent 10 273500 37 
Morgannwg 20 245000 82 
North Wales 23 320100 72 
Other    
Isle of Man 3 76315 39 
Jersey 1 87600 11 
Foreign 31 N/A N/A 
Those in italic and bold are within the Birmingham Retrieval Zone.  
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Appendix H 
 
Cox-Snell Residuals 
The residual most commonly used in the analysis of survival data is the Cox-
Snell Residual, 
iC
r .  The way in which to calculate Cox-Snell residuals is 
dependent on the underlying distribution survival times being considered. 
 
The general form of the Cox-Snell residual, for the ith individual is: 
)(ˆlog)(ˆ iiiiC tStHr i   
where  )(ˆ ii tH  is the estimated cumulative hazard function, 
)(ˆ ii tS  is the estimated survivor function. 
 
The Cox-Snell Residuals for the Weibull Distribution are then: 
)exp(
ii SC
rr   
 
The Cox-Snell Residuals for the Loglogistic Distribution are then: 
)}exp(1ln{
ii SC
rr   
 
The Cox-Snell Residuals for the Lognormal Distribution are then: 
)}(1ln{
ii SC
rr   
 
where 
 ˆ/}ˆ...ˆˆˆ{log 2211 pipiiiS xxxtr i   = the standardised residual 
where 
it  is the observed survival time for patient i, 
ˆ  estimated mean of the data, 
jˆ  estimated coefficient of variable j, 
jix  value of variable j for patient i, 
ˆ  estimated standard deviation of the data. 
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To be a reasonable fit, the 
iC
r  should have a unit exponential distribution.  This 
can be tested for by plotting )(ˆln
iC
rS  against 
iC
r , where )(ˆ
iC
rS  is the Kaplan-
Meier Estimate of the survival function of the Cox-Snell Residuals.  If the fit is 
reasonable this plot should show a straight line with gradient 1 and which passes 
through the origin. 
 
This can help us to find the most appropriate model for each transition.  To 
analyse the appropriateness of the model, i.e., how closely the model fits to the 
data, the residuals have to be analysed.  Plots of the actual data and the fitted 
model are also helpful in visualising the fit. 
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Appendix I 
 
Logistic Regression Models to Capture the 
Outcomes from Referral 
I.1 Introduction 
Logistic regression models were developed to capture the decision of whether to 
list a patient onto the waiting list or not, using the data from Birmingham Liver 
Unit (BLU).  The covariates used are: age at first visit, disease group, MELD 
score (both as a continuous variable and a factor variable), and urgency of 
transplant.  Three approaches (as outlined in Table 4.3, Section 4.3.1) were 
considered.  The models were developed using SPSS.  The forward stepwise 
regression procedure, with entry value set to 0.05 and removal value set to 0.10, 
was adopted.  This appendix details the development of the three models. 
 
The final section compares the distributions of age and primary liver disease for 
the patients from BLU who joined the national waiting list, with the observed 
distributions of patients on the whole of the UK Transplant (UKT) waiting list.  
This analysis confirms whether the models developed using BLU data could be 
generalised for use nationally. 
 
I.2 Model Development and Goodness-of-Fit Tests 
The three statistics: Hosmer and Lemeshow Test, Percentage of Correct 
Classifications, and Cox and Snell R2 were used to develop the models and 
assess their goodness-of-fit. 
 
Hosmer and Lemeshow Test 
At each step, the Hosmer and Lemeshow Test provides a measure of the 
goodness-of-fit of the model, against the null hypothesis that the model 
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adequately fits the data.  If the null hypothesis is true then that statistic should 
have an approximately chi-squared distribution with the displayed degrees of 
freedom.  If the significance of the test is small (i.e., less than 0.05) then the 
model does not adequately fit the data. 
 
Percentage of Correct Classifications 
Assesses the performance of the model created by calculating the percentage of 
patient outcomes correctly classified by the model. 
 
Cox and Snell R2 
The Cox and Snell R2 statistic approximates the percentage of variation in the 
response that is explained by the model.  A larger value indicates that more of 
the variation is explained by the model, to a maximum value of 1. 
 
I.3 Model Development 
This section summaries the results from the development of the three models 
and the covariates present in the final models. 
 
I.3.1 Approach A 
All patients considered in the logistic regression model.  MELD score excluded 
from the analysis. 
 
Table I.1 Referral Outcome Model Development Summary for Approach A. 
Hosmer and Lemeshow Test 
Step 2  
Degrees of 
freedom 
Significance 
Overall % 
Correct 
Classifications 
Cox and 
Snell R
2
 
1 <0.001 0 . 66.4 0.052 
2 <0.001 1 1.000 66.4 0.093 
3 <0.001 2 1.000 67.4 0.107 
4 <0.001 3 1.000 67.9 0.123 
5 7.474 8 0.482 68.9 0.130 
6 4.395 8 0.820 69.0 0.136 
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Table I.2 Resultant Referral Outcome Model for Approach A. 
Attributes B 
Standard 
Error 
Significance Exp(B) 
Age at First Visit -0.021 0.008 0.007 0.979 
Super Urgent of Acute Disease 
Group 
1.748 0.614 0.004 5.743 
Unknown Liver Disease -1.506 0.325 <0.001 0.222 
Cryptogenic Liver Disease -1.113 0.289 <0.001 0.329 
Alcoholic Liver Disease -1.435 0.213 <0.001 0.238 
Hepatitis C -0.556 0.239 0.020 0.573 
Constant 2.153 0.450 <0.001 8.608 
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Figure I.1 Box Plot of the Predicted Probabilities as Estimated using the Final 
Model from Approach A, by the Observed Outcomes of Not Listed or Listed.  
 
I.3.2 Approach B 
Chronic Liver Disease patients only considered in the logistic regression model 
and the covariates age at first visit to the liver unit, disease group, patient 
gender, and MELD score as a continuous covariate. 
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Table I.3 Referral Outcome Model Development Summary for Approach B. 
Hosmer and Lemeshow Test 
Step 2  
Degrees of 
freedom 
Significance 
Overall % 
Correct 
Classifications 
Cox and 
Snell R
2
 
1 <0.001 0 . 63.8 0.044 
2 <0.001 1 1.000 64.9 0.060 
3 <0.001 2 1.000 65.3 0.077 
4 4.482 8 0.811 66.2 0.084 
5 3.766 8 0.878 66.2 0.092 
6 2.124 8 0.977 66.2 0.099 
  
Table I.4 Resultant Referral Outcome Model for Approach B. 
Attributes B 
Standard 
Error 
Significance Exp(B) 
Age at First Visit -0.022 0.008 0.007 0.978 
Unknown Liver Disease -1.503 0.328 <0.001 0.222 
Cryptogenic Liver Disease -1.068 0.292 <0.001 0.344 
Alcoholic Liver Disease -1.457 0.214 <0.001 0.233 
Hepatitis C -0.594 0.241 0.014 0.552 
MELD score (continuous) -0.026 0.011 0.021 0.974 
Constant 2.641 0.513 <0.001 14.021 
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Figure I.2 Box Plot of the Predicted Probabilities as Estimated using the Final 
Model from Approach B, by the Observed Outcomes of Not Listed or Listed.  
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I.3.3 Approach C 
Chronic Liver Disease patients only considered in the logistic regression model 
and the covariates age at first visit to the liver unit, disease group, patient 
gender, and MELD score as 4 factor covariates. 
 
Table I.5 Referral Outcome Model Development Summary for Approach C. 
Hosmer and Lemeshow Test 
Step 2  
Degrees of 
freedom 
Significance 
Overall % 
Correct 
Classifications 
Cox and 
Snell R
2
 
1 <0.001 0 . 63.8 0.044 
2 0.320 2 0.852 63.8 0.073 
3 0.382 4 0.984 64.7 0.085 
4 1.526 4 0.822 65.3 0.099 
5 4.901 8 0.768 67.4 0.109 
6 4.946 8 0.763 66.2 0.118 
  
Table I.6 Resultant Referral Outcome Model for Approach C. 
Attributes B 
Standard 
Error 
Significance Exp(B) 
Age at First Visit -0.025 0.008 0.003 0.975 
Unknown Liver Disease -1.391 0.330 <0.001 0.249 
Cryptogenic Liver Disease -1.072 0.296 <0.001 0.342 
Alcoholic Liver Disease -1.510 0.218 <0.001 0.221 
Hepatitis C -0.645 0.244 0.008 0.525 
MELD Group 2 0.765 0.173 <0.001 2.149 
Constant 1.938 0.462 <0.001 6.948 
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Figure I.3 Box Plot of the Predicted Probabilities as Estimated using the Final 
Model from Approach C, by the Observed Outcomes of Not Listed or Listed.  
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I.4 Comparing BLU and UKT Patient Mixes 
I.4.1 Comparing Disease Group Distributions 
Table I.7 Frequencies by Patient Disease Groups observed to join the Waiting List 
in Both the UKT and BLU data sets. 
Disease Group UKT BLU 
Other Cirrhotic Diseases 428 170 
Cholestatic Liver Disease 197 56 
Cancer 56 2 
Metabolic Liver Disease 71 34 
Other Diagnosed Liver Disease 155 4 
Super Urgent/Acute Liver Disease 523 65 
Unknown and Not Reported Liver Diseases 82 53 
Hepatitis B 84 22 
Cryptogenic Liver Disease 154 62 
Alcoholic Liver Disease 404 154 
Hepatitis C 299 114 
Grand Total 2453 736 
 
2  p-value 1.124x10-263 
  
 
 
Table I.7 and Figure I.4 indicate that there are significant differences between 
the indications (diseases) for which patients are listed on the waiting list, at BLU 
compared to the national proportions. 
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I.4.2 Comparing Age Group Distributions 
Table I.8 Frequencies by Patient Age Groups observed to join the Waiting List in 
Both the UKT and BLU data sets. 
Patient Age Group UKT BLU 
17-20 86 13 
21-25 84 15 
26-30 94 17 
31-35 165 41 
36-40 199 53 
41-45 256 71 
46-50 322 128 
51-55 421 127 
56-60 396 121 
61-65 290 99 
66 plus 140 51 
Grand Total 2453 736 
 
2  p-value 5.3842x10-254 
  
Table I.8 indicates that there are significant differences between the age groups 
of patients listed on the waiting list, by BLU compared to the national 
proportions. 
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Appendix J 
 
Waiting List Outcome Model Analysis and 
Development 
This appendix reports the development of the two models: 
(1) A survival model which captures the event death/removal (DR) censored 
at all other events from the waiting list (WL); and 
(2) A competing risks model which captures the two events (1) 
death/removal, and (2) Transplantation, censored at all other events from 
the waiting list. 
 
J.1 Preliminary Analysis 
This section summarises the main findings of the preliminary analysis (as 
outlined in Section 3.6.3 part [A]).  Only the graphs and tests which help to 
decide which parametric models are appropriate are presented here, however the 
analysis was performed for all covariates. 
 
J.1.1 Identifying Significant Differences in Patient Survival by 
Covariate Levels 
Table J.1 gives a summary of the Log Rank and Wilcoxon tests (pooled over 
strata) which were used to identify the covariates by which the survival curves 
were significantly different.  The tests were based on identifying the outcome 
death/removal and censoring at all other outcomes. 
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Table J.1 Tests to Identify Covariates which Lead to Significantly Different 
Survival Outcomes from the WL. 
Significance of Tests Log Rank 
Wilcoxon 
(Breslow) 
Tarone-Ware 
First Transplant <0.001 <0.001 <0.001 
Disease Group <0.001 <0.001 <0.001 
Gender 0.964 0.369 0.499 
Urgency <0.001 <0.001 <0.001 
Blood Group 0.841 0.929 0.957 
Weight Group 0.391 0.121 0.167 
Age Group 0.013 <0.001 <0.001 
Transplant Centre 0.012 0.009 0.010 
  
 
Survival functions are significantly different over the following factors: first 
transplant or not, disease group, transplant urgency status, age group, and the 
transplant centre at which the patient is registered.  Pair-wise comparisons for 
levels within each covariate also gave similar conclusions but identified which 
levels were most different.  
 
J.1.2 Should there be two separate models for different Transplant 
Urgency Statuses? 
 
Figure J.1 Log-Cumulative Hazard Plot, by transplant urgency.  
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Figure J.1 tests whether the Proportional Hazards (PH) assumption holds in 
modelling the survival distributions by transplant urgency status.  It shows a 
reasonably straight line for the patients requiring transplants as routine urgency, 
however, the vertical distance between the two lines is not constant through log 
time, and so two models may be required.  Further plots indicated that the PH 
could be assumed for the routine patients. 
 
 
Figure J.2 Cumulative Hazard Plot, by transplant urgency.  
 
Figure J.2 considers whether the Accelerated Failure Time (AFT) assumption 
holds in modelling the survival distributions by transplant urgency status.  It 
shows a reasonable straight line for the patients requiring super urgent 
transplants, however, the line representing observations for those requiring a 
routine transplant is not straight.  This means that a AFT is not appropriate for 
modelling survival if considering all the patients, however, it may be applied if 
just the survival times for the patients requiring a super urgent transplant are 
being modelled (more Cumulative Hazard Plots need to be analysed to confirm 
this). 
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J.1.3 Is a PH survival model appropriate? 
The log-cumulative hazard plots for routine patients split by the covariates: 
primary disease group, transplant unit, and age group, resulted in reasonably 
straight parallel lines (not shown here) which would confirm that the PH 
assumption is satisfied across these covariates. 
 
 
Figure J.3 Log-Cumulative Hazard Plot, by first transplant indicator for 
Routine patients.  
 
Figure J.3 presents the log-cumulative hazard plot by first transplant or not.  It 
can be seen that although these lines are reasonably straight, they are not parallel 
(and therefore cross).  This suggests that a stratified model may be more 
applicable in capturing the survival of the routine patients. 
 
J.1.4 Is an AFT survival model appropriate? 
The cumulative hazard plots for super urgent patients by the covariates first 
transplant indicator, transplant unit, and age group, returned reasonably straight 
parallel lines to suggest that AFT models would be appropriate in capturing the 
survival of super urgent patients.  The lines on these graphs were fairly close 
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together, which suggests that the survival of patients within the different groups 
may not be significantly different.   
 
Figure J.4 Cumulative Hazard Function Plot, by disease group for Super Urgent 
patients.  
 
 
Figure J.5 Cumulative Hazard Plot, by patient gender for Super Urgent 
patients.  
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Figures J.4 and J.5 show the plots by disease group and patient gender, 
respectively.  The split by disease group suggests differences in survival 
between the groups, however, some lines are constructed of very few data 
points.  The split by gender also seem to provide reasonably straight lines, but 
the lines are further apart which may suggest significant differences between 
male and female survival chances. 
 
Is a Log-Logistic AFT survival model appropriate? 
 
Figure J.6 The Log-Odds Plot for Super Urgent patients by disease group.  
 
Figure J.6 shows that the log-odds plots by disease group are reasonably straight 
and parallel, suggesting that a log-logistic survival model could be used in 
capturing the survival times. 
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Figure J.7 The Log-Odds Plot for Super Urgent patients by patient gender.  
 
Figure J.7 shows that the log-odds plots by transplant urgency are reasonably 
straight and parallel, suggesting that a log-logistic survival model could be used 
in capturing the survival times. 
 
Is a Lognormal AFT survival model appropriate? 
 
Figure J.8 Testing the overall lognormal AFT assumption for Super Urgent 
patients, plot by disease group.  
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Figure J.8 shows that the curves by transplant urgency are reasonably straight 
and parallel, suggesting that a log-logistic survival model could be used in 
capturing the survival times. 
 
 
Figure J.9 Testing the overall lognormal AFT assumption for Super Urgent 
patients, plot by patient gender.  
 
Figure J.9 shows that the curves by patient gender are reasonably straight and 
parallel, suggesting that a log-logistic survival model could be used in capturing 
the survival times. 
 
To summarise, Figures J.6-J.9 show that either the log-logistic or the lognormal 
survival models are appropriate for the modelling of the death/removal times for 
the patients requiring a super urgent transplant, and show that a log-logistic 
model may be more applicable in modelling the outcome. 
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J.1.5 Is a PH competing risks model appropriate? 
 
Figure J.10 Checking the Proportional Hazards Assumption of the Competing 
Risks Model for Outcomes from the Waiting List.  
Figure J.10 suggests that a PH competing risk model would not be suitable in 
capturing the outcomes to transplantation and death/removal, from the waiting 
list. 
 
J.1.6 Is an AFT competing risks model appropriate? 
 
Figure J.11 Checking the Accelerated Failure Time Assumption of the 
Competing Risks Model for Outcomes from the Waiting List.  
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The cumulative hazard plot in Figure J.11 suggests that an AFT competing risk 
model would be suitable in capturing the outcomes to transplantation and 
death/removal, from the waiting list. 
 
J.1.7 Summary 
The attributes which significantly influence death/removal outcome from the 
waiting list, are: first transplant or not, disease group, transplant urgency status, 
age group, and transplant centre. 
 
The models which would adequately capture the outcomes from the waiting list, 
are: 
(1) Two survival models (for the curves depicted in Figure J.12).  The 
first assuming the AFT assumption for generating survival times for patients 
requiring super urgent transplants and the second a Weibull model which 
assumes the PH assumption, stratified by first transplant or not; or 
(2) A Weibull (AFT) competing risks model which considered the 
outcomes death/removal and transplanted, censored at all other events. 
 
 
Figure J.12 Overall Kaplan-Meier estimates for survival by the patient groups 
1) those requiring a super urgent transplant, 2) those requiring their first 
routine transplant, and 3) those requiring subsequent routine transplants.  
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Figure J.12 shows that the survival times (DR times from the waiting list) are 
initially worse for routine patients waiting for their second or more transplant, 
when compared to routine patients waiting for their first transplant.  However, 
after two years the survival rates are similar for both groups. 
 
J.2 Parametric Model Development & Goodness of Fit 
This section summarises the parametric models developed using the process as 
outlined in Section 3.6.3 part [B]. 
 
J.2.1 Log-logistic Survival model for SU patients 
J.2.1.1 Model Development - Log-logistic Survival model for SU patients 
Table J.2 The overall development process for the Log-logistic model which 
considers all Super Urgent patients. 
Stage Enter/Exit Variable(s) Loglik(model) 
a) Enter -Super Urgent or Acute Disease Group 
-Unknown Liver Disease Group 
-Alcoholic Liver Disease 
-Gender 
-Age at Registration 
-First Transplant or not 
-318.9 
Exit -First Transplant or not -318.9 
Exit -Super Urgent or Acute Disease Group -319.1 
b) 
Exit -Age at Registration -319.8 
c) - -Unknown Liver Disease Group 
-Alcoholic Liver Disease 
-Gender 
-319.8 
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J.2.1.2 Final Model - Log-logistic Survival model for SU patients 
Table J.3 Log logistic Survival model for SU patients. 
Attributes Coefficient 
Standard 
error 
Z p-value 
(Intercept) 2.914 0.2842 10.25 1.14x10-024 
Unknown Liver Disease 
Group 
-3.024 0.8476 -3.57 3.59x10-004 
Alcoholic Liver Disease -1.892 1.1387 -1.66 9.65x10-002 
Gender -0.749 0.3241 -2.31 2.09x10-002 
Standard deviation 1.38    
Log(std dev) 0.320   0.0859 3.72 1.98x10-004 
Loglik(model)= -319.8   Loglik(intercept only)= -331.7 
 Chisq= 23.74 on 3 degrees of freedom, p= 0.000028  
 
J.2.1.3 Goodness of Fit - Log-logistic Survival model for SU patients 
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Figure J.13 Cumulative hazard plot of the Cox-Snell residuals generated from 
the Log-logistic model developed for the super urgent patients.  
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Table J.4 The result (model summary and coefficients) of performing linear 
regression (with no covariates) on the graph depicted in Figure J.13. 
Unstandardised 
Coefficients 
Standardised 
Coefficients 
Model 
B 
Std. 
Error 
Beta 
t Significance 
(Constant) -0.015 0.009  -1.785 0.077 
Cox Snell 
Residual for 
Loglogistic 
model 
(SU patients) 
1.255 0.021 0.986 61.092 <0.001 
R
2
 = 0.972  
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Figure J.14 Plot of the Kaplan-Meier estimate for survival and the estimated 
log-logistic model, for the super urgent patients.  
 
Figure J.14 graphs the Kaplan-Meier Estimate (for the death/removal outcome) 
derived from the data and the final log-logistic curve, for the patients waiting for 
a super urgent transplant.  It can be seen the log-logistic model provides a 
reasonable estimate of the times observed in the data. 
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J.2.2 Weibull Survival model for Routine patients going for First 
Transplant 
J.2.2.1 Model Development - Weibull Survival model for Routine patients 
going for First Transplant 
Table J.5 The overall development process for the Weibull model which 
considers all Routine patients going for their First Liver Transplant. 
Stage Enter/Exit Variable(s) Loglik(model) 
a) Enter -Other Cirrhotic Disease Group 
-Unknown Liver Disease Group 
-Cryptogenic Liver Disease 
-Age at Registration 
-Centre A 
-Centre B 
-Centre D 
-1732.7 
Exit -Cryptogenic Liver Disease -1733.2 
Exit -Centre B -1734.3 
b) 
Exit -Centre A -1735.5 
c) - -Other Cirrhotic Disease Group 
-Unknown Liver Disease Group 
-Age at Registration 
-Centre D 
-1735.5 
  
J.2.2.2 Final Model - Weibull Survival model for Routine patients going for 
First Transplant 
Table J.6 Final Model for Capturing the DR time from joining the WL for 
patients waiting for their first routine transplant (Weibull model). 
Attributes Coefficient 
Standard 
error 
Z p-value 
(Intercept) 7.4888 0.37107 20.18 1.43x10-090 
Other Cirrhotic Disease 
Group 
0.7071 0.20281 3.49 4.89x10-004 
Unknown Liver Disease 
Group 
-0.6994 0.27466 -2.55 1.09x10-002 
Age at Registration -0.0198 0.00668 -2.97 2.97x10-003 
Centre D 0.6409 0.29592 2.17 3.03x10-002 
Standard deviation 1.1    
Log(std dev) 0.0972 0.04874   1.99 4.62x10-002 
Loglik(model)= -1735.5   Loglik(intercept only)= -1752.3 
 Chisq= 33.47 on 4 degrees of freedom, p= 9.6x10-007   
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J.2.2.3 Goodness of Fit - Weibull Survival model for Routine patients 
going for First Transplant 
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Figure J.15 Cumulative hazard plot of the Cox-Snell residuals generated from 
the Weibull model developed for the routine patients going for their first liver 
transplant.  
 
Table J.7 The result (model summary and coefficients) of performing linear 
regression (with no covariates) on the graph depicted in figure J.15 
Unstandardised 
Coefficients 
Standardised 
Coefficients 
Model 
B 
Std. 
Error 
Beta 
t Significance 
(Constant) -0.015 0.001  -10.163 <0.001 
Cox Snell 
Residual for 
Weibull 
model 
(Routine 1
st
 
Transplants) 
1.155 0.006 0.997 184.157 <0.001 
R
2
 = 0.993  
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Figure J.16 Plot of the Kaplan-Meier estimate for survival and the estimated 
Weibull model, for the routine  patients going for their first liver transplant.  
 
Figure J.16 graphs the Kaplan-Meier Estimate (for the death/removal outcome) 
derived from the data and the final Weibull curve for routine patients waiting for 
their first transplant.  It can be seen the Weibull model provides a reasonable 
estimate of the times observed in the data. 
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J.2.3 Weibull Survival model for Routine patients going for 
Successive Transplant 
J.2.3.1 Model Development - Weibull Survival model for Routine patients 
going for Successive Transplant 
Table J.8 The overall development process for the Weibull model which 
considers all Routine patients going for their second or more Liver Transplant. 
Stage Enter/Exit Variable(s) Loglik(model) 
a) Enter -Metabolic Liver Disease 
-Unknown Liver Disease Group 
-Centre B 
-Centre D 
-318.6 
b) Exit -Metabolic Liver Disease -318.9 
- -Unknown Liver Disease Group 
-Centre B 
-Centre D 
-318.9 
c) 
Enter -Unknown Liver Disease Group 
-Centre B 
-Centre D 
-Centre C 
-317.3 
  
J.2.3.2 Final Model - Weibull Survival model for Routine patients going for 
Successive Transplant 
Table J.9 Final Model for Capturing the DR time from joining the WL for 
patients waiting for their second or greater routine transplant (Weibull model). 
Attributes Coefficient 
Standard 
error 
Z p-value 
(Intercept) 6.518 0.340 19.20 3.98x10-082 
Unknown Liver Disease 
Group 
-2.543 0.940 -2.71 6.83x10-003 
Centre B -1.281 0.619   -2.07 3.85x10-002 
Centre C 1.456   0.909 1.60 1.09x10-001 
Centre D -2.210 0.839 -2.64 8.40x10-003 
Standard deviation 1.54    
Log(std dev) 0.432 0.119 3.62 2.95x10-004 
Loglik(model)= -317.3   Loglik(intercept only)= -324.9 
 Chisq= 15.28 on 4 degrees of freedom, p= 0.0041   
 
  
Appendices 
 
329 
J.2.3.3 Goodness of Fit - Weibull Survival model for Routine patients 
going for Successive Transplant 
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Figure J.17 Cumulative hazard plot of the Cox-Snell residuals generated from the 
Weibull model developed for the routine patients going for their second or more liver 
transplant.  
 
Table J.10 The result (model summary and coefficients) of performing linear 
regression (with no covariates) on the graph depicted in Figure J.17. 
Unstandardised 
Coefficients 
Standardised 
Coefficients 
Model 
B 
Std. 
Error 
Beta 
t Significance 
(Constant) -0.031 0.014  -2.184 0.034 
Cox Snell 
Residual for 
Weibull 
model 
(Routine 
successive 
Transplants) 
1.162 0.031 0.984 37.005 <0.001 
R
2
 = 0.967  
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Figure J.18 Plot of the Kaplan-Meier estimate for survival and the estimated 
weibull model, for the routine patients going for their second or more liver 
transplant.  
 
Figure J.18 graphs the Kaplan-Meier Estimate (for the death/removal outcome) 
derived from the data and the final Weibull curve for routine patients waiting for 
their successive transplant.  It can be seen the Weibull model provides a 
reasonable estimate of the times observed in the data. 
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J.2.4 Weibull Competing Risks Model 
J.2.4.1 Final Model - Weibull Competing Risks Model 
Table J.11 Final Model for Capturing the DR time and time to Transplant from 
joining the WL (Weibull Competing Risks model). 
Attributes 
Coefficien
t/Value 
Standard 
error 
Z p-value 
(Intercept) 5.06133 0.12985 38.9786 <0.001 
Cancer -0.44636 0.16072 -2.7772 5.48x10-03 
Other Diagnosed Disease 0.52442 0.10581 4.9561 7.19x10-07 
Hepatitis B -0.17709 0.13174 -1.3443 1.79x10-01 
Centre B -0.26666 0.06979 -3.8208 1.33x10-04 
Centre E 0.09479 0.05988 1.5829 1.13x10-01 
Gender -0.35211 0.05961 -5.9067 3.49x10-09 
Delta 2.50108 0.35208 7.1038 1.21x10-12 
Age at Registration -0.00624 0.00227 -2.7542 5.88x10-03 
Other Cirrhotic Disease -0.00596 0.07676 -0.0776 9.38x10-01 
Disease Not Reported 0.65187 0.21251 3.0674 2.16x10-03 
Centre C -0.27779 0.08499 -3.2686 1.08x10-03 
Transplant Urgency -3.47336 0.08161 -42.5615 <0.001 
Gender:Delta 0.18371 0.15962 1.1509 2.50x10-01 
Age at Registration:Delta -0.01142 0.00618 -1.8479 6.46x10-02 
Strata(first transplant or 
not):Delta 0.25869 0.12553 2.0608 3.93x10-02 
Other Cirrhotic 
Disease:Delta 0.63483 0.24698 2.5704 1.02x10-02 
Disease Not 
Reported:Delta -2.00983 0.3427 -5.8647 4.50x10-09 
Centre C:Delta 0.57704 0.26424 2.1838 2.90x10-02 
Transplant Urgency:Delta -0.79344 0.19738 -4.0199 5.82x10-05 
etype=T, firsttx=1 0.138      0.0164 8.36 6.03x10-017 
Scale 
etype=DR, firsttx=0 1.61 
etype=DR, firsttx=1 1.27 
etype=T, firsttx=0 1.39 
etype=T, firsttx= 1.15 
Loglik(model)= -12599.4   Loglik(intercept only)= -13991.5 
 Chisq= 2784.05 on 19 degrees of freedom, p= 0   
 
J.2.4.2 Goodness of Fit - Weibull Competing Risks Model 
Figures J.19-J.22 show that the competing risks model captures the outcomes to 
death/removal and to transplantation from the waiting list very closely. 
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Figure J.19 Plot of the Kaplan-Meier estimate for survival and the estimated 
Weibull competing risks mode capturing the DR outcome from the WL, for 
patients awaiting a successive transplant.  
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Figure J.20 Plot of the Kaplan-Meier estimate for survival and the estimated 
Weibull competing risks mode capturing the DR outcome from the WL, for 
patients awaiting their first transplant.  
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Figure J.21 Plot of the Kaplan-Meier estimate for survival and the estimated 
Weibull competing risks mode capturing the Transplantation outcome from the 
WL, for patients awaiting a successive transplant.  
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Figure J.22 Plot of the Kaplan-Meier estimate for survival and the estimated 
Weibull competing risks mode capturing the Transplantation outcome from the 
WL, for patients awaiting their first transplant.  
 
J.3 Models to Use 
The model implemented in Hepatica is the competing risk model, as outlined in 
Section J.2.4. 
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Appendix K 
 
Post Transplant Outcome Model Analysis and 
Development 
This appendix reports the development of three parametric survival models 
which capture the outcomes to death/graft failure (DGF) and re-listing (RL) 
post-transplantation, censored at all other events. 
 
K.1 Preliminary Analysis 
This section summarises the main findings of the preliminary analysis (as 
outlined in Section 3.6.3 part [A]).  Only the graphs and tests which help to 
decide which parametric models are appropriate are presented here, however the 
analysis was performed for all covariates. 
 
K.1.1 Identifying Significant Differences in Patient Survival by 
Covariate Levels 
Below is a summary of the Log Rank and Wilcoxon tests (pooled over strata) 
which were used to identify the covariates by which the survival curves were 
significantly different.  The tests were based on identifying the outcome 
death/graft failure or re-listing and censoring at all other outcomes. 
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Table K.1 Tests to Identify Covariates which Lead to Significantly Different 
Survival Outcomes post transplantation. 
Significance of Tests Log Rank Wilcoxon 
(Breslow) 
Tarone-
Ware 
Donor-Patient ABO Match <0.001 <0.001 <0.001 
Cold ischaemic times 0.395 0.355 0.365 
Donor age 0.043 0.033 0.037 
Donor cause of death 0.553 0.575 0.582 
First Transplant <0.001 <0.001 <0.001 
Completeness of liver used 0.049 0.018 0.027 
Disease Group <0.001 <0.001 <0.001 
Patient age at transplant 0.117 0.084 0.092 
Patient/Donor Rhesus match 0.410 0.626 0.530 
MELD score <0.001 <0.001 <0.001 
Donor gender to patient gender 0.436 0.357 0.394 
Donor weight – patient weight 0.010 0.040 0.060 
Patient Body Mass Index 0.004 0.007 0.006 
Urgency of transplant <0.001 <0.001 <0.001 
Patient gender 0.126 0.076 0.091 
  
 
Initial analysis shows that the survival functions are significantly different over 
the following factors: donor-patient ABO match, donor age (greater than 65 
years or not), first transplant or not, urgency of transplant, completeness of liver 
used in the transplant, primary liver disease at registration, MELD score, donor 
weight minus patient weight, and patient BMI.  Pair-wise comparisons for levels 
within each covariate also gave similar conclusions but identified which levels 
were most different.  Other factors which might lead to significantly different 
outcomes (from interpreting the results in Table K.1) include patient age at 
transplant and patient gender. 
 
K.1.2 Should the event Death/Graft Failure be modelled separately 
to Re-Listing? 
Analysis, including the creation of a logistic regression model implied that the 
patients who are re-listed do not have significantly different attributes to patients 
that experience death/graft failure.  Analysis of the times to both events also 
implied no significant difference over the observation period. 
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Figure K.1 The proportions observed to experience the events Death/Graft 
Failure and Re-Listing over Grouped Periods of Time Since Transplantation.  
 
Figure K.1 shows that when considering the two events death/graft failure and 
re-listing through time, roughly 68% of events are death/graft failure and 32% 
are re-listings.  The proportions remain roughly constant through time.  This 
means that one model can be developed to capture the event DGFRL 
(death/graft failure or re-listing) and that 68% of these events will be assigned as 
death/graft failure and the rest re-listing, at random. 
 
K.1.3 Is a PH model appropriate? 
Figure K.2 considers whether the Proportional Hazards (PH) assumption holds 
in modelling the survival distributions by donor and patient blood group match 
(comparing identical blood group matches with non identical blood group 
matches).  The lines are reasonably parallel after the first few days, however, 
over the first few days the distance between the lines changes drastically, 
meaning that a proportional hazards model is probably not suitable in capturing 
the event death/graft failure or re-listing censored at all other events. 
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Figure K.2 Log-Cumulative Hazard Plot, by Identical Blood Group Match.  
 
K.1.4 Is an AFT model appropriate? 
 
Figure K.3 Cumulative Hazard Plot, by Identical Blood Group Match.  
 
Figure K.3 considers whether the accelerated failure time models are suitable in 
modelling the survival distributions by donor and patient blood group match 
(comparing identical blood group matches with non identical blood group 
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matches).  The lines are reasonably parallel and straight which would suggest 
that an AFT model is suitable in capturing the event death/graft failure or re-
listing censored at all other events. 
 
Further plots indicated that any of the AFT survival models (Weibull, Log 
Logistic, or Lognormal) would be appropriate in capturing the post transplant 
outcomes.  Therefore, all these models were developed and the best one chosen 
to use in the simulation. 
 
K.1.5 Is a PH competing risks model appropriate? 
Figure K.4 indicates that the PH competing risks model is not suitable for 
capturing the post transplant outcomes, since the log cumulative hazard lines 
cross. 
 
 
Figure K.4 Checking the Proportional Hazards Assumption of the Competing 
Risks Model for the Post Transplant Outcomes.  
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K.1.6 Is an AFT competing risks model appropriate? 
 
Figure K.5 Checking the Accelerated Failure Time Assumption of the 
Competing Risks Model for the Post Transplant Outcomes.  
 
Figure K.5 indicates that the AFT competing risks model is not suitable for 
capturing the post transplant outcomes, since the cumulative hazard lines cross. 
 
K.1.7 Summary 
From section K.1.1 we can see that the attributes which significantly influence 
post transplant outcomes, are: donor-patient ABO match, donor age (greater 
than 65 years or not), first transplant or not, urgency of transplant, completeness 
of liver used in the transplant, primary liver disease at registration, MELD score, 
donor weight minus patient weight, and patient BMI. 
 
From the analysis performed in section K.1.2-K.1.6 it was concluded that the 
models most appropriate for capturing the post transplant outcomes, are AFT 
survival models. 
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K.2 Parametric Model Development & Goodness of Fit 
This section summarises the parametric models developed using the process as 
outlined in Section 3.6.3 part [B]. 
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K.2.1 Weibull Survival Model 
K.2.1.1 Model Development - Weibull Survival Model 
Table K.2 The overall development process for the Weibull model (DGF/RL). 
Stage Enter/Exit Variable(s) Loglik(model) 
a) Enter -Whole Liver 
-Split Liver 
-First Transplant 
-Donor Gender 
-Donor Age Group (>= 65 years) 
-Donor Cause of Death Due to 
Trauma 
-Donor Cause of Death Due to 
Infection 
-Donor Weight minus Patient 
Weight 
-Female Donor to Female Patient 
-Patient Age 
-Transplant Urgency 
-Patient Underweight 
-Patient Obese 
-Other Cirrhotic Disease Group 
-Other Diagnosed Disease Group 
-Super Urgent or Acute Disease 
Group 
-Alcoholic Liver Disease 
-Identical Blood Groups 
-Compatible Blood Groups 
-MELD Group 2 
-MELD Group 3 
-MELD Group 4 
-2933 
Exit -Split Liver 
-Transplant urgency 
-MELD Group 2 
-2933.2 
Exit -Patient Obese -2933.4 
Exit -Donor Cause of Death Due to 
Trauma 
-2933.7 
Exit -MELD Group 4 -2934 
Exit -Donor Gender -2934.8 
b) 
Exit -First Transplant -2935.8 
c) - -Whole Liver 
-Donor Age Group (>= 65 years) 
-Donor Cause of Death Due to 
Infection 
-Donor Weight minus Patient 
Weight 
-Patient Age 
-Other Cirrhotic Disease Group 
-Other Diagnosed Disease Group 
-Super Urgent or Acute Disease 
Group 
-Alcoholic Liver Disease 
-2935.8 
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K.2.1.2 Final Model - Weibull Survival Model 
Table K.3 Final Weibull Model for Capturing the Event DGF/RL. 
Attributes Coefficient 
Standard 
Error 
Z p-value 
(Intercept) 4.6041 2.20341 2.09 3.67x10-02 
Whole Liver 1.6491 0.58913 2.8 5.12x10-03 
Donor Age Group (>= 65 years) -1.0423 0.4278 -2.44 1.48x10-02 
Donor Cause of Death Due to 
Infection -1.9357 0.96616 -2 4.51x10-02 
Donor Weight minus Patient 
Weight -0.0258 0.00959 -2.69 7.08x10-03 
Patient Age -0.0354 0.01267 -2.79 5.27x10-03 
Other Cirrhotic Disease Group 0.8842 0.46082 1.92 5.50x10-02 
Other Diagnosed Disease Group -1.3874 0.60211 -2.3 2.12x10-02 
Super Urgent or Acute Disease 
Group -2.2331 0.41046 -5.44 5.31x10-08 
Alcoholic Liver Disease 1.3008 0.53598 2.43 1.52x10-02 
Identical Blood Groups 6.6536 2.0359 3.27 1.08x10-03 
Compatible Blood Groups 5.6068 2.05649 2.73 6.40x10-03 
MELD Group 3 -0.9883 0.36178 -2.73 6.30x10-03 
Log(scale) 1.0419 0.04769 21.84 8.73x10-106 
Loglik(model)= -2935.8   Loglik(intercept only)= -2989.9 
 Chisq= 108.26 on 12 degrees of freedom, p= 0   
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K.2.1.3 Goodness of Fit - Weibull Survival Model 
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Figure K.6 Cumulative hazard plot of the Cox-Snell residuals generated from 
the Weibull model developed for the outcome DGF/RL.  
 
Table K.4 The result (model summary and coefficients) of performing linear 
regression (with no covariates) on the graph depicted in Figure K.6. 
Unstandardised 
Coefficients 
Standardised 
Coefficients 
Model 
B 
Std. 
Error 
Beta 
t Significance 
(Constant) 0.016 0.002  8.601 <0.001 
Cox Snell 
Residual for 
Lognormal 
model 
0.888 0.010 0.977 92.834 <0.001 
R
2
 = 0.977  
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K.2.2 Log-Logistic Survival Model 
K.2.2.1 Model Development - Log-Logistic Survival Model 
Table K.5 The overall development process for the Log-Logistic model 
(DGF/RL). 
Stage Enter/Exit Variable(s) Loglik(model) 
a) Enter  -Whole Liver 
-Split Liver 
-First Transplant 
-Donor Age Group (>= 65 years) 
-Donor Cause of Death Due to 
Infection 
-Donor Weight minus Patient 
Weight 
-Female Donor to Female Patient 
-Patient Age 
-Transplant Urgency 
-Patient Underweight 
-Patient Normal Weight 
-Patient Obese 
-Other Cirrhotic Disease Group 
-Other Diagnosed Disease Group 
-Super Urgent or Acute Disease 
Group 
-Alcoholic Liver Disease 
-Identical Blood Groups 
-Compatible Blood Groups 
-MELD Group 1 
-MELD Group 2 
-MELD Group 4 
-2927.5 
Exit  -Transplant Urgency 
-Patient Underweight 
-Patient Normal Weight 
-2927.5 
Exit -Split Liver -2927.6 
Exit -Female Donor to Female Patient -2927.7 
Exit -Patient Obese -2928 
Exit -MELD Group 4 -2928.7 
Exit -MELD Group 1 -2929.8 
b) 
Exit -Compatible Blood Groups -2930.9 
c) Enter -Whole Liver 
-First Transplant 
-Donor Age Group (>= 65 years) 
-Donor Cause of Death Due to 
Infection 
-Donor Weight minus Patient 
Weight 
-Patient Age 
-Other Cirrhotic Disease Group 
-Other Diagnosed Disease Group 
-Super Urgent or Acute Disease 
Group 
-Alcoholic Liver Disease 
-2930.9 
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K.2.2.2 Final Model - Log-Logistic Survival Model 
Table K.6 Final Log-Logistic Model for Capturing the Event DGF/RL. 
Attributes Coefficient 
Standard 
Error 
Z p-value 
(Intercept) 9.1516 1.0062 9.1 9.42x10-20 
Whole Liver 1.8506 0.6378 2.9 3.71x10-03 
Donor Age Group (>= 65 
years) -1.047 0.4481 -2.34 1.95x10-02 
Donor Cause of Death Due 
to Infection -2.4763 1.1041 -2.24 2.49x10-02 
Donor Weight minus 
Patient Weight -0.0279 0.0101 -2.77 5.61x10-03 
Patient Age -0.0373 0.0134 -2.78 5.39x10-03 
Other Cirrhotic Disease 
Group 0.8896 0.4635 1.92 5.49x10-02 
Other Diagnosed Disease 
Group -1.5045 0.6336 -2.37 1.76x10-02 
Super Urgent or Acute 
Disease Group -2.3895 0.4333 -5.51 3.50x10-08 
Alcoholic Liver Disease 1.3394 0.5305 2.52 1.16x10-02 
Identical Blood Groups 1.2883 0.4853 2.65 7.94x10-03 
MELD Group 3 -1.0072 0.3856 -2.61 9.00x10-03 
Log(scale) 0.944 0.0464 20.34 6.02x10-92 
Loglik(model)= -2930.6   Loglik(intercept only)= -2985.6 
 Chisq= 110.11 on 11 degrees of freedom, p= 0   
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K.2.2.3 Goodness of Fit - Log-Logistic Survival Model 
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Figure K.7 Cumulative hazard plot of the Cox-Snell residuals generated from 
the Log-Logistic model developed for the outcome DGF/RL.  
 
Table K.7 The result (model summary and coefficients) of performing linear 
regression (with no covariates) on the graph depicted in Figure K.7. 
Unstandardised 
Coefficients 
Standardised 
Coefficients 
Model 
B 
Std. 
Error 
Beta 
t Significance 
(Constant) -0.111 0.002  -55.129 <0.001 
Cox Snell 
Residual for 
Log-Logistic 
model 
0.943 0.007 0.989 136.468 <0.001 
R
2
 = 0.978  
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K.2.3 Lognormal Survival Model 
K.2.3.1 Model Development - Lognormal Survival Model 
Table K.8 The overall development process for the Lognormal model (DGF/RL). 
Stage Enter/Exit Variable(s) Loglik(model) 
a) Enter -Whole Liver 
-Split Liver 
-First Transplant 
-Donor Cause of Death Due to 
Infection 
-Donor Weight minus Patient Weight 
-Patient Age 
-Transplant Urgency 
-Patient Normal Weight 
-Patient Obese 
-Other Cirrhotic Disease Group 
-Cholestatic Liver Disease 
-Other Diagnosed Disease Group 
-Super Urgent or Acute Disease 
Group 
-Alcoholic Liver Disease 
-Identical Blood Groups 
-Compatible Blood Groups 
-MELD Group 2 
-MELD Group 3 
-MELD Group 4 
-2922.4 
Exit -Split Liver 
-Patient Normal Weight 
-MELD Group 2 
-2922.5 
Exit -Transplant urgency 
-Patient Obese 
-2922.7 
Exit -First Transplant 
-MELD Group 4 
-2923.4 
Exit -Cholestatic Liver Disease -2923.8 
Exit -Compatible Blood Groups -2924.8 
b) 
- -Whole Liver 
-Donor Cause of Death Due to 
Infection 
-Donor Weight minus Patient Weight 
-Patient Age 
-Other Cirrhotic Disease Group 
-Other Diagnosed Disease Group 
-Super Urgent or Acute Disease 
Group 
-Alcoholic Liver Disease 
-Identical Blood Groups  
-MELD Group 3 
-2924.8 
c) Enter -Donor Age Group (>= 65 years) 
-Donor Death Due to Intracranial 
Injuries 
-2921.3 
b) Exit -Donor Death Due to Intracranial 
Injuries 
-2922.5 
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K.2.3.2 Final Model - Lognormal Survival Model 
Table K.9 Final Lognormal Model for Capturing the Event DGF/RL. 
Attributes Coefficient 
Standard 
Error 
Z p-value 
(Intercept) 9.3227 1.0702 8.71 3.01x10-18 
Whole Liver 1.925 0.6785 2.84 4.55x10-03 
Donor Cause of Death Due 
to Infection -2.6866 1.1644 -2.31 2.10x10-02 
Donor Weight minus Patient 
Weight -0.0304 0.0105 -2.89 3.86x10-03 
Patient Age -0.0349 0.0141 -2.48 1.32x10-02 
Other Cirrhotic Disease 
Group 0.8948 0.4706 1.9 5.73x10-02 
Other Diagnosed Disease 
Group -1.4859 0.6766 -2.2 2.81x10-02 
Super Urgent or Acute 
Disease Group -2.3982 0.4613 -5.2 2.01x10-07 
Alcoholic Liver Disease 1.3821 0.5322 2.6 9.41x10-03 
Identical Blood Groups 1.3937 0.5313 2.62 8.71x10-03 
MELD Group 3 -0.9671 0.4115 -2.35 1.88x10-02 
Donor Age Group (>= 65 
years) -1.0273 0.4755 -2.16 3.08x10-02 
Log(scale) 1.579 0.0422 37.41 
3.13x10-
306 
Loglik(model)= -2922.5   Loglik(intercept only)= -2977.1 
 Chisq= 109.32 on 11 degrees of freedom, p= 0   
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K.2.3.3 Goodness of Fit - Lognormal Survival Model 
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Figure K.8 Cumulative hazard plot of the Cox-Snell residuals generated from 
the Lognormal model developed for the outcome DGF/RL.  
 
Table K.10 The result (model summary and coefficients) of performing linear 
regression (with no covariates) on the graph depicted in Figure K.10. 
Unstandardised 
Coefficients 
Standardised 
Coefficients 
Model 
B 
Std. 
Error 
Beta 
t Significance 
(Constant) 0.091 0.003  30.827 <0.001 
Cox Snell 
Residual for 
Lognormal 
model 
0.898 0.025 0.873 36.564 <0.001 
R
2
 = 0.762  
 
K.3 Model to Use 
Figure K.9 compares the Kaplan-Meier Estimate with the parametric models 
fitted for the outcome death/graft failure or re-listing post transplant, censored at 
all other times.  All the models fit well, and the log-logistic model was chosen 
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for use in Hepatica, as it returned the best results in the goodness of fit analysis 
(see Sections K.2.1.3, K.2.2.3, and K.2.3.3). 
 
120010008006004002000
Time (days)
1
0.95
0.9
0.85
0.8
0.75
0.7
S
u
rv
iv
a
l 
F
u
n
c
ti
o
n
Lognormal Survival 
Function
Log-Logistic 
Survival Function
Weibull Survival 
Function
Kaplan-Meier 
Survival Estimate
 
Figure K.9 Fitted Survival Models to the Post Transplant Outcomes and the 
Kaplan-Meier Survival Estimate.  
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Appendix L 
 
Assigning Patient and Donor Attributes 
L.1 Attributes to Assign 
As explained previously (Section 3.6.1) the attributes that need to be assigned to 
patients and donors arriving into the system are those which play a significant 
role in patient progression through the system (i.e., those that determine pre- and 
post-transplant survival, and those that determine who is chosen for 
transplantation) and in patient and donor arrivals. 
 
From the analysis in Sections 4.3-4.5 and the allocation rules as described in 
Section 3.3.4, the list of attributes which require assigning, are: 
(1) for patients: 
a. the type of disease (only those groups significant in patient 
progression and survival); 
b. the urgency of the transplant required by the patient; 
c. age; 
d. first transplant or not; 
e. centre; 
f. gender; 
g. MELD group; 
h. weight; 
i. blood group. 
(2) for donors: 
a. if the donated liver is a whole liver or a reduced/split liver; 
b. cause of death; 
c. weight; 
d. age; 
e. blood group; 
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f. centre. 
 
L.2 Dependencies between Attributes 
Before assigning attributes to the patients and donors within Hepatica, tests were 
performed to check if all the attributes could be assigned at random, or if there 
were any dependencies which needed to be taken into account. 
 
L.2.1 Statistical Tests 
Where the two attributes being compared both had a small number of 
values/factors, a contingency table was set up and the Chi-squared statistic 
evaluated to identify dependencies between the two attributes. 
 
Where either one of the attributes was continuous or the other attribute a factor, 
then a test was performed to identify if the averages were significantly different 
(ANOVA techniques). 
 
Where both attributes were continuous then a test to determine the correlation 
between the two variables was performed. 
 
L.2.2 Data Sets Used 
As we are assigning patient attributes as patients join the waiting list, we need to 
check the dependencies between variables for those that have joined the WL (as 
given by UK Transplant).  This will avoid incorporating any bias as a result of 
the current allocation policy that is in.  The donor attributes were tested using 
the donor data provided by UK Transplant.  Dependencies between donor and 
patient attributes were not considered, as again these dependencies will arise 
from the allocation policy which is in place. 
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L.2.3 Missing Values 
Cases with missing attributes were omitted for the tests which considered the 
attributes. 
 
L.2.4 Tests to Determine the Dependencies between Patient  
The chi-squared tests (Table L.1) confirmed dependencies between the patient 
attributes: (1) Disease group and Transplant urgency, (2) Disease group and 
First transplant, (3), Disease group and Transplant centre, (4) Disease group and 
gender, (5) Transplant urgency and First transplant, (6) Transplant centre and 
Transplant urgency, (7) Transplant urgency and gender, (8) Transplant urgency 
and MELD group, (9) First transplant and MELD group, and (10) Transplant 
centre and Blood group. 
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Table L.1 Results of Chi-Squared Tests for Patient Attributes. 
Patient Attributes 
Number 
of valid 
cases 
Degrees 
of 
Freedom 
Pearson 
Chi Square 
Value 
Significance 
(2-sided) 
disease group * 
urgency 
2453 7 1424.733 <0.001 
disease group *  
first transplant or not 
2453 7 347.980 <0.001 
disease group *  
centre 
2453 42 203.875 <0.001 
disease group *  
gender 
2453 7 536.002 <0.001 
disease group *  
meld 
1948 7 8.801 0.267 
disease group * 
blood group 
2453 21 22.784 0.356 
urgency *  
first transplant or not 
2453 1 43.979 <0.001 
urgency *  
centre 
2453 6 22.572 0.001 
urgency *  
gender 
2453 1 50.127 <0.001 
urgency *  
meld 
1948 1 4.997 0.025 
urgency *  
blood group 
2453 3 2.240 0.524 
first transplant or not 
* centre 
2453 6 11.339 0.078 
first transplant or not 
* gender 
2453 1 1.090 0.297 
first transplant or not 
* meld 
1948 1 11.047 0.001 
first transplant or not 
* blood group 
2453 3 3.952 0.267 
centre *  
gender 
2453 6 6.304 0.390 
centre *  
meld 
1948 6 9.153 0.165 
centre *  
blood group 
2453 18 29.137 0.047 
gender *  
meld 
1948 1 0.928 0.335 
gender *  
blood group 
2453 3 0.437 0.932 
meld *  
blood group 
1948 3 1.388 0.708 
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The ANOVA tests (Table L.2) confirmed dependencies between the patient 
attributes weight and gender. 
 
Table L.2 Results of ANOVA Tests for Patient Attributes. 
Patient Attributes Eta Eta Squared 
age * disease group 0.423 0.179 
age * urgency 0.372 0.139 
age * first transplant or not 0.109 0.012 
age * centre 0.082 0.007 
age * gender 0.077 0.006 
age * meld 0.011 <0.001 
age * blood group 0.061 0.004 
weight * disease group 0.283 0.080 
weight * urgency 0.061 0.004 
weight * first transplant or not 0.110 0.012 
weight * centre 0.055 0.003 
weight * gender 0.412 0.170 
weight * meld 0.027 0.001 
weight * blood group 0.038 0.001 
  
The correlation tests (Table L.3) confirmed dependencies between the patient 
attributes age and weight. 
 
Table L.3 Results of Correlation Tests for Patient Attributes. 
Patient Attributes 
Number 
(valid 
cases) 
Pearson 
Significance  
(2-tailed) 
age * weight 2372 0.139 <0.001 
  
 
L.2.5 Tests to Determine the Dependencies between Donor 
Attributes 
The chi-squared tests (Table L.4) confirmed dependencies between the donor 
attributes: (1) Whole liver and Cause of death, (2) Whole liver and Transplant 
centre, (3) Age and Whole liver, and (4) Age and Cause of death. 
 
  
Appendices 
 
356 
Table L.4 Results of Chi-Squared Tests for Donor Attributes. 
Donor Attributes 
Number 
of valid 
cases 
Degrees 
of 
Freedom 
Pearson 
Chi Square 
Value 
Significance 
(2-sided) 
whole * 
cause of death 
2082 1 5.050 0.025 
whole * 
blood group 
2082 3 5.772 0.123 
whole * 
centre 
2082 6 35.674 <0.001 
cause of death * 
blood group 
2082 3 3.516 0.319 
cause of death * 
centre 
2082 6 5.566 0.474 
blood group * 
centre 
2082 18 16.662 0.546 
age * 
whole 
2082 1 15.194 <0.001 
age * 
cause of death 
2082 1 4.497 0.034 
age * 
blood group 
2082 3 5.693 0.128 
age * 
centre 
2082 6 7.474 0.279 
  
The ANOVA tests (Table L.5) were not significant for any of the combination 
of donor attributes tested. 
 
Table L.5 Results of ANOVA Tests for Donor Attributes. 
Donor Attributes Eta Eta Squared 
weight * whole 0.031 0.001 
weight * donor cause of death 0.004 <0.001 
weight * donor blood group 0.032 0.001 
weight * centre 0.061 0.004 
weight * age 0.012 <0.001 
  
L.3 Summary of How the Attributes will be Assigned 
As detailed in Section L.2 several dependencies were found, these are 
summarised in Table L.6 and are captured within Hepatica. 
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Table L.6 Dependencies Captured in Hepatica. 
 Dependencies Between 
Patient 
Characteristics 
Disease group and Transplant urgency 
Disease group and First transplant 
Disease group and Transplant centre 
Disease group and Patient gender 
Transplant urgency and First transplant 
Transplant centre and Transplant urgency 
Transplant urgency and Patient gender 
Transplant urgency and MELD group 
First transplant and MELD group 
Transplant centre and Blood group 
Patient weight and Patient gender 
Patient age and Patient weight 
Donor Characteristics 
Whole liver and Donor cause of death 
Whole liver and Transplant centre 
Donor age and Whole liver 
Donor age and Donor cause of death 
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